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2 Summary 
Tight regulation of immune responses is essential to prevent immune 
disorders such as allergies. A healthy response to innocuous environmental 
antigens is characterized by immunological tolerance while allergies are the 
result of an exaggerated immune response towards such antigens (also 
referred to as allergens). The exact mechanisms that determine whether an 
individual develops allergies are still not fully understood. Some of the key 
events that underlie the development of an allergic response are the 
differentiation and expansion of allergen-specific T helper (Th) 2 cells that 
mediate the activation of allergen-specific B cells, leading to the production of 
allergen-specific IgE antibodies. Healthy individuals that are exposed to an 
allergen frequently mount an active immune response without developing 
allergies. Such a response is characterized by the development of allergen-
specific inducible interleukin (IL)-10-producing regulatory T (Tr1) cells. IL-10 is 
an immunosuppressive cytokine that inhibits antigen-specific T cell 
proliferation and cytokine production and is essential in peripheral tolerance to 
allergens, autoantigens and tumor antigens. Furthermore, IL-10 inhibits IgE 
production by B cells while augmenting the production of non-inflammatory 
IgG4 antibodies. Recent studies have identified IL-10-producing B (regulatory) 
cells as important regulators of immune responses primarily in autoimmune 
diseases. 
 
This thesis is focused on the role of B cells in the regulation of immune 
responses, particularly in relation to induction and maintenance of peripheral 
tolerance to allergens. We characterized the phenotype and function of 
human inducible IL-10-producing regulatory B cells (Br1 cells) from peripheral 
blood (described in chapter 6.1). We identified Br1-related surface markers 
(high expression of CD25 and CD71 and low expression of CD73), 
demonstrated that Br1 cells potently suppress antigen-specific CD4+ T cell 
proliferation and represent precursors of IgG4-producing plasma cells. We 
looked at the frequencies of allergen-specific Br1 cells from beevenom allergic 
patients before and after receiving allergen-specific immunotherapy (SIT), and 
from highly beevenom-exposed non-allergic beekeepers. We found that the 
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frequency of allergen-specific Br1 cells was low in allergic individuals and 
increased upon SIT to levels comparable to those observed in beekeepers. 
Next, we studied the effect of IL-10 overexpression on the function and 
phenotype of B cells (described in chapter 6.2). We found that IL-10 
overexpression induces a regulatory phenotype in B cells, and arms them to 
suppress antigen-specific proliferation of PBMC, production of inflammatory 
cytokines and maturation and differentiation of monocyte-derived dendritic 
cells. Furthermore, IL-10-overexpressing B cells suppressed TLR2-L or TLR4-
L-induced proinflammatory cytokines and chemokines from PBMC. Finally, we 
investigated activation of B cells by different TLR-ligands, cytokines, and 
CD40L stimulation and the modulation of these responses by mammalian 
suppressive telomeric oligodeoxynucleotide (ODN) sequences (described in 
chapter 6.3). We found that direct and indirect stimulation of human B cells 
through endosomal associated TLRs plays a pivotal role in polyclonal B cell 
activation and immunoglobulin production to maintain long-term serological 
memory in humans. Furthermore, we observed a direct and general 
suppressive effect of mammalian telomeric ODN on the activation of human B 
cells at the level of proliferation, class-switch recombination, plasma cell 
differentiation and immunoglobulin production. Suppression of B cell 
responses by telomeric ODN may represent a natural mechanism to control B 
cell activation under chronic inflammatory conditions. 
 
The findings described in this thesis provide new insights into the role of B 
cells in the regulation of immune tolerance. 
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3 Zusammenfassung 
Eine strikte Regulierung der Immunantwort ist notwendig um Erkrankungen 
wie Allergien zu verhindern, die durch eine Überreaktion des Immunsystems 
ausgelöst wird. Eine gesunde Immunantwort auf ungefährliche Antigene aus 
der Umwelt zeichnet sich durch immunologische Toleranz aus, während 
Allergien das Resultat einer übertrieben Immunantwort auf eben diese 
Antigene (auch Allergene genannt) sind. Die exakten Mechanismen welche 
entscheiden ob ein Individuum Allergien entwickelt, oder nicht, sind bis heute 
nicht vollständig verstanden. Eines der Schlüsselereignisse das zur 
Entstehung einer allergischen Immunantwort führt, ist die Differenzierung und 
Proliferation von allergenspezifischen T Helferzellen die wiederum die 
Aktivierung von allergenspezifischen B Zellen vermittelt. Dies führt zur 
Produktion von allergenspezifischen IgE Antikörpern. Gesunde Individuen, die 
regelmässig einem Allergen ausgesetzt sind, entwickeln eine Immunantwort 
gegen dieses Allergen ohne dabei Allergien zu entwickeln. Diese gesunde 
Immunantwort ist durch die Entwicklung von IL-10-produzierende, 
induzierbare T Zellen (Tr1) charakterisiert. IL-10 ist ein immunsuppressives 
Zytokin, das antigenspezifische T Zellproliferation und Zytokinproduktion 
unterdrückt und somit essentiell für die periphere Toleranz gegenüber 
Allergenen, Autoantigenen und Tumorantigenen ist. Ausserdem kann IL-10 
die IgE-Produktion von B Zellen inhibieren, während es die Produktion der 
anti-inflammatorisch wirkenden IgG4 Antikörper erhöht. Kürzlich 
veröffentlichte Studien haben vornehmlich in Autoimmunerkrankungen IL-10-
produzierende B Zellen (B regulatorische Zellen) als wichtige Regulatoren der 
Immunantwort identifiziert. 
 
Diese Dissertation konzentriert sich auf die Rolle von B Zellen in der 
Regulation der Immunantwort, im Besonderen mit Bezug auf die Induktion 
und den Erhalt der peripheren Toleranz zu Allergenen. Wir haben den 
Phänotyp und die Funktion von humanen, induzierbaren, IL-10-
produzierenden, regulatorischen B Zellen (Br1 Zellen) aus humanem, 
peripherem Blut charakterisiert (beschrieben in Kapitel 6.1). Wir haben 
Oberflächenmarker für Br1 Zellen identifiziert (hohe Expression von CD25 
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und CD71, niedrige Expression von CD73). Des weiteren haben wir gezeigt, 
dass Br1 Zellen effizient die Proliferation von antigenspezifischen CD4+ T 
Zellen unterdrückt und nachgewiesen, dass Br1 Zellen Vorläuferzellen von 
IgG4-produzierenden Plasmazellen sind. Bei der Betrachtung der Frequenz 
von Br1 Zellen in Bienengift-allergischen Patienten vor  und nach spezifischer 
Immuntherapie und in häufig Bienengift ausgesetzten nicht-allergischen 
Imkern, fanden wir, dass die Anzahl von Br1 Zellen in allergischen Individuen 
niedrig ist. Durch spezifische Immuntherapie werden Br1 Zellen induziert und 
erreichen dabei ein Niveau vergleichbar mit denen von Imkern. Nächstfolgend 
haben wir den Effekt einer IL-10 Überexpression auf die Funktion und den 
Phänotyp von B Zellen unersucht (beschrieben in Kapitel 6.2). Wir konnten 
aufzeigen, dass eine IL-10-Überexpression einen regulatorischen Phänotyp in 
B Zellen induziert und sie mit der Fähigkeit ausrüstet antigenspezifische 
Proliferation von mononukleäre Zellen des peripheren Blutes und die 
Produktion von inflammatorischen Zytokinen zu unterdrücken. Zusätzlich 
wurde die Reifung und Differenzierung von aus Monozyten differenzierten 
Dendritische Zellen zu unterdrückt. IL-10-überexpermierende B Zellen können 
ausserdem die Zytokin- und Chemokinproduktion der mononukleären Zellen 
des peripheren Blutes nach TLR2- und TLR4-Stimulation unterdrücken. 
Schlussendlich haben wir die Aktivierung von B Zellen nach Stimulation mit 
unterschiedlichen TLR-Liganden, Zytokine und CD40-Ligand untersucht und 
die Modulation dieser Aktivierung durch suppressive Telomersequenzen von 
Säugetieren analysiert (beschrieben in Kapitel 6.3). Wir fanden heraus, dass 
die direkte und indirekte Stimulation von humanen B Zellen durch endosomal-
assoziierte TLRs ein Schlüsselrolle in der polyklonalen B Zellaktivierung und 
Immunglobulinproduktion spielen und diese Stimulation notwendig ist um ein 
langfristiges serologisches Gedächtnis im Menschen aufrechtzuhalten. 
Ausserdem haben wir einen direkten und generalisierten suppressiven Effekt 
durch Oligodinukleotide aus Telomeren von Säugetieren auf die Aktivierung 
von B Zellen beobachtet. Sie unterdrückten die Proliferation, den 
Isotypenklassenwechsel, Plasmazellendifferenzierung und 
Immunglobulinproduktion. Unterdrückung der B Zellantwort durch 
telomerische Oligodinukleotide könnte einen natürlichen Mechanismus 
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darstellen, der die B Zellaktivierung unter entzündlichen Bedingungen 
kontrolliert.  
 
Die Ergebnisse, die in dieser Dissertation beschrieben werden, geben neue 
Einsichten in die Rolle von B Zellen in der Regulation der Immuntoleranz. 
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4 Abbreviations 
  
AID/AICDA Activation-Induced (Cytidine) Deaminase 
APC  antigen-presenting cell 
APRIL  a proliferation-induced ligand 
B10  IL-10-competent B cell 
BAFF  B-cell activating factor of the TNF-family  
BAFF-R BAFF receptor 
B10pro progenitor B10 
BCR  B cell receptor 
BCMA  B cell maturation antigen  
Be  B effector 
BSA  bovine serum albumin 
CIA  collagen-induced arthritis 
CH  immunoglobulin heavy chain constant  
CHS  contact hypersensitivity 
CV  immunoglobulin heavy chain variable  
CSR  class switch recombination 
CTLA-4 cytotoxic T lymphocyte antigen 4 
D  immunoglobulin heavy chain diversity region 
DAMP  danger-associated molecular pattern 
DC  dendritic cell 
DTH  delayed-type hypersensitivity 
ds  double stranded 
EAE  experimental autoimmune encephalomyelitis 
GARP  glycoprotein A repetitions predominant 
HR  histamine receptor 
ICOS  inducible T cell costimulator  
Ig:  immunoglobulin 
IGH@  immunoglobulin heavy locus  
IGK@  immunoglobulin kappa locus 
IGL@  immunoglobulin lambda locus 
ILC  innate lymphoid cell 
IL-10-/- B cell chimeric mice specifically lacking IL-10-producing B cells 
IPEX  immunodysregulation polyendocrinopathy enteropathy X-linked  
iTreg  induced Treg 
JH  immunoglobulin heavy chain joining region 
L  ligand 
LAT  linker for activation of T cells 
LPS  lipopolysaccharide 
LYN  tyrosine-protein kinase Lyn  
mAb  monoclonal antibody 
MHC  major histocompatibility complex  
MOG  myelin oligodendrocyte glycoprotein  
MZ  marginal zone 
NK  natural killer 
nTreg  natural Treg 
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NOD  nucleotide-binding oligomerization domain  
ODN  oligodeoxynucleotide 
OVA  ovalbumin  
PAMP  pathogen-associated molecular pattern 
PCR  polymerase chain reaction 
PD-1  programmed cell death protein 1  
pDC  plasmacytoid dendritic cell 
PRR  pattern recognition receptor 
RAG  Recombination activating gene 
RIG-I  retinoic acid-inducible gene 1 
sIgA  secretory IgA 
SIT  specific immunotherapy 
SLE  systemic lupus erythematosus 
STAT  signal transducer and activator of transcription 
SYK  spleen tyrosine kinase 
ss  single stranded 
TACI  Transmembrane activator and cyclophilin ligand interactor 
TIR  Toll/IL-1R homology 
TIRAP TIR domain containing adaptor protein 
T2-MZP transitional 2 marginal zone precursor  
TCR  T cell receptor 
TD  thymus-dependent 
TFH  T follicular helper 
TLR  toll-like receptor  
TNP  trinitrophenyl 
TRAF  TNF receptor associated factors 
TRAM  TLR4 adaptor protein  
Treg  regulatory T cell 
TRIF  TIR-domain-containing adaptor-inducing IFN-β 
Th  T helper  
TI  thymus independent 
VH  immunoglobulin heavy chain variable region 
wt  wild type 
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5 General introduction 
5.1 History 
The earliest documented cases of allergies date back to ancient times. King 
Menes of Egypt who lived around 3000 BC, died after a wasp sting. In the 
Roman Empire, several members of the Julio-Claudian imperial house 
suffered from atopic diseases. Emperor August suffered from seasonal rhinitis 
and pruritic skin disease. Claudius suffered from rhinoconjunctivitis and his 
son Brittanicus was allergic to horse dander. 
 
In 1809 John Bostock was the first to accurately describe hay-fever as a 
disease that affected the upper respiratory tract.1 Later, in 1873, Charles 
Blackely identified pollen as causative agent for allergic reactions.2 In 1906, 
Clemens von Pirquet introduced the term ‘allergy’ (Greek allos, other; ergon, 
reaction), to describe the phenomenon that patients who had previously 
received horse serum or smallpox vaccine showed an altered reaction to a 
subsequent application.3 This initial description of an allergic reaction included 
protective immunity as well as hypersensitivity and basically relates to the 
concept of immunological memory.  
 
In the late 1900s, von Behring and Kitasato experimented with tetanus and 
diphtheria toxins. They immunized animals with cell-free filtrates of these 
pathogens and demonstrated that the serum from these immunized animals 
could protect a naïve recipient from developing disease. They proposed a 
‘lock and key’ interaction between receptors (of immune cells) and specific 
toxins (derived from pathogens) to be the trigger for antibody production.4 
This lock and key principle was confirmed by Pauling in 1940.5 Heidelberger 
and Avery demonstrated that antibodies were proteins that could precipitate 
when antigens were added.6 In 1921 Carl W. Prausnitz and Hans Küster 
demonstrated that reactivity to an allergen could be transferred by intradermal 
injection of serum from a sensitized individual to a healthy recipient.7 In the 
late 1960s, IgE was discovered independently by two different groups: 
Kimishige and Teruko Ishizaka8 and Hans Bennich and S.G.O Johansson.9  
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Currently, the term allergy is used synonymously with IgE-mediated allergic 
disease and represents the first type of four classical hypersensitivity 
responses as proposed by Coombs and Gell in 1963.10  
 
5.2 The immune system 
The immune system can be divided into two distinct, but highly interactive 
components: innate and adaptive immunity. The principal difference between 
the two is that innate immunity is germline-encoded, while a key feature of 
adaptive immunity is the rearrangement and mutation of the genes encoding 
B cell receptors (BCR) and T cell receptors (TCR) resulting in a broad 
repertoire of receptors, each with its own unique structure and resulting 
antigen-specificity. Innate immunity provides quick and general protection 
against invading microbes. The key components that make up the innate 
immune system are the skin, lung and intestinal epithelium, mucosal layers 
and other physical barriers. The major innate immune cell types are 
monocytes, macrophages, dendritic cells (DCs), granulocytes, 
megakaryocytes and innate lymphoid cells (ILCs). ILCs form a recently 
described family of innate cells consisting of ILC1, ILC2, ILC3, LTi and natural 
killer (NK) cells. NK cells have been known for many years already and can 
be considered the founding members of the ILC family.11 Adaptive immune 
responses to newly encountered antigens require a relatively long time to 
develop compared to innate responses. The main cell types of the adaptive 
immune system are B and T lymphocytes. 
5.2.1 Innate immune system 
Cells and tissues of the innate immune system 
The innate immune system provides a first line of defense against invading 
pathogens. It involves (I) physical barriers that are formed by the cornified 
layers and keratinocytes of the skin as well as the epithelial and mucosal 
layers of the respiratory, urogenital and gastrointestinal tracts; (II) Soluble 
factors including antimicrobial peptides, lysozyme and chemokines as well as 
acute phase proteins such as C-reactive protein, anti-bacterial proteins such 
as mannose-binding lectin and finally the complement system, which consists 
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of a complex system of plasma proteins that can be activated through 
different pathways and ultimately leads to lysis of microbes; (III) Cytokines 
play a key role in the regulation of innate immune cells as well as in the 
crosstalk between the innate and adaptive immune responses;12 (IV) Immune 
cells including phagocytic cells (macrophages, neutrophils and DCs), 
granulocytes (basophils and eosinophils), mast cells, and NK cells. Some 
immune cell types cannot be easily classified as a member of the innate or 
adaptive immune system. The recently described family of ILCs fits the 
definition of innate immune cells as cells that do not have genetic receptor 
rearrangements. However, these cells appear to require priming phases to be 
fully functional and therefore may not be a typical first line of defense quick 
responder cell type.11 Splenic marginal zone B cells and γδ T cells may also 
be regarded as innate-like immune cells, since they can mount rapid humoral 
responses against blood-borne antigens and do not frequently have mutated 
antigen receptor genes.13, 14 
 
Receptors of the innate immune system 
Many innate immune cells express germline-encoded pattern recognition 
receptors (PRRs). The main groups of PRRs are Toll-like receptors (TLRs), 
retinoic acid-inducible gene 1 (RIG-I)-like receptors, nucleotide-binding 
oligomerization domain (NOD)-like receptors, and C-type lectin receptors. 
These receptors recognize a broad range of conserved pathogen-associated 
molecular patterns (PAMPs). These PAMPs are typically molecules that are 
not expressed by mammalian cells but are essential for survival or 
proliferation of pathogens. Recent studies have demonstrated that certain 
PRRs also recognize endogenous molecules that are released by damaged 
cells. These endogenous PRR-activating molecules are also referred to as 
danger-associated molecular patterns (DAMPs). Most PRRs upregulate 
expression of genes that mediate inflammatory responses including pro-
inflammatory cytokines like type I interferons, IL-1, IL-6 and TNF as well as 
chemokines and antimicrobial proteins.15 
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TLRs form the best-characterized PRR family and they recognize a broad 
range of pathogens including bacteria, viruses, parasites, fungi and protozoa. 
All TLRs consist of an N-terminal leucine-rich repeat domain, a 
transmembrane region and an intracellular Toll/IL-1R homology (TIR) domain. 
So far, 10 human and 13 murine TLRs have been described. Here I will focus 
on the human TLRs. TLR1, TLR2, TLR4, TLR5 and TLR6 are expressed on 
the cell membrane while TLR3, TLR7, TRL8, TLR9 and TLR10 are found in 
endolysosomes. Each TLR recognizes a distinct group of microbial (and in 
some cases host-derived) ligands and some TLRs function as heterodimers 
(listed in table 1 and illustrated in figure 1). TLR1 forms dimers with TLR2 and 
recognizes bacterial triacylated lipoproteins, TLR2 alone recognizes 
lipoproteins from varying origin, TLR3 recognizes viral double stranded RNA 
(dsRNA) and TLR4 recognizes bacterial lypopolysaccharide (LPS). Binding of 
LPS to TLR4 requires interaction with CD14 and the adaptor protein MD2. 
TLR5 recognizes bacterial flagellin. TLR6 forms functional heterodimers with 
TLR2, which recognize bacterial and viral diacylated lipoproteins, TLR7 and 8 
recognize single stranded RNA (ssRNA), which can be of viral, bacterial or 
host origin. TLR9 recognizes unmehtylated DNA with CpG motifs, which are 
primarily from microbial origin. In humans TLR9 is mainly expressed by B 
cells and plasmacytoid DCs (pDCs).16 The optimal ligand for activating human 
TLR9 consists of unmethylated CpG dinucleotides and a TCGTT and/or 
TCGTA motif in its flanking region. Three major classes of CpG ODNs have 
been described: A-class (also known as D-type ODNs), B-class (also known 
as K-type ODNs) and C-class. A-class CpG ODNs consist of a mixed 
phosphodiester–phosphorothioate backbone and contain a hexameric purine–
pyrimidine–CG–purine–pyrimidine motif flanked by self-complementary bases 
and a poly-G tail at its 3’ end. A-class CpG ODNs potently activate human 
pDC to produce IFN-α.17 B-class CpG ODNs have multiple CpG motifs on a 
phosphorothioate backbone and strongly induce proliferation and activation of 
B cells.18, 19 C-class CpG ODNs have structural features of both A- and B-
class CpG ODNs as they typically consist of a phosphorothioate backbone 
containing a 5’ TCGTCG sequence (similar to B-class CpG ODNs) and have 
palindromic sequences combined with stimulatory CpG motifs (similar to A-
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class CpG ODNs) but no poly G motif. C-class CpG ODNs can activate both 
human pDCs and B cells.20 All three classes of CpG ODNs depend on TLR9 
for signaling. Under certain conditions TLR9 also recognizes self DNA which 
can lead to autoimmune diseases like systemic lupus erythematosis (SLE).21 
The ligand for TLR10 remains unknown. All nucleotide-binding TLRs are 
localized in endolysosomes. This compartmentalization prevents unwanted 
chronic activation by host cell-derived nucleotides.15  
 
With the exception of TLR3, all TLRs can signal through the adapter molecule 
MyD88. TLR1/2 and TLR2/6 signal through TIR domain containing adaptor 
protein (TIRAP), which is alternatively named MyD88 adapter-like (MAL) and 
MyD88, while TLR3 does not use MyD88 but signals through a different 
adapter molecule called TIR-domain-containing adaptor-inducing IFN-β 
(TRIF). TLR4 utilizes TIRAP/MAL and MyD88 but can also signal through 
TLR4 adaptor protein (TRAM) and TRIF. TLR5, 7, 8 and 9 can only signal 
through MyD88. Activation of MyD88 is followed by recruitment of IRAK1/4 
and TRAF6 ultimately leading to the activation of NF-κB, MAPK and AP-1 and 
production of inflammatory cytokines. TLR7/8 and TLR9 signaling through 
MyD88 and IRAK4 induces, in addition to NF-κB-dependent cytokine 
production, activation of IRF7 and ultimately production of type I interferons 
(illustrated in figure 1).15 The ultimate outcome of TLR signaling in terms of 
cellular responses, including cytokine production, strongly depends on the cell 
type. DCs respond to TLR stimulation by upregulation of major 
histocompatibility complex (MHC) and costimulatory molecules as well as 
production of proinflammatory cytokines including TNF-α, IL-1, IL-6 and Th1-
inducing cytokines IL-12 and IL-18. Lack of TLR signaling as demonstrated in 
MyD88-deficient mice leads to enhanced Th2 responses and consequently 
elevated IgE production.22 In the following section the focus will lay on the 
effect of TLR signaling on human B cells. 
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Figure 1. Ligands, cellular localization and initiation of signaling of TLRs. 
TLR1, TLR2, TLR5 and TLR6 are located on the surface membrane, while 
TLR3, TLR7, TLR8 and TLR9 are located on endosomal membranes. TLR1/2 
heterodimers recognize triacylated bacterial lipoproteins, while TLR2/6 
heterodimers bind diacilylated lipoproteins. Both heterodimers signal through 
TIRAP and MyD88. TLR3 recognizes dsRNA and signals through TRAM and 
TRIF. TLR7 and TLR8 recognize ssRNA and both signal through MyD88. 
TLR9 recognizes hypomethylated CpG DNA and also signals through MyD88. 
 
TLRs in B cell responses 
Human peripheral B cells express TLR1, TLR6, TLR7, TLR8, TLR9 and 
TLR10. These TLRs can be detected in resting naïve B cells and are strongly 
upregulated upon B cell activation in response to BCR or CD40 ligation and 
exposure to CpG ODN. Circulating memory B cells also show higher 
expression of these TLRs than naïve B cells. TLR9 and TLR10 are among the 
strongest expressed TLRs on B cells. Murine and human B cells have a 
similar expression profile of TLRs, with the exception that human B cells do 
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not express TLR4 while this receptor is readily detected in murine resting B 
cells.23  
 
TLR signaling provides a third signal in addition to antigen (through BCR 
signaling) and T cell help (through CD40 ligation) that is required for efficient 
B cell proliferation, isotype switch and plasma cell differentiation. Pasare and 
Medzitov showed that mice that specifically lacked MyD88 in B cells mounted 
less efficient antibody responses to thymus-dependent (TD) antigens.24 The 
expression of TLRs is strongly elevated in activated and memory B cells. As a 
result, these cells respond much stronger to TLR signaling (which reflects 
microbial exposure) and may be triggered by TLR signaling to differentiate to 
immunoglobulin-producing plasma cells while naïve cells first require antigen-
specific activation.25 TLR signaling can also lead to cytokine production in B 
cells as will be discussed in the section concerning regulatory B cells. The 
role of TLR signaling in the regulation of class-switch recombination (CSR) 
will be discussed below in the section concerning CSR. 
 
Table 1. TLRs, their cellular localization and ligands. (Adapted from15) 
TLR Localization Ligand Origin of the Ligand 
TLR1 Plasma membrane Triacyl lipoprotein Bacteria 
TLR2 Plasma membrane Lipoprotein Bacteria, viruses, parasites, self 
TLR3 Endolysosome dsRNA Viruses 
TLR4 Plasma membrane LPS Bacteria 
TLR5 Plasma membrane Flagellin Bacteria 
TLR6 Plasma membrane Diacyl lipoprotein Bacteria, viruses  
TRL7/8 Endolysosome ssRNA Viruses, bacteria, self 
TLR9 Endolysosome CpG-DNA Viruses, bacteria, protozoa, self 
TLR10 Endolysosome Unknown Unknown 
5.2.2 Adaptive immune system 
T and B lymphocytes are the cells that form the core of the adaptive immune 
system. They express highly specific and diverse antigen-specific cell-surface 
receptors. Furthermore these cells are unique in their capacity to generate a 
memory compartment following initial antigen exposure. This allows rapid 
clearance of pathogens upon a secondary exposure. The two pillars of the 
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adaptive system response are humoral (mediated by B cells and 
immunoglobulins) and cell-mediated immunity (mediated by T cells). This 
section outlines the basic mechanisms that define adaptive immune 
responses with an emphasis on B cells and humoral immunity. 
 
Generation of receptor diversity in T and B lymphocytes 
Both T and B cells have surface-membrane-associated receptors that enable 
specific recognition of antigens: TCR and BCR. An intriguing feature of T and 
B cells is the wide range of antigens that are specifically recognized by their 
surface receptors. The variety of different antigen-specific TCR and BCR 
expressed by T and B lymphocytes respectively is much larger than can be 
expected based on the size of the genome. Below I will describe the 
mechanism that generates this tremendous diversity of antigen-specific 
receptors in B cells. TCR diversity is generated in a similar manner but will not 
be discussed here. 
 
The genes encoding the human BCR heavy and light chains are located in the 
immunoglobulin heavy locus (IGH@) on chromosome 14 and the 
immunoglobulin light chain lambda (IGL@) and kappa (IGK@) loci on 
chromosomes 22 and 2 respectively. The germline IGH@ locus contains 
>100 functional variable (V) gene segments, 27 diversity (D) gene segments 
and 9 joining (J) segments. Both light chain loci contain 30-35 V segments 
and 4-5 J segments while D segments are absent from light chain loci. The 
key mechanism that is required for the generation of receptor diversity is a 
process called V(D)J recombination. In order for a B lymphocyte to express a 
functional BCR, it needs to rearrange the germline V(D)J genes in such a way 
that one V, one D (only for IGH@) and one J segment are selected and joined 
to form a new V(D)J exon (This process is illustrated for the IgH chain locus in 
figure 2). This is the first step in generating receptor diversity. A second layer 
of diversification is added through removal or addition of nucleotides at the 
junctions between the V and D, the D and J, or the V and J segments.26 
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Figure 2. V(D)J recombination of the immunoglobulin heavy chain locus. 
Germline DNA contains an array of different V, D and J genes. During the 
process of V(D)J recombination one V, one D and one J gene are fused to 
form a recombined V(D)J gene. First a single D and a single J gene 
recombine and any intervening DNA is excised and deleted from the 
chromosome. Then V to DJ recombination takes place resulting in the 
formation of a rearranged VDJ gene. The mature mRNA transcript that is 
generated from this sequence contains the rearranged VDJ segment together 
with the constant region of the IgH chain (Cµ or Cδ in mature naïve cells) and 
translates into an IgM or IgD immunoglobulin heavy chain protein. (Adapted 
from27). 
 
T lymphocytes 
T cells mature in the thymus where the cells that strongly recognize self-
antigens presented by thymic epithelial cells are eliminated to prevent the 
maturation of autoreactive T cells. Furthermore, T cells are positively selected 
for their capacity to interact with MHC class I or MHC class II molecules. 
During this stage the fate of the T cell to become a CD4+ or a CD8+ T cell is 
determined. Thymus-selected T cells are released into the circulation as 
mature naïve T cells and can be activated when they are presented with their 
cognate antigen in the context of MHC class I (for CD8+ T cells) or MHC class 
II (for CD4+ T cells). CD8+ T cells are cytotoxic cells that can lyse virus-
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infected host cells and tumor cells. CD4+ T cells are also referred to as helper 
T cells because they help other cells to carry out their effector function.  
 
CD4+ T cells 
Naïve CD4+ T cells can differentiate into different types of effector T cells 
depending on the context in which they are activated. The best-characterized 
Th cell subsets are Th1, Th2, Th17, natural (n) regulatory T cells (Treg) and 
induced (i)Treg cells. DCs are essential during this process. DCs capture 
antigens, migrate to draining lymph nodes and present antigenic peptides on 
MHC class II molecules to naïve T cells. DCs are activated and mature in 
response to PRR signaling as a result of exposure to PAMPs. The cytokines 
that are secreted by DCs during their interaction with antigen-specific naïve 
CD4+ T cells are crucial for the fate of these T cells. If IL-4 is present at this 
stage, CD4+ T cells mainly differentiate to Th2 cells, which secrete IL-4, IL-5 
and IL-13.28 IL-12 induces IFN-γ-producing Th1 cells while a combination of 
IL-6, TGF-β and IL-1β induces Th17 cells, which produce IL-17A, IL17F and 
IL-22.29 Furthermore, some less clearly defined Th subsets have been 
described including IL-9-producing Th9 cells, IL-10-producing Tr1 cells, TGF-
β-producing Th3 cells, and IL-21-producing T follicular helper (Tfh) cells and 
IL-22-producing Th22 cells.30, 31 Most of these Th cell subset have a master 
transcriptional regulator that drives the differentiation program. These 
transcription factors are induced by APC-derived cytokines that initiate the 
differentiation of naïve T cells and the following are generally accepted: Tbet 
for Th1 cells, GATA3 for Th2 cells, RORγt for Th17 cells, Bcl6 for Tfh cells.31 
PU.1 has been proposed as the master regulator for Th9 cells.32 nTregs and 
iTregs express FoxP3.33 A master regulator for Tr1, Th3 and Th22 cells 
remains to be identified.  
 
Regulatory T cells 
Regulatory T cells are key factors in the maintenance of peripheral tolerance. 
There are two major types of regulatory T cells: nTreg and iTreg cells. 
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nTregs are characterized by the expression of high levels of the IL-2Rα chain 
(CD25) and the transcription factor FoxP3. The majority of nTregs is 
generated in the thymus as antigen-primed and mature T cells. Under certain 
conditions nTregs can develop in the periphery from conventional naïve T 
cells.34 Their main function is to suppress effector cells at sites of 
inflammation. nTregs strongly suppress proliferation of both naïve and 
memory CD4+ T cells.35 FoxP3 is critical for the development of nTreg cells 
and human mutations in the FOXP3 gene lead to dysfunctional Tregs 
culminating in immunodysregulation polyendocrinopathy enteropathy X-linked 
(IPEX) syndrome, which is characterized by the development of autoimmune 
diseases, inflammatory bowel disease and allergies.36 activated nTreg cells 
produce immunosuppressive cytokines including IL-10 and TGF-β. 
Interestingly, the suppressive function of nTregs does not critically depend on 
these cytokines.37 nTreg cells express cytotoxic T lymphocyte antigen 4 
(CTLA-4) and programmed cell death protein 1 (PD-1) on their surface 
membrane. Both molecules belong to the CD28 family of co-stimulatory 
receptors and negatively regulate signaling in activated T cells. Another 
nTreg-associated surface marker is glucocorticoid-induced tumor necrosis 
factor receptor (GITR). Stimulation of GITR inhibits nTreg-mediated 
suppression through breaking the anergic state of nTreg cells.38, 39 The 
frequency of nTregs in human PBMC is approximately 3%. 
 
Induced Treg cells are suppressor cells that develop in the periphery from 
conventional CD4+CD25- T cells. These cells exert their function primarily in a 
contact-independent manner through secretion of suppressive cytokines such 
as IL-10 and TGF-β.40 There are two major types of induced Treg cells: Tr1 
and Th3 cells.  
 
Tr1 cells can be generated from naïve or resting CD4+ T cells. This was first 
demonstrated by stimulation of naïve T cells from OVA TCR transgenic mice 
(all T cells are specific for OVA in this model) with IL-10 and OVA. This led to 
the differentiation of a Th cell subset with a cytokine profile that was different 
from Th1 or Th2 cells and included IL-10, IL-5 and IFN-γ production in 
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absence or presence of TGF-β.41 Like nTreg cells, Tr1 cells constitutively 
express CTLA-4, while a subset of Tr1 cells expresses PD-1. Tr1 cells can 
suppress the activation of naïve and memory T cells, Th1 and Th2 responses 
and the antigen-presentation capacity of DCs. Tr1-mediated suppressive 
mechanisms critically depend on IL-10.40 
 
Th3 cells were initially identified in an experimental autoimmune 
encephalomyelitis (EAE) model. Mice were orally exposed to an autoantigen 
(myelin base protein) to which autoreactive T cells were generated. The 
majority of myelin base protein-specific CD4+ T cells secreted TFG-β and 
protected against EAE.42 Th3 cell-mediated immune suppression is antigen-
nonspecific and primarily mediated through secretion of TGF-β.40 
 
B lymphocytes 
B cells are responsible for the generation of humoral immune responses. 
These cells are the precursors of immunoglobulin-producing plasma cells. B 
cell develop in the bone marrow. Like all myeloid and lymphoid cells, B cells 
differentiate from hematopoietic stem cells. The earliest B cell-specific 
precursors are called pre-pro B cells. Pre-pro B cells still have germline 
immunoglobulin heavy and light chain genes and do not express CD19 or 
BCR on their surface membrane. These cells express the IL-7 receptor (IL-7 
is essential for proliferation of B cell precursor cells) and downregulate c-kit 
expression (which is expressed at earlier developmental stages). The 
expression of recombination activating genes (RAG)1 and RAG2 and terminal 
deoxynucleotidyl transferase (TdT) are upregulated at this stage. These 
genes encode enzymes that are essential for the process of V(D)J 
recombination. The next B cell precursor stage is the pro-B cell stage. At this 
stage expression of B cell lineage-specific transcription factors including 
Paired box protein-5 PAX5 and early B-cell factor 1 (EBF1) is strongly 
upregulated. Furthermore, surface expression of the B cell lineage marker 
CD19 and the BCR-associated adaptor proteins CD79α and CD79β, which 
mediate BCR signaling, is upregulated. Transition from pro B cells to early Pre 
B cells is characterized by surface expression of IgM with a rearranged VDJ 
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on its IgH chain. The Ig light chain has not rearranged at this stage and 
surface IgM heavy chains are linked to so-called surrogate light chains. Early 
Pre B cells that fail to express surface IgM with surrogate light chains will not 
progress to the late pre B cell stage and are eliminated. Late Pre B cells 
undergo VJ recombination of their Ig light chain genes and then progress to 
the immature B cell stage expressing surface IgM consisting of rearranged 
IgH and Ig light chains. If an immature B cell recognizes self antigens it can 
either become anergic (non-responsive) or undergo another round of V(D)J 
recombination (this process is referred to as receptor editing) to avoid the 
generation of autoreactive B cells. Non-autoreactive immature B cells are 
released into the circulation and migrate to the spleen where they undergo 
further maturation. Mature B cells can be roughly divided into two subsets: 
conventional follicular B cells (frequently referred to as B-2 cells) and non-
conventional extrafollicular B cells (including B-1 cells, which have been 
mainly characterized in the mouse and marginal zone (MZ) B cells).43, 44  
 
B cell responses to thymus-dependent antigens 
Follicular B cells participate in TD responses. These cells interact with helper 
T cells in germinal centers that are mainly found in secondary lymphoid 
organs. B cell activation to T-cell dependent antigens requires BCR 
stimulation and CD40 ligation. Antigens can be captured directly by B cells or 
can be presented by follicular DCs in the lymphoid follicles. BCR stimulation is 
typically mediated through binding of a specific antigen to the BCR leading to 
internalization, processing and presentation of antigenic peptides in MHC 
class II molecules. Antigen can be presented in this way to CD4+ T cells, 
which are activated in this manner. B cells are believed to be poor activators 
of naïve T cells and primarily interact with effector memory CD4+ T cells. 
Activated CD4+ T cells upregulate CD40L and secrete cytokines. The type of 
cytokines that are produced by these T cells depends on how these cells were 
primed as naïve T cells. CD40L binds to CD40 on the B cell. CD40-CD40L 
interaction and the local cytokine milieu provide the second signal that is 
required for efficient B cell activation including proliferation, CSR and plasma 
cell differentiation.  
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Recently a subset of CD4+ helper T cells was described that specializes in B 
cell help during germinal center reactions. These cells are called Tfh cells. 
The master regulator transcription factor for Tfh cells is Bcl-6 and Tfh cells 
express high levels of CXCR5, PD-1 and inducible T cell costimulator (ICOS). 
Due to their expression of CXCR5, these cells migrate towards CXCL13, 
which is found in B cell follicles of germinal centers. The signature cytokine of 
TFH cells is IL-21, which induces strong B cell proliferation and promotes CSR 
and plasma cell differentiation.45 Besides IL-21, TFH cells can produce IL-4, 
IFN-γ and IL-10. To date, the developmental relation between Tfh cells and 
other helper T cells subsets remains controversial. Tfh cells may represent an 
independent lineage of specialized cells that aid B cells during germinal 
center reactions but they might also derive from other differentiated Th cell 
subsets.46 Nevertheless, it is clear that these cells are essential for efficient 
germinal center reactions involving follicular B cells. 
 
Follicular B cells that receive T cell help (through CD40L and cytokines) will 
become germinal center B cells and upregulate Bcl6. These cells upregulate 
activation-induced deaminase (AID) expression and will undergo CSR and 
somatic hypermutation. Somatic hypermutation induces point mutations in the 
recombined V(D)J genes. These mutations may lead to increased or 
decreased affinity for the antigen to which the BCR is specific. Within the 
follicles, follicular DCs present antigens to B cells, which compete for binding 
of the antigen. A B cell expressing a BCR with high affinity for the antigen will 
receive strong survival signals and as a result antigen-specific B cells with a 
high affinity for the antigen will survive. This process is referred to as affinity 
maturation.47, 48 The B cells that emerge from such a germinal center reaction 
will either become circulating memory B cells or plasma cells. The majority of 
plasma cells will home to the bone marrow where some of them will find a 
niche, where they can survive for many years as long-living immunoglobulin-
secreting plasma cells that provide a constant source of high-affinity antigen-
specific immunoglobulins.49 
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B cell responses to thymus independent antigens 
Extrafollicular B cells including B-1 cells and MZ B cells are the main B cell 
subsets that mount rapid thymus-independent (TI) humoral responses. The 
term TI originates from experiments performed with mice lacking a thymus 
and as a result lacking T cells. B cell responses that are not significantly 
impaired in thymectomized mice are considered to be independent of T cell 
help. TI responses are rapidly induced mostly in response to conserved 
microbial carbohydrate or glycolipid structures. These responses result in the 
production of polyspecific low affinity IgM antibodies and do not involve 
somatic hypermutation. Extrafollicular B cells receive activation signals that 
resemble CD40 ligation in the form of secreted factors like B-cell activating 
factor of the TNF-family (BAFF) and a proliferation-induced ligand (APRIL) 
that are produced among others by TLR-activated DCs and macrophages.47  
 
Immunoglobulins 
Immunoglobulins (alternatively named antibodies) are identical to the BCR of 
the B cell from which they originate, with the exception of a C-terminal 
sequence that anchors the molecule to the cell membrane. As a result 
immunoglobulins are secreted and do not form surface-bound receptors. 
Immunoglobulins are key mediators of humoral immunity that are secreted by 
plasma cells and are found in blood and tissue fluids of vertebrates. They are 
composed of two identical pairs of heavy and light chains (illustrated in figure 
3). Immunoglobulin light chains consist of a constant (CL) and a variable (VL) 
domain. Immunoglobulin heavy chains consist of a variable domain (VH) 
together with 3 constant domains (CH) and a hinge region (IgG, IgA and IgD) 
or 4 CH domains and no hinge region (IgM and IgE). A functional 
immunoglobulin monomer is composed of two pairs of heavy and light chains 
that are linked by disulfide bridges between their hinge regions (IgG, IgA and 
IgD) or between their CH2 domains (IgM and IgE). 
 
Immunoglobulins have a functionally polarized structure, with on one side the 
Fab region harboring a hypervariable region, which is responsible for antigen 
binding, and on the other side a constant Fc region. The structure of the 
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constant region determines the effector function of the immunoglobulin. 
Immunoglobulins are typically classified according to the isotype of their 
heavy chain. In humans there are five major immunoglobulin heavy chain 
isotypes: IgM, IgD, IgG, IgA and IgE. Each of these isotypes mediates distinct 
functions through interaction with specific receptors on effector cells and 
serum factors. This adds another level of regulation to humoral immune 
responses.  Different immunoglobulin isotypes are secreted as monomers or 
multimers. IgG and IgE molecules are secreted as a monomer while IgA is 
typically secreted as a dimer and IgM as a pentamer. The process 
responsible for the generation of different immunoglobulin heavy chain 
isotypes is called CSR. 
 
Biological functions of immunoglobulins 
Immunoglobulins exert a wide range of biological activities. An important 
function of immunoglobulins in host defense is neutralization of microbes. 
Pathogen-specific antibodies can neutralize the capacity of viruses or 
intracellular bacteria to enter host cells and thereby prevent infection and 
replication of the pathogen.27 Immunoglobulins can also activate the 
complement system by recruiting the complement protein C1 to an opsonized 
microbe. This initiates the so-called classical complement activation cascade, 
which ultimately leads to elimination of the target microbe through the 
formation of a membrane attack complex.50 Another mechanism through 
which immunoglobulins regulate immune responses is by interaction with Fc 
receptors that are expressed on effector cells. This triggers specific responses 
in effector cells upon recognition of a molecule that is specifically recognized 
by the Fc receptor-bound immunoglobulin. Some examples of Fc receptor-
mediated effector functions of different cell types are degranulation of mast 
cells and basophils and phagocytosis by neutrophils and monocytes.27 
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Figure 3. Structure of an immunoglobulin molecule. Immunoglobulins are Y-
shaped molecules that consist of two heavy (H) chains and two light (L) 
chains. The light chains contain a constant (CL) and a variable (VL) domain. 
The heavy chains contain a VH region and 3 or 4 CH domains depending on 
the isotype. IgG, IgA and IgD have 3 CH domains and a hinge region between 
CH1 and CH2 while IgE and IgM have 4 CH domains and no hinge regions. 
The two heavy chains are linked through disulfide bonds (S-S) between their 
hinge regions (IgG, IgA and IgD) or between their CH2 domains (IgE and IgM) 
and each H chain is linked to a L chain by a disulfide bond. Adapted from27. 
 
Class switch recombination 
CSR is the mechanism that is required for the production of different 
immunoglobulin isotypes. To understand the process of CSR, it is important to 
understand the structure of the immunoglobulin (Ig) heavy (H) chain locus. 
Each Ig molecule consists of two heavy (IgH) and two light chains, both of 
which both contain variable (V) and constant (C) regions. The genes encoding 
the heavy chains of human immunoglobulins are located on chromosome 14. 
The region of the heavy chain that determines antigen-specificity is made up 
by the variable (VH), diversity (D) and joining (JH) exons that are randomly 
combined during early B cell development to form a VH(D)JH cassette. The 
VH(D)JH is located upstream of the C exons. The C region of the IgH chain 
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determines the isotype of the Ig. Each CH gene has its own promoter, an 
intervening (I) exon and a switch (S) region directly upstream of the coding 
exons.51, 52 In mature naïve B cells, the VH(D)JH cassette is linked to the 
constant region of the µ chain (Cµ).53 Consequently, mature naïve B cells 
express surface IgM and, as a result of alternative splicing, IgD as their BCR 
(Illustrated in figure 4). 
 
Upon activation, naïve B cells can undergo CSR, a process in which the B cell 
changes the isotype of the produced immunoglobulin while its antigen-
specificity is retained. There are 9 human IgH chain isotypes: IgM, IgD, IgG1, 
IgG2, IgG3, IgG4, IgA1, IgA2 and IgE and 8 murine Ig isotypes: IgM, IgD, 
IgG1, IgG2a, IgG2b, IgG3, IgA and IgE.51 Essentially CSR is the process in 
which double strand breaks are generated at two different S regions within the 
IgH chain locus followed by the deletion of the intervening DNA and ligation of 
the remaining S regions. The S regions are located upstream of the gene 
segments encoding the various IgH chains. The generation of double strand 
(ds) DNA breaks at selected S regions requires the activity of several 
enzymes that include AID, uracil DNA glycosylase (UNG) and 
apyrimidic/apurinic endonucleases (APE).54 The expression of ε-germline 
transcripts precedes CSR to IgE and is required for IgE synthesis. The 
proposed mechanism by which germline expression facilitates CSR is the 
‘accessibility model’. This model implies that germline transcription (induced 
by cytokines) leads to opening of the chromatin structure of the S region 
making it accessible to AID. AID converts cytosines to uracils in such a 
transcriptionally active S region.55-57 These uracils can be excised by the DNA 
base excision repair enzyme UNG leading to the generation of abasic sites 
that can be processed by APE1 leading to the formation of nicks and 
ultimately result in dsDNA breaks.58 The dsDNA breaks are repaired by the 
non-homologous end-joining repair system resulting in the ligation of a 
downstream CH region (Cε in the case of IgE CSR) next to the VDJ gene 
segments (Figure 4).52 The ends of the excised DNA can be joined resulting 
in the formation of an extrachromosomal circular DNA (also referred to as 
  5 General introduction 
 
 33 
excision circle). These excision circles can be detected using polymerase 
chain reaction (PCR) and are indicative of a recent CSR event.  
 
 
Figure 4. Organization of the human immunoglobulin heavy chain locus in 
mature naive B cells and class switch recombination to IgE. Mature naive B 
cells carry the germline IgH chain locus. These cells have their rearranged 
VH(D)JH  domain located directly upstream of the Cµ domain and as a result 
they express IgM and IgD as surface receptors. CSR to IgE is requires ε-
germline transcription and finally results in the generation of double strand 
DNA breaks at Sε followed by ligation of the Sµ to Sε. Adapted from59. 
 
The selection of the CH chain gene that will be recombined to VDJ region 
depends on the expression of germline IgH gene expression. In murine B 
cells it has been shown that IL-4 selectively induces ε and γ1-germline 
transcription while IFN-γ selectively induces γ2b germline transcription.60 In 
human B cells, there is not such a specific regulation of germline transcripts. It 
was found that γ1, γ2, γ3 and ε germline transcripts are constitutively 
expressed in naïve tonsillar B cells. Stimulation with anti-CD40 + IL-4 
upregulated expression of γ1, γ2, γ3, γ4 and ε germline transcripts. ε germline 
transcript expression was however upregulated 10-fold stronger in response 
to anti-CD40 + IL-4 than γ germline expression.61 On the other hand, IL-10 
enhances survival, proliferation, differentiation and isotype switching of human 
B cells.62 IL-10 augments IgG4 production, whereas it inhibits IL-4-induced 
IgE CSR.63-65 
Immunoglobulin isotypes 
IgM 
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IgM makes up 5-10% of the total circulating immunoglobulins and is secreted 
from plasma cells mostly as a pentamer (and to a lesser extent as a hexamer) 
containing five (or six) IgM molecules that are covalently linked at their Fc 
regions by a J-chain. Because of its large size, IgM does not easily diffuse 
and is found in interstitial fluids only in very small amounts. The presence of 
the J-chain allows active transport of IgM by epithelial cells and, as a result, 
IgM can be secreted into mucosae. IgM is usually produced early during the 
course of an infection and mainly functions by opsonizing microbes and 
targeting them for complement-mediated destruction. Antigen-specific IgM 
antibodies generally have a lower affinity for their antigens compared to other 
immunoglobulin isotypes. Despite this, IgM is a potent complement activator, 
a feature that primarily results from its multimeric structure and its consequent 
high avidity. 
 
IgD 
Circulating IgD can be detected only in small amounts. It has a short serum 
half-life and constitutes less than 0.5% of the total serum immunoglobulins. In 
contrast to its secreted form, membrane-bound IgD is abundantly expressed 
on mature naïve B cells, which co-express IgM. Recently, it was found that a 
small subset of human B cells expresses IgD in absence of IgM. This has 
been attributed to antigen-induced transcriptional inactivation of the IgM locus 
and not to classical CSR. These cells are mainly found in the upper 
respiratory mucosa.66 The biological function of secreted IgD remains largely 
unknown. There have been no specific Fc receptors identified that bind IgD, 
but IgD can bind to basophils, mast cells, neutrophils and myeloid DCs.67 
 
IgG 
IgG is the most abundant immunoglobulin isotype in circulation as it accounts 
for 80% of all serum immunoglobulins. In humans there are four subtypes of 
IgG (IgG1-4). The numbering of IgG subtypes from one to four corresponds to 
the concentrations that are normally found in serum. IgG1 is found at the 
highest concentration, while IgG4 has the lowest concentration. IgG 
antibodies can cross the placenta and are the primary source of maternal 
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antibodies that are transferred to the developing fetus. These four IgG 
subtypes show 95% homology, but have some structural differences that are 
mainly found in the size of their hinge region and the number and position of 
interchain disulfide bonds, which link the two heavy chains. The primary 
functions of IgG antibodies are clearance of pathogens by opsonization 
leading to complement activation and Fc-receptor-mediated effector cell 
activation.68 As a result of their structural differences, the different subtypes of 
IgG have distinct biological functions, which will be briefly discussed below. 
 
There are five different Fcγ receptors that have different affinities for the 
individual IgG subclasses. Four of these are activating receptors that carry 
immunoreceptor tyrosine-based activation motif (ITAM) sequences in their 
intracellular domains or on their associated subunits. These activating Fcγ 
receptors are: FcγRI (alternative name CD64), FcγRIIA (alternative name 
CD32A), FcγRIIIA (alternative name CD16A) and FcγRIIIB (alternative name 
CD16B). There is one inhibitory Fcγ receptor: FcγRIIB (alternative name 
CD32B). FcγRIIB carries an immunoreceptor tyrosine-based inhibitory motif 
(ITIM). FcγRI is a high affinity IgG receptor while the other Fcγ receptors have 
low affinity for IgG.69 Most immune cells of the hematopoietic system express 
one or more types of activating Fcγ receptors as well as inhibitory Fcγ 
receptors. NK cells only express activating receptors while B cells only 
express inhibitory receptors and T cells do not express any Fcγ receptors. As 
most immune cells express both activating and inhibitory Fcγ receptors, the 
effect of Fcγ receptor ligation depends on the interplay between these two 
types of receptors. Depending on the cell type involved activating Fcγ 
receptors can mediate degranulation, phagocytosis, cytokine production or 
antibody-dependent cellular cytotoxicity. Inhibitory FcγRIIB on B cells 
functions as a sensor for IgG and thereby facilitates a feedback inhibition loop 
that suppresses B cell activation and can even induce apoptosis of low affinity 
or autoreactive B cells.68 
 
IgG1 is the most abundant human IgG subtype. IgG1 has a 15 amino acid-
long hinge region that gives it a relatively high degree of flexibility. IgG1 binds 
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to all Fcγ receptors with relatively high affinity and as a result it is efficient at 
mediating microbial clearance through phagocytosis by effector cells.70 IgG1 
responses are primarily mounted against protein antigens. IgG1 can activate 
the complement system with intermediate efficiency.71 
 
IgG2 has a low affinity for all Fcγ receptors and only shows detectable binding 
to FcγRII.70 Therefore IgG2 is a relatively weak mediator of microbial 
clearance through effector cells. It also is a poor activator of the complement 
system. IgG2 responses are typically mounted against polysaccharide 
antigens.71  
 
IgG3 has a relatively high binding affinity for all Fcγ receptors.70 It is the 
strongest complement activating IgG subtype. Like IgG1, IgG3 responses are 
primarily mounted against protein antigens.71 
 
In healthy individuals IgG4 has the lowest serum concentration of all IgG 
isotypes. IgG4 binds most Fcγ receptors with lower affinity than IgG1 and 
IgG3 but with higher affinity than IgG2. Interestingly the FcγRIIB binds to IgG4 
with a higher affinity than to any other IgG subclass.70 IgG4 can not activate 
the classical complement pathway.72 An interesting feature of IgG4 is its 
inability to cross-link antigens. This was initially observed using sera from 
individuals with high levels of allergen-specific IgG4, which showed impaired 
capacity to cross-link fluid-phase allergen to solid-phase allergen. It was also 
shown that IgG4 did not precipitate with allergen while IgG1 did.73 Thus it was 
concluded that IgG4 was a non-precipitating, functionally monovalent 
immunoglobulin isotype. This functional monovalency results from the unique 
capacity of IgG4 antibodies to rearrange their heavy chains by means of a 
mechanism referred to as Fab arm exchange, which involves the exchange of 
Fab arms between two different IgG4 molecules by swapping a heavy chain 
and attached light chain. Support for this model came from the finding that 
IgG4 antibodies in sera from patients with IgG4 antibodies specific for both 
house dust mite and grass pollen could induce cross-linking of Sepharose-
bound grass pollen antigen to radiolabelled house dust mite allergen Der p I.74 
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Furthermore, injection of two monoclonal IgG4 antibodies with different 
specificities into immunodeficient mice led to the generation of bispecific 
antibodies while injection of control IgG1 antibodies did not yield bispecific 
antibodies.75 This process did not occur readily in vitro as it requires the 
presence of a reducing agent such as reduced glutathionine. Mutagenesis 
studies demonstrated that the hinge region and the CH3 domain of IgG4 are 
essential for Fab arm exchange to occur.75 This process leads to the 
generation of functionally monovalent antibodies that are bispecific because 
they contain the variable regions from two different IgG4 antibodies. This 
feature strongly impairs the ability of IgG4 antibodies to form immune 
complexes and may result in IgG4-mediated inhibition of immune complex 
formation by other isotypes.75, 76 Because of its relatively low affinity for 
activating Fcγ receptors, its inability to fix complement and its functional 
monovalency, IgG4 can be regarded as a non-inflammatory antibody isotype. 
IgG4 production is strongly induced in response to prolonged exposure to 
soluble protein antigens. Allergen-specific IgG4 antibodies can also compete 
with IgE for the same antigens and thereby it may dampen IgE-mediated 
release of inflammatory mediators from basophils and mast cells. 
Furthermore, allergen-specific IgG4 can inhibit IgE-facilitated antigen-
presentation (this process will be discussed below).77 
 
IgA 
IgA accounts for 10%-15% of the total immunoglobulins present in the body. It 
exists in serum, but it also is the major immunoglobulin isotype present at 
mucosal surfaces and in secretions such as saliva and breast milk. Serum IgA 
exists mostly as a monomer, while IgA that is found at mucosal areas and 
secretions (frequently referred to as secretory IgA or sIgA) is present as a 
dimer. Like pentameric IgM, dimeric IgA is formed by linkage of the CH3 
domains by a J-chain. This J-chain is required for active transport of the 
molecule through epithelial cells. In humans, there are two subtypes of IgA; 
IgA1 and IgA2. Like IgG subtypes, these molecules mainly differ in the 
structure of their hinge regions. IgA1 has a longer hinge region than IgA2, 
which makes it more sensitive to bacterial protease digestion and could 
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explain the relative predominance of IgA2 in mucosal areas while the 
dominant IgA subtype in serum is IgA1. IgA is important in the protection of 
mucosal surfaces against pathogens and toxins. It mainly functions through 
neutralization of these pathogens. IgA is a poor activator of the complement 
system, but it can bind to Fcα receptors on neutrophils and thereby mediate 
pathogen clearance through antibody-dependent cell-mediated cytotoxicity. 
Glycan structures on IgA molecules have been proposed to bind distinct 
bacteria in a Fab-independent manner. This enables IgA antibodies of 
different specificities to neutralize common pathogenic bacteria without the 
need for antigen-specific immunoglobulins.71 
 
IgE 
IgE has a short serum half-life and accounts for less than 0.01% of the total 
immunoglobulin in healthy individuals. It is the key immunoglobulin associated 
with type I hypersensitivity reactions and has been linked with protection 
against parasitic worm infections.78, 79 Helminth infections, which are typically 
chronic, induce strong Th2 responses and induce IgE production. Interestingly 
the incidence of allergic disorders is lower among people that are infected by 
helminthes than among non-infected individuals.80 IgE does not efficiently 
activate complement.81 There are two types of Fc receptors that bind IgE; 
FcεRI and FcεRII (alternatively named CD23). Furthermore a protein called 
galectin-3 can bind IgE as well as FcεRI.78 FcεRI is the high-affinity IgE 
receptor, which is expressed on mast cells, basophils and certain antigen-
presenting cells (APCs) (primarily Langerhans cells). FcεRII is the low affinity 
IgE receptor of which there are two forms; CD23a and CD23b. CD23a is 
expressed on follicular B cells while CD23b can be induced by IL-4 on T-cells, 
monocytes, Langerhans cells, eosinophils, macrophages and epithelial 
cells.78 The effector mechanisms of IgE and its role in allergic disease are 
discussed in more detail in the following section. 
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5.3 Allergic disease 
The immunological mechanisms that lead to the development of allergic 
disease have been extensively studied in the past decades and can be 
divided into two phases: The sensitization phase and the effector phase, 
which can be further subdivided into immediate and late responses.82  
5.3.1 Allergic Sensitization 
Allergic sensitization is characterized by the development of allergen-specific 
T and B cell responses. The initial step in the initiation of allergic sensitization 
is the priming of allergen-specific naïve CD4+ T cells. Tissue resident DCs 
capture allergen, mature and migrate to lymph nodes, where allergen-derived 
antigens are presented to T cells. If these DCs produce Th2-priming cytokines 
(IL-4 or IL-13), allergen-specific naïve CD4+ T cells differentiate to Th2 cells, 
which produce IL-4, IL-5, IL-9 and IL-13.83 As a result of clonal expansion, 
allergen-specific Th2 cells dramatically increase in number. Furthermore, 
predominance of Th2 cells in atopic individuals may result from a higher rate 
of activation-induced cell death of IFN-γ-producing Th1 cells.84 Th2 derived 
cytokines have various effector functions including induction of IgE CSR and 
clonal expansion of allergen-specific B cells, development and recruitment of 
eosinophils, mucus production, smooth muscle cell contraction and Th2 
homing.85 During the sensitization phase, allergen-specific IgE antibodies are 
produced as a result of IgE CSR in B cells (illustrated in figure 5). These IgE 
antibodies circulate and bind to high affinity FcεRI receptors on the surface of 
mast cells and basophils as well as APCs such as Langerhans cells. This is 
the key event of sensitization. Subsequent encounter with the same allergen 
leads to cross-linking of IgE bound to FcεRI on these effector cells and the 
release of inflammatory mediators and marks the onset of the immediate 
phase (type 1) hypersensitivity reaction. The mechanisms involved in this 
process are discussed in more detail below. 
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Figure 5. Key events in the process of sensitization to allergens. Upon 
allergen encounter, DCs capture allergens and migrate to draining lymph 
nodes where they present allergen-derived peptides to allergen-specific naïve 
CD4+ T cells. In response to polarizing cytokines produced by DCs, naïve T 
cells differentiate to Th2 cells and undergo clonal expansion. Allergen-specific 
naïve B cells bind and internalize allergen and present allergen-derived 
peptides to Th2 cells. Th2 cells provide IL-4 and IL-13, which facilitate CSR to 
IgE. Naïve B cells undergo CSR to IgE and differentiate to IgE-switched B 
cells or IgE-secreting plasma cells. Adapted from86. 
5.3.2 Effector functions of IgE-receptor-expressing cells 
The human FcεRI can be expressed as a tetrameric or a trimeric receptor 
whereas murine FcεRI is only expressed as a tetramer. The tetrameric 
receptor is expressed by mast cells and basophils and is composed of three 
different membrane-bound chains: the α, β and γ chains.87 FcεRI expression 
enables cells to stably interact with IgE molecules through high affinity binding 
of the Fc portion of these antibodies to the α-chain of FcεRI, forcing the 
antigen-specific regions of the IgE molecules to stick out and function as 
sentinels for their specific antigens. When multivalent allergens bind to cell 
surface-bound IgE molecules, FcεRI is crosslinked and, dependent on the cell 
type, cells either release a distinct set of preformed pro-inflammatory 
mediators (degranulation) or they internalize the captured allergens for 
subsequent antigen presentation. The early events following antigen-
mediated crosslinking of IgE bound to FcεRI are activation of proto-oncogene 
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tyrosine-protein kinase Src-family kinases followed by tyrosine 
phosphorylation of cytoplasmic FcεRIβ- and γ-associated ITAMs. These 
phosphorylated ITAMs provide docking sites for SH2 domains of tyrosine-
protein kinase Lyn (LYN), ZAP70 and spleen tyrosine kinase (SYK) which will 
activate the linker for activation of T cells (LAT) protein which is central to 
many of the downstream signaling cascades that are required for the release 
of pro-inflammatory mediators (reviewed in more detail in88, 89). Degranulation 
upon allergen binding occurs in sensitized mast cells and basophils, leading 
to the release of preformed mediators such as histamine and heparin, and the 
rapid synthesis of leukotrienes, prostaglandins, cytokines and chemokines. 
This reaction is referred to as the immediate hypersensitivity reaction. 
Crosslinking of IgE bound to FcεRI receptors on APCs such as Langerhans 
cells and DCs can result in internalization and processing allergens. This 
leads to presentation of allergen fragments on MHC class II molecules 
together with co-stimulatory molecules, enabling activation of allergen specific 
CD4+ T cells. Compared to non-sensitized APCs, sensitized DCs or 
Langerhans cells demonstrate an increased affinity for specific allergens, 
which enhances the efficiency of allergen internalization. The allergen 
concentration required for activation of allergen specific T cells is significantly 
reduced when APC carry allergen specific IgE molecules on FcεRI.90 
 
CD23 is the low affinity IgE receptor. The extracellular portion of CD23 
contains a C-type lectin domain, which facilitates IgE binding and an α-helical 
coiled coil stalk that drives the formation of trimers in the cell membrane.91 
Because of the relatively low binding affinity, stable binding of IgE to this 
receptor occurs mostly when multiple IgE molecules are clustered in 
complexes.92, 93 CD23 can be cleaved from the cell surface by ADAM10 and 
Der p1 (a house dust mite derived protease and a major allergen) yielding 
soluble CD23 proteins of different sizes.94, 95 
 
Besides IgE, a number of other ligands for CD23 have been described. These 
include CD21 and αMβ2-integrin, αXβ2-integrin, αVβ3-integrin and αVβ5-
integrin78. Soluble CD23 can have a pro-inflammatory effect as it binds to the 
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αMβ2-integrin and αXβ2-integrin on monocytes, which respond with nitric 
oxide production, cyclic adenosine monophosphate synthesis and the 
production of pro-inflammatory cytokines like TNF, IL-1 and IL-6.96 CD23 and 
CD21 have been proposed to coordinately regulate IgE production. The 
binding surfaces on CD23 for IgE and CD21 are spatially separated, which 
means that CD21 and IgE can bind simultaneously to CD23.97. CD23 can 
interact with CD21 in soluble as well as membrane-bound form. CD23 has 
been proposed to regulate IgE production both positively and negatively. 
Soluble CD23 may positively regulate IgE production through simultaneously 
binding CD21 and membrane IgE on IgE-switched memory B cells. This will 
culminate in the formation of an extensive signaling platform that might 
promote the survival and differentiation of IgE-switched B cells. Negative 
regulation of IgE production can occur by co-ligation of membrane-bound 
CD23 and IgE by allergen-IgE complexes.78 
  
CD23 has been demonstrated to increase the antigen-presenting capacity of 
B cells through a mechanism referred to as IgE-facilitated antigen 
presentation (IgE-FAP). B cells are able to internalize, process allergens and 
present allergenic peptide fragments on MHC class II molecules. This results 
in the activation of allergen specific CD4+ T cells. B cells expressing CD23 on 
their surface membrane can bind immune complexes consisting of IgE 
antibodies and allergens in a B cell receptor-independent manner. This results 
in the cross-linking of CD23 molecules and subsequent internalization of IC by 
means of receptor-mediated endocytosis. This mechanism of antigen capture 
is much more efficient than the uptake and presentation of allergens via 
pinocytosis and results in the activation of CD4+ T cells at a 100- to 1000 fold 
lower allergen concentration.98 Therefore, IgE-FAP could be a major 
contributor to the induction of CD4+ T cell responses after exposure to low 
allergen doses. The relevance of this mechanism has been demonstrated for 
several respiratory allergies such as birch pollen or house dust mite allergy.98 
The first study showing the mechanism of IgE-FAP was published in 1989. 
This study demonstrated that trinitrophenyl (TNP)-IgE complexes could bind 
to B cells via CD23 resulting in internalization and activation of TNP-specific T 
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cells. 99 It has been shown that IgE-allergen complexes can induce up to 10 
fold stronger T cell responses in vivo than uncomplexed allergen.100 The first 
human studies comprised incubation of purified Der p II with sera from atopic 
patients containing Der p II specific IgE. Subsequently, Epstein–Barr virus 
(EBV)-transformed B cells were incubated with these IC and used as APC in 
a lymphocyte proliferation assay. This resulted in strong proliferation of Der p 
II specific T cells at a 1000-fold lower allergen concentration than required for 
T cell activation by uncomplexed Der p II. These enhanced antigen-presenting 
properties are abolished by treatment with anti-CD23 or anti-IgE, stressing 
that antigen focusing is largely dependent on CD23-IgE interaction. No other 
APC than B cells show significant surface expression of CD23a on their 
surface membrane. Interestingly IgE-FAP circumvents the need for an 
antigen-specific B cell in order to efficiently capture antigens. Therefore it has 
been proposed that this mechanism could be an important contributor to 
epitope spreading.78 
5.3.3 Late phase reactions 
Late phase reactions are characterized by the infiltration of Th2 cells and 
eosinophils to the site of allergen exposure. Cytokines produced by activated 
Th2 cells include IL-4, IL-5, IL-9 and IL-13. These factors mediate IgE 
induction, eosinophil infiltration, mucus production and smooth muscle cell 
contraction. If the allergen persists the late phase response can convert into a 
chronic inflammatory response, which can manifest for example as chronic 
asthma or atopic dermatitis.86 
 
5.4 Healthy immune responses to allergens 
Allergic responses are the result of an imbalanced response to innocuous 
environmental antigens that leads to the production of Th2 cells and IgE 
antibodies. Some individuals develop allergies while others do not and the 
mechanisms by which immune responses to innocuous antigens lead to either 
allergy or non-harmful immunity remain largely unknown. One possibility is 
that healthy individuals simply do not mount an immune response to 
allergens. This is certainly not always the case since allergen-specific 
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immunoglobulins and T cells can be frequently found in healthy individuals.101 
Allergen-specific Th cells play a key role in the initiation of allergic responses. 
The frequencies of allergen-specific Th1, Th2 and Tr1 can be determined by 
labeling cytokine-producing CD4+ T cells in response to stimulation with 
environmental allergens. IFN-γ- (Th1 cells), IL-4- (Th2 cells) and IL-10- (Tr1 
cells) producing Th cells show different frequencies in allergic individuals 
compared to healthy individuals. IL-10-producing Tr1 cells are the dominant 
allergen-specific Th cell subset while IL-4-producing Th2 cells have a high 
frequency in allergic individuals.101 As mentioned before, Tr1 cells use 
different mechanisms to suppress immune responses including production of 
IL-10 and TGF-β and surface expression of CTLA-4 and PD-1. Despite 
differences in the frequencies of Th cell subsets, both healthy and allergic 
donors have allergen-specific Th1, Th2 and Tr1 cells. This suggests that 
changes in the frequencies of these subsets may result in development of 
allergy or recovery.101 
 
Healthy immune responses to high-dose allergen exposure in humans have 
been studied in two different models: Immune responses to bee venom 
allergens in beekeepers and immune responses to cat allergens in cat 
owners. The beekeeper model is an elegant model that can be used to study 
the mechanisms of immune tolerance to venom antigens. During the season, 
beekeepers receive multiple bee stings and as a result these individuals are 
repeatedly exposed to high dose bee venom antigen. After several bee stings, 
Th1 and Th2 cells specific for the major bee venom allergen Api m 1 show a 
switch towards Tr1 cells. At the same time cutaneous late-phase swelling 
responses are suppressed. These changes persist as long as exposure to 
bee venom is present and return to initial levels several months after the end 
of the beekeeping season.102 Furthermore, bee venom allergen-specific IgG4 
levels are high in beekeepers and the ratio of specific IgG4/IgE is 
approximately 1000 times higher than in allergic individuals.103 Similar findings 
were observed upon exposure to cat allergens, which induced cat allergen-
specific IgG4 antibodies and IL-10-producing Tr1 cells.104, 105 
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5.5 Allergen-specific immunotherapy and peripheral 
tolerance 
Allergen-specific immunotherapy (SIT) is the only treatment that can induce to 
long-term improvement of clinical allergy symptoms. The principle of allergen-
SIT has already been applied for over a century and involves repeated 
administration of allergens to an allergic patient. The earliest reports on the 
protective effects of allergen-SIT against allergies date back to the beginning 
of the 20th century when Noon and Freeman were the first to experiment with 
allergen-SIT. They reported clinical improvement in hay fever patients after 
applying subcutaneous injections of grass pollen extracts.106, 107 The basic 
principle of allergen-SIT has not changed much since then. This principle 
comprises repeated administration of increasing doses of allergen. Allergen-
SIT is most frequently applied for the treatment of hymenoptera venom 
allergies and allergic rhinitis caused by grass or tree pollen as well as house 
dust mite.108 
 
Many patients that receive allergen-SIT become tolerant to late-phase skin 
responses at early stages of the therapy. One of the events associated with 
this observation is that mast cell and basophil degranulation activity is 
reduced already after the first administration of allergen. The mechanism 
underlying this effect remains largely unknown. A role for histamine receptor 
(HR) 2 expression on basophils in the suppression of basophil degranulation 
has been suggested. A rapid upregulation of HR2 expression on basophils 
was observed in allergic patients receiving SIT. HR2 expression was strongly 
upregulated within 6 hours after the initiation of SIT. HR2 strongly suppressed 
FcεRI-mediated basophil degranulation.109 Furthermore a switch from a Th2 
cytokine profile to a Th1 cytokine profile was observed in response to 
allergen-SIT as was measured by stimulating PBMC with relevant 
allergens.110, 111 
 
Induction of a tolerant state in peripheral T cells is another critical step for the 
success of allergen-SIT. Both inducible Tr1 cells and thymic-selected 
CD4+CD25+ Treg cells play a role in the induction of a tolerant state in 
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peripheral T cells.  This tolerant state is characterized mainly by the induction 
of antigen-specific Tr1 cells, which produce IL-10 and TGF-β.112, 113 
Furthermore, CD4+CD25+ Treg cells from atopic donors could only poorly 
suppress proliferation of effector T cells.114 
 
Humoral immune responses are also affected by allergen-SIT. Allergen-
specific IgE levels transiently increase during the first months of allergen-SIT 
but decline in the later course of allergen-SIT. Circulating allergen-specific IgG 
antibodies show a gradual increase starting from the early phases of allergen-
SIT. Allergen-specific IgG4 levels show the strongest increase during the 
course of allergen-SIT. This can result in decreases in the ratio of allergen-
specific IgE:IgG4 of 10- to 100-fold.115, 116 IgG antibodies can be directed 
against the same epitopes as IgE and therefore could function as blocking 
antibodies that compete with IgE for the same epitope. There have been 
mixed reports on the correlation between increases in allergen-specific IgG 
levels and clinical outcome of allergen-SIT.117, 118 It can be argued that rather 
than the absolute concentration of allergen-specific IgG antibodies, one 
should assess the affinity and/or blocking activity of allergen-specific IgG to 
find a good correlation with clinical outcome of allergen-SIT. 
 
The decreased ratio of allergen-specific IgE/IgG4 that is frequently observed 
during the course of allergen-SIT can be attributed to some extent to a 
skewing from allergen-specific Th2 cells towards Treg cell predominance. 
These cells could play a role in regulating both IgE and IgG4 production. Both 
IgG4 and IgE are induced upon stimulation with IL-4 and CD40L. The addition 
of IL-10 however has opposite effects on IgE and IgG4 production. IgE 
production is suppressed by IL-10 while IgG4 production is augmented in the 
presence of IL-10.64 Furthermore it was shown that co-culturing IL-4 + CD40L-
stimulated PBMC as well as B cells with IL-10-secreting Tr1 cells or 
CD4+CD25+ Treg cells results in reduced IgE production and increased IgG4 
production. In contrast, addition of CD4+CD25- effector T cells to IL-4 + 
CD40L-stimulated PBMC or B cells did not affect IgE or IgG4 production.65 
These findings indicate that IL-10, Treg and Tr1 cells regulate antibody 
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isotype formation and skew the specific response from an IgE- to an IgG4-
dominated phenotype. 
 
5.6 Cytokines associated with peripheral tolerance 
IL-10 and TGF-β are the cytokines involved in the immunosuppressive 
function of inducible regulatory T cell subsets. IL-10 is secreted as a 
homodimer and binds to a tetrameric receptor complex that is composed of 
two IL-10R1 and two IL-10R2 chains.119, 120 The IL-10R1 chain is expressed 
on many cell types including B and T cells, NK cells, monocytes, mast cells 
and DCs while the IL-10R2 chain is ubiquitously expressed.121 IL-10 receptor 
signaling is mediated by activation of Jak1 and Tyk2 followed by 
phosphorylation of signal transducer and activator of transcription (STAT) 1, 
STAT3 and STAT5.122 Human IL-10 is primarily produced by monocytes, T 
cell subsets, DCs, macrophages, B cell subsets and mast cells.121, 123 The 
mechanisms regulating expression of the IL-10 gene have not been fully 
elucidated but expression of IL-10 requires the ubiquitously expressed 
transcription factors Sp1 and Sp3.124 Furthermore the 3’ untranslated region 
of the IL-10 mRNA contains multiple copies of mRNA destabilizing motifs 
indicating that IL-10 production is also regulated by posttranscriptional 
mechanisms.125 IL-27 potently induces IL-10 expression in T cells in a STAT1- 
and STAT3-dependent manner.126 In addition IL-27 can promote Tr1 
differentiation from naïve cells by induction of c-Maf and AhR expression.127  
 
As mentioned earlier, IL-10 is a key immunosuppressive cytokine that plays 
an important role in the protection of the host against exaggerated 
inflammatory responses to infections as well as chronic inflammatory 
diseases such as autoimmunity and allergy. IL-10 directly suppresses the 
antigen-presenting capacity of APCs by inducing downregulation of the co-
stimulatory molecules CD80 and CD86.62 Furthermore, IL-10 inhibits the 
production of a large number of cytokines and chemokines62 and suppresses 
CD4+ T cell proliferation mainly indirectly through its suppressive effects on 
APCs. Interestingly, IL-10 can also directly suppress T cell cytokine 
production through suppression of CD28 and ICOS.128 In contrast to its 
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suppressive effects on a variety of cells, IL-10 enhances survival, 
differentiation and CSR of both human and murine B cells.129-131  
 
TGF-β is a pleiotropic cytokine that is produced by many different cell types of 
both hematopoietic and non-hematopoietic origin. It plays a role in a wide 
variety of biological processes including embryonic development, wound 
healing and immune responses. In mammals three isoforms of TGF-β are 
expressed: TGF-β1, TGF-β2 and TGF-β3.132 TGF-β1 is the main TGF-β 
isoform expressed in immune cells. TGF-β is secreted in a latent form 
complexed with latent TGF-β binding protein and latency-associated peptide. 
This complex can be activated through proteolytic cleavage by proteases 
such as plasmin or matrix metalloproteases.132 The first evidence for an 
immunoregulatory function of TGF-β came from the generation of mice with a 
targeted mutation of the TGF-beta 1 allele. These animals showed no 
developmental abnormalities, but developed a multifocal, mixed inflammatory 
cell response and tissue necrosis, leading to organ failure and death.133 TGF-
β is a key cytokine produced by human and murine CD4+CD25+ nTregs as 
well as inducible Th1 and Th3 cells.40 
 
5.7 Regulatory B cells 
5.7.1 Cytokine production by B cells 
The classical function of B cells in immune responses is the production of 
antibodies. It was only recently that their capacity to produce cytokines was 
recognized as a relevant feature of this cell type. Much like Th cells, B cell 
subsets can be categorized based on the cytokines that they produce. Studies 
using mouse models have demonstrated functional B effector (Be) 1 and Be2 
subsets. INF-γ- and IL-12-producing Be1 cells and IL-4- and IL-6-producing 
Be2 cells were obtained upon co-culturing naïve B cells with polarized Th1 or 
Th2 cells respectively. Under these conditions, both Be1 and Be2 cells 
produced IL-10. Interestingly, this polarizing effect was reciprocal, as in vitro 
differentiated Be1 cells could drive naïve CD4+ T cells to Th1 cells while in 
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vitro differentiated Be2 cells could drive naïve CD4+ T cells to Th2 cells.134 So 
far, clear Be1 and Be2 subsets have not been identified in humans. 
5.7.2 Regulatory B cells in murine autoimmune models 
The earliest studies that indicated the existence of B cells with suppressive 
capacity date back to 1974. Adoptive transfer of B cell-depleted splenocytes 
did not inhibit delayed-type hypersensitivity (DTH) skin reactions in guinea 
pigs.135, 136 Over 20 years later a study using B cell-deficient (µMT) mice 
demonstrated that, unlike wild-type (wt) mice, µMT mice did not recover from 
EAE. This finding suggested that B cells might be able to protect against 
autoimmune disease. A key role for IL-10-producing B cells in protection 
against EAE was demonstrated using chimeric mice that specifically lacked 
IL-10 expression in B cells. Like µMT mice, these mice did not recover from 
EAE. Similarly, chimeric mice that specifically lacked CD40 expression in B 
cells failed to recover from EAE. These findings indicate that B cells can 
regulate autoimmunity by provision of IL-10 which requires a CD40-mediated 
signal.137 
 
At the same time another group found that under chronic intestinal 
inflammatory conditions a B cell subset is induced, which is characterized by 
upregulation of CD1d and IL-10 production. This B cell subset could suppress 
the progression of intestinal inflammation by downregulation of IL-1-
associated inflammatory cascades and STAT3 activation.138 Several years 
later, the same group reported that CD1dhiCD5+ B cells could negatively 
regulate T cell-mediated inflammatory responses as demonstrated in an 
oxazolone-induced contact hypersensitivity (CHS) model. IL-10 production 
was induced upon LPS stimulation (and to a lesser extent by anti-IgM + anti-
CD40 mAb) and was largely restricted to this B cell population, which they 
designated ‘B10’ cells. CD1dhiCD5+ B cells make up 1%-2% of spleen B220+ 
cells and 7%-8% of peritoneal cavity B cells in wt mice but were absent from 
blood or lymph nodes. Adoptive transfer of wt CD1dhiCD5+ B220+ splenocytes 
isolated from oxazolone-sensitized mice into oxazolone-sensitized Cd19-/- 
mice (which lack the BCR co-receptor CD19 and have reduced numbers of 
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B10 cells) significantly reduced ear swelling upon challenge. This protective 
effect was not transferred by non-CD1dhiCD5+ B220+ wt splenocytes, neither 
by CD1dhiCD5+ B220+ splenocytes isolated from sensitized IL-10-/- mice. This 
indicates that protection against T cell-mediated inflammation in a CHS model 
can be mediated by CD1dhiCD5+ B cells and is dependent on IL-10.139 
Recently it was shown that maturation of functional B10 cells that can 
suppress EAE requires IL-21 and CD40-dependent interaction with T cells. 
Furthermore in vitro stimulation of splenic B cells for four days with CD40L, 
BAFF and IL-4 followed by five days stimulation with IL-21 drives B10 cell 
development and induces strong proliferation of B10 cells. Adoptive transfer 
of in vitro expanded B10 cells could inhibit established EAE in recipient 
mice.140  
 
To determine the role of TLR-activated B cells on EAE, several B cell-
restricted TLR and MyD88 deficient mice were studied. Splenic B cells from 
C57BL/6 mice were shown to secrete IL-10 in response to LPS and CpG, 
while stimulation with anti-CD40 and/or anti-Igκ mAbs did not induce IL-10. 
This observation does raise questions about the different stimuli that are used 
by different research groups to induce IL-10 production in B cells, since 
several other studies described significant IL-10 production upon stimulation 
with anti-CD40 mAb and/or BCR crosslinking reagents.137, 139, 141 As expected, 
LPS-induced IL-10 production was abrogated in splenic B cells from TLR2/4-/- 
as well as MyD88-/- mice while CpG-induced IL-10 production was only 
abrogated in splenic B cells form MyD88-/- mice. Chimeric mice lacking 
MyD88 only in B cells did not recover from EAE induced by MOG-induced 
EAE. These mice displayed a stronger self-reactive T cell proliferative 
response in combination with elevated IL-17 and IFN-γ production compared 
to wt mice.142  
 
As was shown in another study, chimeric mice lacking MyD88 only in B cells 
showed improved control of bacterial replication and prolonged survival upon 
Salmonella typhimurium infection compared to wt mice. MyD88 signaling in B 
cells suppressed neutrophils, NK cells and inflammatory T cells leading to 
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impaired clearance of Salmonella typhimurium. The key mediator in this 
process was IL-10.143 
 
Infection of C57BL/6 mice with Helicobacter felis, a strain that is closely 
related to the human gastrointestinal pathogen Helicobacter pylori, leads to 
development of early gastric carcinogenesis in a subset of mice, 
characterized by infiltration of inflammatory cells, atrophic gastritis, 
hyperplasia and intestinal metaplasia. Th1-polarized cells are the main 
effector cells that drive this pathology while at the same time they are required 
for control of the infection. A key role for IL-10-producing B cells in the 
prevention of formation of gastric premalignant lesions was demonstrated. B 
cells can be activated by Helicobacter-derived TLR-2 ligands in a MyD88-
dependent manner leading to IL-10 production and IL-10-dependent 
suppression of CD4+ T cells and the induction of Tr-1 cells. This suppression 
depended on TCR signaling, CD40/CD40L and CD80/CD28 interaction.144 
 
Stimulation of splenocytes isolated from arthritic mice with agonistic anti-
CD40 mAb induced IL-10-producing B cells. When adoptively transferred into 
DBA/1-TcR-β-Tg mice (transgenic mice expressing the collagen type-II-
specific β-chain, which develop a severe form of chronic relapsing polyarthritis 
that shares characteristics with human rheumatoid arthritis145), these cells 
could inhibit Th1 differentiation and arthritis in a collagen-induced arthritis 
(CIA) model.146 To address the relative role of B cells at different stages of 
development in the protection against CIA, different types of transitional and 
mature B cells were transferred during the induction phase of CIA. Only the 
transfer of transitional 2 marginal zone precursor (T2-MZP) cells (identified as 
AA4+CD21high CD23+CD24highIgMhighIgD+CD1d+) could inhibit Th1 responses, 
DTH responses and the development of arthritis by provision of IL-10.147 
 
CD40 ligation with anti-CD40 mAb was shown to enrich Bregs upon short-
term in vitro culture. Transfer of in vitro anti-CD40-generated T2 B cells 
derived from mice with established lupus could significantly improve renal 
disease and survival. These cells suppressed Th1 responses and induced 
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differentiation of IL-10-producing Tr1 cells. Furthermore, in vivo application of 
agonistic anti-CD40 could reverse established lupus.141 
 
Administration of apoptotic cells together with OVA peptide and complete 
Freund’s adjuvant into mice carrying OVA-specific transgenic T cells 
(DO11.10) induced a dramatic increase in OVA-specific IL-10 secretion. The 
initial increase in IL-10 production was derived from splenic B cells that 
responded directly to apoptotic cells and in turn induced IL-10 in antigen-
specific CD4+ T cells. This was accompanied by a reduction of circulating 
pathogenic anti-collagen II antibodies. Transfer of B cells from apoptotic cell-
treated mice conferred protection to CIA.148 
 
Chimeric mice lacking IL-10 specifically in B cells (IL-10-/- B cell) have been 
used to study the role of B cell-derived IL-10 in several models of chronic 
inflammation. These mice develop more severe arthritis compared to wt B cell 
mice in a methylated BSA arthritis model. This was accompanied by an 
increase in Th1 and Th17 cells and a decrease in the number of Foxp3+ 
regulatory T (Treg) cells, which expressed lower levels of Foxp3. Transfer of 
wt T2-MZP B cells but not follicular of marginal zone B cells to arthritic IL-10-/- 
mice could restore the frequencies of Th1, Th17 and Treg cells to those 
observed in wt mice, demonstrating that this subset of B cells is able to confer 
protection to methylated bovine serum albumin (BSA)-induced arthritis.149 
 
TCRα-/- mice develop spontaneous chronic colitis, which closely resembles 
human ulcerative colitis. This pathology is mediated by autoreactive CD4+ 
TCRα-βlow T cells and is characterized by the presence of autoantibodies. The 
disease was further exacerbated TCRα-/- crossed with Igµ-/- (B cell deficient) 
mice. Adoptive transfer of B cells could suppress pathogenic CD4+ TCRα-βlow 
T cell responses and colitis. B cells derived from CD40-deficient mice or wt B 
cells that were pretreated with a blocking anti-CD40 mAb were unable to 
prevent disease symptoms.150 
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5.7.3 Regulatory B cells in allergy 
A role for IL-10-producing B cells in the protection against allergic responses 
has been demonstrated in several mouse models.  
 
To study the role of B cells in the modulation of allergic airway disease an 
OVA model was used to induce allergic airway inflammation or local 
inhalational tolerance. Allergic airway inflammation manifests when OVA-
sensitized mice are exposed to aerosolized OVA for a short period (1 hour per 
day for 7 days) while local inhalational tolerance occurs upon chronic 
exposure (daily challenge for 42 days) to OVA. Local inhalational tolerance 
was characterized by minimal airway and tissue eosinophilia, reduced airway 
lymphocytosis, absence of airway hyper-reactivity but persistent high levels of 
OVA-specific IgE and IgG1. JhD−/− mice (mice that have a targeted mutation 
in their JH locus, which prevents rearrangement of the V(D)J recombination 
and blocks B cell development, rendering these mice B cell deficient151) 
developed local inhalational tolerance normally. However adoptive transfer of 
B cells isolated from hilar lymph nodes of chronically OVA-exposed mice to 
OVA-sensitized recipients could suppress allergic airway inflammation. B cells 
isolated from short-term challenged mice did not have such a suppressive 
effect. These findings support a role for B cell in mediating tolerance. In vitro 
experiments demonstrated that B cells isolated from hilar lymph nodes of 
chronically OVA-exposed mice mediated TGF-beta-dependent conversion of 
T effector cells into functionally suppressive CD4+CD25+Foxp3+ Treg cells. 
Interestingly, it seems that B-cell-mediated suppression of allergic airway 
inflammation did not require IL-10 since local inhalational tolerance was 
maintained in IL-10-deficient mice. Furthermore, blocking of IL-10 did not 
inhibit B cell-mediated in vitro Treg cell conversion.152 
 
Chronic helminth infections have frequently been associated with reduced 
incidence of atopy.153 Regulatory B cells may be involved in protect against 
allergic inflammation as a result of chronic helminth infections. This has been 
demonstrated by several studies. 
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Mice infected with Schistosoma mansoni were protected from anaphylaxis in 
a Pen V model. Worm-infected mice did not show a decrease in body 
temperature after being passively sensitized and challenged with antigen. 
This protective effect of Schistosoma mansoni infection on systemic 
anaphylaxis was dependent on IL-10-producing B cells. The frequency of IL-
10-producing B cells was two-fold higher in Schistosoma mansoni-infected 
mice compared to uninfected mice. B-1-deficient mice were still resistant to 
anaphylaxis in this model indicating that a B-2 cell population mediates 
resistance from anaphylaxis. Interestingly, adoptive transfer of B cells from 
worm-infected wt mice did not protect from anaphylaxis. Only B cells from IL-
4-/- mice conferred protection to anaphylaxis in recipient mice.154 
 
A role of helminth-induced regulatory B cell responses in the protection 
against allergic airway responses was demonstrated by infecting mice with 
the helminth Schistosoma mansoni. These mice were subsequently sensitized 
and challenged with OVA to induce airway inflammation. In order to determine 
the effect of acute and chronic helminth infection, mice were sensitized and 
challenged at 8 (acute infection), 12 (intermediate infection) or 16 weeks 
(chronic infection) after helminth infection. Allergic airway inflammation was 
more severe during acute helminth infection but ameliorated during chronic 
infection. OVA-specific IgE levels were not affected by helminth infections. 
Mesenteric lymph node cells or splenocytes from chronically helminth-infected 
mice secreted less IL-13, IL-4 and IFN-γ upon stimulation with OVA or 
helminth antigens than cells isolated from uninfected mice. IL-10 production in 
response to restimulation with OVA or helminth antigen peaked during 
intermediate helminth infection but was comparable between acute and 
chronic helminth infection. Inhibition of airway inflammation could be 
transferred to OVA-sensitized recipient mice by B cells and CD4+ T cells from 
spleens of chronically, but not acutely, infected mice. This protective effect 
was reversed when neutralizing anti-IL-10R antibodies were applied indicating 
a critical role for both B and T cell-derived IL-10.155 
 
  5 General introduction 
 
 55 
Subsequent studies have focused on the mechanisms involved in B cell-
mediated suppression of OVA-induced allergic airway inflammation. Using a 
similar model, another group set out to identify and characterize the helminth-
induced B cell population that mediates suppression of allergic airway 
inflammation. Spleen-derived IL-10-producing B cells from Schistosoma 
mansoni-infected mice expressed increased levels of CD1d compared to total 
B cells from infected mice. Furthermore, CD5, CD21 and IgM expression were 
increased in IL-10+CD1dhi B cells while CD23 and IgD expression were lower. 
B cells expressing low (non-Breg) or high (Breg) levels of CD1d were sorted 
from splenocytes of helminth-infected mice. Adoptive transfer of CD1dhi but 
not CD1dlo B cells to OVA-sensitized recipients could prevent and reverse 
allergic airway inflammation in an IL-10-dependent manner. Furthermore 
CD1dhi B cells induced pulmonary infiltration of FoxP3+ Treg cells.156  
 
In order to determine which organs are involved in Schistosoma mansoni-
mediated protection against OVA-induced allergic airway inflammation, B cells 
isolated from lungs, mesenteric lymph nodes or spleens from OVA-sensitized 
helminth-infected mice were adoptively transferred to OVA-sensitized mice. 
Both lung-and spleen-derived B cells suppressed allergic airway inflammation. 
Interestingly, only suppression of inflammation by splenic B cells (of which 
CD1d+ cells were the main source of IL-10) was reversed upon anti-IL-10R 
mAb treatment indicating that lung-derived B cells utilize and IL-10-
independent mechanism to suppress allergic airway inflammation. Similar to 
the findings by Amu et al.156 an increase in pulmonary FoxP3+ Treg cells was 
observed after adoptive transfer of splenic B cells. In vivo depletion of FoxP3+ 
Treg cells only partially reversed splenic B cell-mediated protection against 
allergic airway inflammation indicating that Treg cells are not the main subset 
involved in protection against allergic airway inflammation. Interestingly, the 
frequency of IL-10+CD1dhi B cells in peripheral blood of Schistosoma 
heamatobium-infected children was increased compared to uninfected 
children.157 
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5.7.4 Regulatory B cells in humans 
In analogy to the mouse models used to study regulatory B cells, human 
regulatory B cells have been mainly studied in relation to autoimmune 
diseases such as SLE and multiple sclerosis. It was found that CD40L 
stimulation of peripheral B cells (using human CD40L-transfected murine 
fibroblasts) induced IL-10 production primarily in CD27- naïve B cells. The 
frequency of IL-10-producing B cells and the amount of secreted IL-10 was 
strongly reduced in MS patients when compared to healthy controls. The 
phenotype of IL-10-producing B cells was not further delineated in this 
study.158 A human B cell population characterized as CD19+CD24hiCD38hi 
was shown to produce IL-10 in response to CD40L stimulation (using human 
CD40L-transfected Chinese hamster ovary cells). This B cell population also 
expressed CD5 and high levels of CD1d as was described in the murine 
system. Furthermore these cells could suppress Th1 differentiation. Addition 
of a combination of blocking anti-IL-10, anti-CD80 and anti-CD86 mAbs could 
fully reverse the suppression of Th1 differentiation. This indicates that this 
suppression was partially dependent on IL-10, as well as CD80 and CD86. In 
SLE patients CD19+CD24hiCD38hi B cells failed to produce IL-10 and 
suppress Th1 differentiation in response to CD40L stimulation but still 
produced IL-10 after CpG stimulation.159  
 
Helminths may also play a role in the induction of human regulatory B cells. It 
was found that MS patients that were infected with helminths showed 
increased IL-10 production by B cells in response to anti-CD40-coated murine 
fibroblasts. These IL-10+ B cells were characterized as CD5-
CD27+IgD+CD11b-CD1dhi. In infected patients the amount B cell-derived IL-10 
production increased to levels comparable to what was observed in healthy 
individuals. In order to identify co-stimulatory factors required for IL-10 
production by B cells, co-cultures of myelin basic protein- and myelin 
oligodendrocyte glycoprotein-primed specific T cell lines with purified B cells 
were performed and the frequency of IL-10-producing B cells was measured 
by intracellular IL-10 staining. Addition of blocking anti-B7RP-1 mAb reduced 
the frequency of IL-10+ B cells by approximately 75%. Blocking anti-CD40L or 
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anti-CD80/CD86 mAbs reduced the IL-10+ B cell frequency by approximately 
30%. It must be noted here that the frequency of IL-10+ B cells that was 
measured in the T-B cell co-cultures was around 40%-50% of total B cells. 
This is much higher than what was observed in other human studies where 
frequencies of Breg cells were typically <5% of total B cells.159-161. 
 
Another study described human IL-10-competent B cells that were found 
primarily among CD24hiCD27+ B cells. In this study IL-10 was measured by 
intracellular staining after two different regimens of stimulations. The first 
stimulation regimen consisted of 5 hours stimulation with LPS or CpG 
together with PMA/Ionomycin and Brefeldin A or Monensin. Cells that were 
stained positive for IL-10 after this stimulation were referred to as B10 cells 
and represented around 0.6% of the peripheral B cells. The second 
stimulation regimen consisted of 48 hours stimulation with LPS or CpG with or 
without recombinant CD40L followed by 5 hours stimulation with 
PMA/Ionomycin and Brefeldin A. Cells that were stained positive for IL-10 
after this stimulation were referred to as B10 + progenitor-B10 (B10pro) cells 
and represented around 5% of the peripheral B cells. The highest frequency 
of IL-10+ B cells was observed after 48h of CpG + CD40L + 5h of 
PMA/Ionomycin and Brefeldin A stimulation. B10 and B10pro cells were 
predominantly found within the CD24hiCD27+ subpopulation. CD24hiCD27+ B 
cells were able to suppress monocyte cytokine production in an IL-10-
dependent manner. The mean frequency of B10 + B10pro cells was 
significantly increased in patients with different autoimmune diseases 
including rheumatoid arthritis, systemic lupus erythematosus, primary Sjögren 
syndrome, autoimmune vesiculobullous skin disease, or multiple sclerosis 
compared with healthy controls.161  
 
To investigate whether IL-10 and Bregs play a role in viral infection. A cohort 
of chronic hepatitis B patients undergoing spontaneous flares of liver disease 
was studied. The frequency of IL-10-producing B cells was measured by 
intracellular cytokine staining after 4d stimulation with CpG followed by 4 
hours of stimulation with PMA/Ionomycin/Brefeldin A. Chronic hepatitis B 
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patients had approximately two-fold higher frequencies of IL-10-producing B 
cells than healthy controls. IL-10 production in response to CpG was not 
restricted to a single B cell subset but all B cell subsets were producing IL-10. 
IL-10 staining without any stimulation was used to identify the in vivo 
circulating IL-10-producing B cells. The majority of these cells were 
CD24hiCD38hi immature B cells. However, the extremely low frequencies of IL-
10 positive cells that could be detected this way (0.02%-0.04%) and the fact 
that data from only one patient are shown make it difficult to judge the value of 
these data. Furthermore, the frequency of CD24hiCD38hi B cells increased 
during flares of liver disease while frequencies of other B cell subsets did not 
correlate with disease flares. Depletion of CD24hiCD38hi B cells from PBMC 
by FACS resulted in a 2-4-fold increase in IFN-γ-producing CD8+ T cells in 
response to stimulation with hepatitis B virus-derived peptides. When sorted 
CD24hiCD38hi B cells were added back to hepatitis B virus peptide-stimulated 
PBMC, the IFN-γ-production by CD8+ T cells was fully suppressed and could 
be restored by addition of anti-IL-10R blocking mAb. These data suggest that 
IL-10-producing B cells can suppress antiviral CD8+ T cell responses and 
therefore implicate a pathogenic role for Bregs and IL-10 in chronic hepatitis B 
infection.160 
 
5.7.5 B cell depletion therapy 
Support for a relevant role in immune homeostasis mediated by regulatory B 
cells in humans comes from patients that underwent B cell depletion therapy 
using the anti-CD20 antibody Rituximab. This therapy is used to treat certain 
leukemias and lymphomas as well as autoimmune diseases including MS and 
RA.162-164 Rituximab is currently also regarded as a promising drug to prevent 
antibody-mediated rejection of transplanted solid organs.165 Besides its 
relatively high success rate (around 80% of treated rheumatoid arthritis 
patients show clinical improvement), there have been several reports that B 
cell depletion therapy leads to exacerbation of ulcerative colitis and 
development of psoriasis.166, 167 This indicates that in certain cases the 
depletion of B cells can lead to pathogenesis and supports a functional role 
for regulatory B cells in humans. 
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5.7.6 Phenotype and isolation strategy for regulatory B cells 
Interestingly, there are different subsets of B cells that are capable of 
producing IL-10. This is strongly dependent on the stimulation conditions to 
which the cells are exposed. Murine B cells express TLR4 and respond to 
LPS while human B cells lack TLR4 expression and are therefore 
unresponsive to LPS. Stimulation of murine B cells with TLR2-L and TLR4-L 
induced IL-10 and IL-6 production in MZ B cells while follicular B cells respond 
with IL-6 and IFN-γ production. Subsequent addition of agonistic anti-CD40 
antibody boosted TLR-L-induced cytokine production.168 The two major 
stimulants that induce IL-10 production by human B cells are CD40L and 
CpG. As mentioned earlier, there are several reports that describe helminth-
derived antigens that may induce IL-10 production by B cells. 
 
The general picture that arises from the different published studies on IL-10-
producing B cells is that there are multiple subsets of B cells that can produce 
IL-10. The main murine B cell subsets that produces IL-10 in response to 
CD40 stimulation are MZ-like B cells (CD19+CD1dhiCD21hiCD23-CD24hi 
IgMhiIgDlo) and T2-MZP B cells (CD19+CD1dhiCD21hiCD23hiCD24hi 
IgMhiIgDhi).169 Human B cells that produce IL-10 in response to CD40 
stimulation have been characterized as immature transitional B cells 
(CD19+CD24hiCD38hiCD5+CD1dhi).159 It must be stressed that the above-
mentioned combinations of surface markers are not exclusively expressed by 
IL-10-producing B cells. There is merely an enrichment of cells that produce 
IL-10 in response to CD40 stimulation within these subpopulations of B cells. 
In contrast, TLR-L-induced IL-10 production is not confined to immature B 
cells. This is true both in the murine and human system. A summary of 
reported surface markers that have been associated with regulatory B cells is 
listed in table 2.  
 
CD1d expression has been used in both the human and mouse system to 
distinguish IL-10-producing B cells form non-IL-10-producing B cells. The 
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typical gating strategy is to sort CD1dhi B cells (in some cases combined with 
gating on CD5+ B cells) as IL-10-producing B cells and CD1dlo B cells as non-
IL-10-producing B cells. There are some limitations to this approach. CD1dhi B 
cells do not form a separate population and therefore gating of different cell 
populations remains somewhat arbitrary. Furthermore, even though IL-10-
producing B cells are enriched among CD1dhi B cells, only a fraction of the IL-
10-producing B cells expresses CD1dhi while the majority of IL-10-producing 
B cells do not express high levels of CD1d. This means that sorting CD1dhi B 
cells allows enrichment of IL-10-producing cells but on the other hand 
bypasses a large fraction of IL-10-producing B cells because they do not 
express CD1d. The same applies to other surrogate markers that have been 
proposed to target regulatory B cells. Therefore the best strategy for the 
isolation of IL-10-producing B cells is sorting based on IL-10 secretion. This is 
technically challenging but provides the only means to obtain the pure 
population of all IL-10-producing cells. 
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Table 2. Reported markers for human and murine regulatory B cells 
Marker Function 
Expression level on 
IL-10-producing B 
cells 
Expressed on murine or 
human regulatory B cells 
CD1d Presentation of lipid 
antigens 
High Both 
CD5 Ligand for CD72 involved 
in B-T cell interaction 
Positive Both 
CD19 BCR co-receptor Positive Both 
CD21 BCR co-receptor Positive Murine 
CD23 Low-affinity IgE receptor Both high and low 
expression levels 
reported on different 
IL-10+ subsets 
Both 
CD24 Highly expressed on B 
cell progenitor cells and 
mature resting B cells. 
Functions as co-
stimulatory molecule for T 
cell activation 
High Both 
CD27 Binds to CD70. Functions 
as co-stimulatory 
molecule for T cell 
activation. Used as 
marker for memory B 
cells 
Both high and low 
expression levels 
reported on different 
IL-10+ subsets 
Human 
CD38 Expressed at both early 
and late stages of B and 
T-cell maturation. Marker 
for activation; monitors 
intracellular calcium 
levels. Also detected on 
erythroid and myeloid 
progenitors in bone 
marrow. 
Both high and low 
expression levels 
reported on different 
IL-10+ subsets 
Human 
IgD BCR expressed on 
mature naïve B cells. 
Both high and low 
expression levels 
reported on different 
IL-10+ subsets 
Murine 
IgM BCR expressed on 
mature naïve B cells. 
High Both 
IL-10 Anti-inflammatory 
cytokine 
High Both 
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5.8 Scope of the thesis 
This thesis provides novel insights into the role of B cells in the regulation of 
immune responses. The first part of the data presented in this thesis is 
focused on the functional and phenotypical characterization of inducible IL-10-
producing B cells, which we designated Br1 cells (Chapter 6.1). The fact that 
certain B cells have the capacity to produce IL-10 combined with the notion 
that IL-10 can potently augment IgG4 production by B cells led us to 
investigate human IL-10-producing B cells and their link with immunoglobulin 
production. Furthermore we investigated the effect of SIT on allergen-specific 
IgG4 and IgE production and the frequency of allergen-specific Br1 cells. 
 
Next we studied the effect of IL-10 overexpression on the function and 
phenotype of B cells (Chapter 6.2). We found that IL-10 overexpression 
induces a regulatory phenotype in B cells and arms them to suppress antigen-
specific proliferation of PBMC, production of inflammatory cytokines and 
maturation and differentiation of monocyte-derived dendritic cells. 
 
Tissue injury can lead to the release of host cell DNA, which is capped by 
telomeres containing large numbers of TTAGGG repeats. These hexamer 
nucleotide repeats have immunosuppressive capacity and may have 
therapeutic potential for treatment of chronic inflammatory diseases.170 We 
studied the modulation of human B cell proliferation, differentiation and 
immunoglobulin production by mammalian telomeric DNA sequences 
containing immunosuppressive TTAGGG motifs (Chapter 6.3). 
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Abstract 
Background: IL-10-producing regulatory B cells suppress immune responses 
and lack of these cells leads to exacerbated symptoms in mouse models of 
chronic inflammation, transplantation and chronic infections. IgG4 is a 
blocking antibody isotype with anti-inflammatory potential that is induced in 
human high-dose antigen tolerance models.  
Objective: To characterize human inducible IL-10-secreting B regulatory 1 
(Br1) cells and to investigate their immunoregulatory capacity through 
suppression of cellular immune responses and production of anti-
inflammatory immunoglobulins. 
Methods: Highly purified IL-10-secreting B cells were phenotypically and 
functionally characterized by whole genome expression analysis, flow 
cytometry, suppression assay and antibody production. B cells specific for the 
major bee venom allergen phospholipase A2 were isolated from beekeepers 
who displayed tolerance to bee venom antigens and allergic patients before 
and after specific immunotherapy. 
Results: Human IL-10+ Br1 cells expressed high surface CD25 and CD71, 
and low CD73. Sorting of CD73-CD25+CD71+ B cells allowed enrichment of 
human Br1 cells that produced high levels of IL-10 and potently suppressed 
antigen-specific CD4+ T cell proliferation. IgG4 was selectively confined to 
human Br1 cells. B cells specific for the major bee venom allergen 
phospholipase A2 isolated from non-allergic beekeepers show increased 
expression of IL-10 and IgG4. Furthermore, the frequency of IL-10+ PLA-
specific B cells increased in allergic patients receiving allergen specific 
immunotherapy. 
Conclusion: Our data show the characterization of IL-10+ Br1 cells and in 
vivo evidence for two essential features of allergen tolerance; the suppressive 
B cell and IgG4-expressing B cell that are confined to IL-10+ Br1 cells in 
humans. 
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Key messages 
• Human IL-10-secreting Br1 cells potently suppress antigen-specific T 
cell responses. 
• Human Br1 cells can be isolated based on IL-10 secretion and surface 
expression of CD25 and CD71 and CD73. 
• IgG4-producing antibody forming cells essentially develop from Br1 
cells. 
• IgG4 producing and IL-10 positive Br1 cells increase in allergen-SIT 
and high dose venom exposure in non-allergic beekeepers. 
 
Capsule summary: IL-10-secreting Br1 cells suppress antigen-specific T cell 
proliferation and selectively upregulate IgG4 production demonstrating a dual 
anti-inflammatory role for Br1 cells. Allergen-specific Br1 cells are increased 
during allergen-SIT and high dose bee venom tolerance. 
 
Key words: Immune tolerance, regulatory B cells, IL-10, IgG4 
 
Abbreviations: BCR: B cell receptor, Br1: B regulatory 1, CFSE: Carboxy-
fluorescein succinimidyl ester, CSR: class switch recombination, L: ligand, 
PBMC: peripheral blood mononuclear cell, PLA: phospholipase A2, PPD: 
purified protein derivative, SIT: specific immunotherapy, TLR: toll like 
receptor, Tr1: T regulatory 1, Treg: regulatory T 
  6 Results 
 
 66 
Introduction 
Peripheral tolerance to allergens utilizes multiple mechanisms to suppress 
allergic inflammation, including suppression of dendritic cells that support the 
generation of effector T cells; induction of dendritic cells that support the 
generation of regulatory T (Treg) cells; suppression of effector T cells; 
suppression of mast cells, basophils and eosinophils; interaction with resident 
tissue cells and remodeling; suppression of allergen-specific IgE and 
induction of allergen-specific IgG4.171 Peripheral tolerance as a result of high-
dose allergen exposure as occurs in beekeepers, cat owners or helminth-
infected individuals is accompanied by increased amounts of specific IgG4 
antibodies.115, 172, 173 Because of its unique structural features in the hinge 
region, IgG4 has several non-inflammatory properties including low affinity for 
the classical Fcγ receptors and the capacity to form bi-specific, functionally 
monovalent, antibodies through Fab arm exchange.75 IgG4 antibodies lack 
the ability to cross-link antigen and form immune complexes. In addition, IgG4 
is unable to activate the complement cascade.72, 174 
 
Studies on the mechanisms of immune responses to allergens have 
demonstrated that inducible Tr1 cells are dominant in healthy individuals.101, 
102 Tr1 cells not only suppress Th1 or Th2 cell responses but also have a 
direct influence on B cells. Tr1 cells as well as natural CD4+CD25+ Treg cells 
suppress IgE and induce IgG4. Both subsets of regulatory T cells (inducible 
and natural) reduce the IgE-secreting plasma cell frequency and 
simultaneously augment the IgG4-secreting plasma cell frequency.65 A useful 
tool to study the in vivo regulation of immune tolerance in response to high-
dose antigen exposure in humans is the beekeeper model.102 Continuous 
exposure to high doses of bee venom antigens in non-allergic beekeepers 
diminishes T cell-mediated cutaneous late-phase swelling reactions, 
suppresses allergen-specific T cell proliferation and induces an in vivo switch 
from allergen-specific Th1 and Th2 cells toward IL-10-producing Tr1 cells.102 
Although they produce IgE antibodies against venom antigens, beekeepers 
do not show anaphylaxis. Furthermore beekeepers have high levels of 
circulating IgG4 antibodies specific for the major bee venom allergen 
phospholipase A2 (PLA).103, 175 Bee venom allergic patients on the other hand 
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develop IgE antibodies mainly to PLA, but show increased production of 
specific IgG4 in response to bee venom specific immunotherapy (SIT).176  
 
B cells contribute to immune responses essentially through antigen 
presentation to T cells, secretion of cytokines and production of antibodies 
after differentiation to plasma cells.134 When they receive the right survival 
signals plasma cells can reside for many years in dedicated niches in the 
bone marrow and continuously produce antibodies independent of antigen 
exposure.49 Upon activation IgM+IgD+ naïve B cells may undergo class-switch 
recombination (CSR) leading to the expression of IgA, IgG or IgE antibodies. 
Human B cells express several toll like receptors (TLR) including TLR1, 6, 7, 
8, 9 and 10. TLR7 (activated by single stranded RNA) and TLR9 (activated by 
hypomethylated CpG DNA) are the highest expressed TLRs on B cells.23 
 
IL-10 is a key regulator of inflammatory responses and protects the host from 
tissue damage as a result of excessive inflammation.62 It suppresses antigen 
presentation and the production of pro-inflammatory chemokines and 
cytokines. On the other hand, IL-10 enhances survival, proliferation, 
differentiation and isotype switching of human B cells.62 IL-10 augments IgG4 
production, whereas it inhibits IL-4-induced IgE CSR.63, 64 IL-10-mediated 
immunosuppressive functions of B cells have been described in murine 
models of autoimmunity137, 146, 177, 178, infection154, 179, cancer180 and allergic 
airway inflammation.156, 181 The relevance of immunoregulatory functions of 
human B cells was illustrated in rheumatoid arthritis patients treated with the 
B cell depleting antibody rituximab who showed exacerbation of ulcerative 
colitis and development of psoriasis.166, 167 
 
We hypothesize that if a B cell plays an anti-inflammatory role, the antibody 
isotype produced by the plasma cell originating from this B cell should also be 
anti-inflammatory. In the present study, we characterized human inducible IL-
10-producing B cells which we designate B regulatory 1 (Br1) cells and their 
immunoglobulin production. Whole genome microarray expression analysis 
was performed to characterize human circulating Br1 cells. Functional 
experiments demonstrated that Br1 cells could directly suppress antigen-
  6 Results 
 
 68 
specific CD4+ T cell responses and significantly upregulate IgG4, but not 
IgG1, IgA or IgE upon differentiation to plasma cells. High-dose bee venom-
exposed beekeepers and bee venom allergic patients before and after bee 
venom specific immunotherapy (SIT) were used to demonstrate these findings 
in vivo.  
 
Materials and Methods 
Study group. Heparinised peripheral blood samples form healthy donors and 
beekeepers as well as allergic patients before and after ultra rush bee venom 
SIT were employed in the study. For staining of IL-10 secreting PLA- and 
PLA+ B cells four allergic patients aged 18 to 65 years with a history of 
moderate-to-severe systemic allergic reactions to honeybee stings grade II to 
IV, positive intracutaneous skin tests to BV of less than or equal to 1024 g/ L, 
and BV-specific serum IgE levels of 0.7 kU/L or greater in the Immuno-CAP 
FEIA were included in the study. Details on the immunotherapy protocol have 
been described elsewhere.182 Blood samples were taken before the start of 
therapy and on day 110. The study was approved by the ethical commission 
of the Canton of Graubünden, Switzerland and by the Ethical Commission of 
the Canton of Bern, Switzerland. 
 
Isolation of PBMC, B cells and IL-10-secreting B cells. PBMCs were 
isolated by Ficoll (Biochrom, Berlin DE) density gradient centrifugation of 
peripheral venous blood. Cells were washed three times and resuspended in 
RPMI 1640 medium supplemented as previously described.101 For 
experiments with purified B cells, untouched CD19+ cells were isolated by 
labeling non-B cells using a cocktail of biotin-conjugated antibodies against 
CD2, CD14, CD16, CD36, CD43 and CD235a and anti-biotin microbeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany) followed by immunomagnetic 
separation (AutoMacs; Miltenyi Biotec). The purity of isolated CD19+ B cells 
was routinely >98% (Figure E1, A in the Online Repository). For some 
experiments pre-enriched B cells were labeled with anti-CD27-PE and CD27- 
and CD27+ B cells were sorted by flow cytometry. For the isolation of alive IL-
10+ B cells, purified peripheral B cells were stimulated with 1 µM CpG 2006 
(Microsynth GmbH, Balgach, Switzerland). After 3 d culture at 37° C in 
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humidified 5% CO2, cells were harvested and labeled with 50 µg/ml anti-IL-
10/CD45 antibody-antibody conjugates (Miltenyi Biotec) for 10 min at a 
concentration of 108 cell/ml in ice-cold supplemented RPMI 1640 medium. 
The cells were diluted with 37° C medium to a final concentration of 105 
cells/ml and were allowed to secrete and capture IL-10 for 2 hours at 37° C. 
After capturing the secreted IL-10 on their surface, cells were centrifuged at 
300xg for 5 min at 4°C and resuspended at a concentration of 108 cells/ml in 
ice-cold buffer containing 0.5% BSA and 2 mM EDTA (Sigma-Aldrich, St. 
Louis, MO USA) in PBS. Control cells were stained without the CD45/IL-10 
antibody/antibody conjugate. The cells were then stained with 5 µg/ml PE-
conjugated anti-IL-10 for 10 min at 4°C and washed and resuspended in BSA-
EDTA PBS. Dead cells were excluded using 7-AAD and IL-10+ and IL-10- B 
cells were sorted using a FACSAria II cell sorter (BD Biosciences, Franklin 
Lakes, NJ USA).  
 
Cell cultures. Cells were cultured in RPMI 1640 medium supplemented as 
previously described.101 Unless otherwise indicated cells were cultured at a 
density of 1x106/ml. The following reagents were used for stimulation of B 
cells: 1 µM of the TLR7-L 3M-013 (3M Pharmaceuticals, St Paul MN, USA), 1 
µM of synthetic phosphorothioate B type TLR9-L CpG 2006 (Microsynth), 
10µg/ml of rabbit anti-human IgG + IgM (Jackson ImmunoResearch Europe, 
Suffolk, UK) for BCR stimulation, soluble CD40L ligand (sCD40L) was used 
as described previously65, 100 U/mL of IL-2 (Proleukin ProreoPharma, Liestal, 
Switzerland), 50 ng/ml of IL-10 (PeproTech, London, UK), 25 ng/ml of IL-7, IL-
9, IL-15 and IL-21 (PeproTech, London, UK). 
 
Flow cytometry. The following antibodies and staining reagents were used: 
CD19-ECD, CD19-PC5, CD25-PC5, CD3-PC5, CD16-PC5, CD14-PC5 
(Beckman Coulter, Fullerton, CA USA), IgM-PerCP/Cy5.5, CD5-PC7, CD24-
AF488, CD38-PC7, CD73-APC, CD71-FITC, CD19-APC/Cy7 (Biolegend, San 
Diego, CA USA), CD27-PE, IgD-FITC, CD274-FITC (BD Biosciences), CD25-
PE (DAKO, Glostrup, Denmark). PLA was labeled with FITC or Alexa Fluor-
647. Matching isotype controls were used as negative controls. Samples were 
measured with a FACSAria II instrument (Beckton Dickinson) or Galios flow 
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cytometer (Beckman Coulter) and analyzed using Kaluza software (Beckman 
Coulter).  
 
RNA isolation and cDNA synthesis. RNA was isolated using RNeasy kits 
(Qiagen, Hilden, DE). Reverse transcription was performed with reverse-
transcription reagents (Fermentas, St. Leon-Rot, DE) with random hexamers 
according to the manufacturer’s protocol.  
 
Real-time PCR. cDNAs were amplified using SYBR green PCR master mix 
(Bio-Rad Laboratories, Hercules, CA USA) according to the manufacturer’s 
recommendations using an ABI PRISM 7000 Sequence Detection System 
(Applied Biosystems, Foster City, CA USA). Relative quantification was 
performed using the comparative ΔΔCT method.183 The housekeeping gene 
EF1α was used for normalization. Figure 4b shows 2-(ΔCT) values multiplied 
such as to set the average expression level of IL-10- cells to 1, where ΔCT 
corresponds to the difference between the CT value for the gene of interest 
and EF1α. Primers used: EF1a fw 5’-CTGAACCATCCAGGCCAAAT-3’ rv 5’-
GCCGTGTGGCAATCCAAT-3’; IL-10 fw 5’-GTGATGCCCCAAGCTGAGA-3’ 
rv 5’-CACGGCCTTGCTCTTGTTTT-3’; IgE fw 5'-ACACATCCACAGGCACCA 
AA-3' rv 5'-TTGCAGCAGCGGGTCAA-3'; IgG4 fw 5'-ACCC/ATGGTCACCGTC 
TCCTCA-3' rv 5'-GGGACCATATTTGGACTC-3'; IgA fw 5'-CGCTGGCCTTCA 
CACAGAA-3' rv 5'-CGCCATGACAACAGACACA-3'; IgG1 fw 5'-CTCTCAGC 
CAGGACCAAGGA-3' rv 5'-GGTGGGCATGTGTGAGTTTTG-3'; ; IL2RA fw 5'-
AAACTCTAGCCACTCGTCCTG-3' rv 5'-ACTTGTTTCGTTGTGTTCCGA-3'; 
IL2RB fw 5'-GGACTTCAAGCCCTTTGAGAAC-3' rv 5'-TAGTGGGAGGCTTG 
GGAGAT-3'; JAK1 fw 5'-GGCATGCCGTATCTCTCCTC-3' rv 5'-GTGATGG 
TGCGATTTGGAGC-3'; STAT1 fw 5'-GTTATGGGACCGCACCTTCA-3' rv 5'-
CATGCAGGGCTGTCTTTCCA-3'; STAT3 fw 5'-ACCAGCAGTATAGCCGCT 
TC-3' rv 5'-GCCACAATCCGGGCAATCT-3'; STAT5A fw 5'-
GCAGAGTCCGTGACAGAGG-3' rv 5'-CCACAGGTAGGGACAGAGTCT-3'; 
TFRC/CD71 fw 5'-GGCTACTTGGGCTATTGTAAAGG-3' rv 5'-
CAGTTTCTCCGACAACTTTCTCT-3'; PDL1/CD274 fw 5'-ACTGGGACATT 
  6 Results 
 
 71 
CGGGTTTTGA-3' rv 5'- CCTCACTTTCTGAGCGATGAGT-3'; CD73 fw 5'-
ACTGGGACATTCGGGTTTTGA-3' rv 5'-CCTCACTTTCTGAGCGATGAGT-
3'; PTPN11 fw 5'-AGAGAAAGGTGTTGACTGCGAT-3' rv 5'-TCCTGCGCTGT 
AGTGTTTCA-3'. Immunoglobulin mRNA expression was always measured 
after 5 d. Expression of differentially regulated genes in IL-10- compared to IL-
10+ B cells that were identified by gene array were measured after 3 d 
(immediately after sorting IL-10-and IL-10+ cells). 
 
Suppression assay. IL-10+ and IL-10- B cells were co-cultured with 2 x 105 
autologous PBMC in ratios of B cells:PBMC of 1:100, 1:50 and 1:25. CD73-
CD25+CD71+, CD73-CD25-CD71-, CD73+CD25+CD71+ and CD73+CD25-
CD71- B cells were sorted from resting B cells and subsequently stimulated 
for 48 hours with TLR9-L. Cells were then washed and co-cultured with 2 x 
105 autologous PBMC in ratios of B cells:PBMC of 1:25 and 1:12. For CFSE 
dilution experiments PBMC were labeled with 5 µM CFSE (Invitrogen) and 
washed twice with supplemented RPMI 1640. As a control for proliferation 
without suppression no B cells were added in a control group. Cells were 
stimulated with 1 µg/ml PPD (Statens Serum Institut, Copenhagen, DK) and 
cultured in a 96-well plate. For [3H]thymidine incorporation measurements 
cells were pulsed for 8 hours at 37° C with 1 µCi/well [3H]thymidine (DuPont; 
New England Nuclear), and the incorporation of labeled nucleotide was 
measured in an LKB β plate reader (GE Healthcare). To determine CFSE 
dilution, cells were stained with anti-human CD4-APC (Beckton Dickinson) 
and analyzed using a Gallios flow cytometer (Beckman Coulter). IL-10R 
blocking antibodies and isotype control (Biolegend) were used at 5 µg/ml. rIL-
10 (Peprotech) was used at a concentration of 25 ng/ml.  
 
Quantification of cytokines and immunoglobulins. IL-10 was measured 
using ELISA as described previously63 or the Bio-Plex Hu Cytokine Panel, 17-
Plex Group 1 (Bio-Rad Laboratories). Human IgG1, IgG4, IgA, and IgE in cell 
culture supernatants were measured after a total 10d culture period using a 
Bio-Plex Pro™ Human Isotyping Panel (Bio-Rad Laboratories). Fluorescent 
signals were read and analyzed using the Bio-Plex 200 System (Bio-Rad 
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Laboratories). PLA-specific IgE and IgG4 from serum samples were 
measured by ELISA as previously described.101 
 
Statistical Analysis. Unless otherwise indicated data show mean ± SEM. 
Statistical tests were performed using GraphPad Prism 5.0c. Paired t-tests 
and Wilcoxon signed rank tests were used for assessing statistical 
significance. The ratio of serum measurement of anti-PLA IgG4:IgE was 
analyzed by one-way ANOVA with Turkey posthoc test. Statistical analysis 
applied to gene array data is described in the methods section of the whole 
human genome microarray analysis. The grade of statistical significance is 
displayed in the legends to the figures. P values of <0.05 were considered 
significant. 
 
Whole human genome microarray analysis. IL-10- and IL-10+ B cells from 6 
healthy individuals were purified after 3 d TLR9-L stimulation. 5000 IL-10+ and 
5000 IL-10- B cells were sorted using a FACSAria II cell-sorter (BD 
biosciences) and cells were lysed in SuperAmp Lysis Buffer (Miltenyi Biotec) 
following the manufacturer’s instructions and stored at -80°C. A dual-color 
hybridization of human RNAs on Agilent Whole Human Genome Oligo 
Microarrays and bioinformatics analysis was performed by Miltenyi Biotec. 
Gene expression analysis using the Agilent platform (Agilent Technologies, 
Palo Alto, USA) was performed at Miltenyi Biotec’s gene array facility 
(Bergisch Gladbach, Germany). RNA was isolated using paramagnetic 
oligo(dT) MicroBeads. Uniform-sized cDNA fragments were generated by an 
in-column cDNA synthesis procedure. All cDNA fragments were tailed at the 
3’-end and amplified by single-primer global PCR. cDNA was quantified using 
the ND-1000 Spectrophotometer (NanoDrop Technologies). The integrity of 
the amplified cDNA was determined using the Agilent 2100 Bioanalyzer 
platform (Agilent technologies). The average length of the highly amplified 
cDNA products ranged between 200–1,000 bp. 250 ng of each of the cDNAs 
were used as template for Cy3 and Cy5 labeling in a Klenow Fragment 
reaction. IL-10+ samples were Cy5-labeled and IL-10- samples were Cy3-
labeled. The Cy3- and Cy5- labeled cDNAs were combined and hybridized 
overnight (17 hours, 65°C) to an Agilent Whole Human Genome Oligo 
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Microarrays 4 x 44K. Finally, the microarrays were washed once with 6x 
SSPE buffer containing 0.005% N-lauroylsarcosine for 1 min at room 
temperature followed by a second wash with pre-heated 0.06x SSPE buffer 
(37 °C) containing 0.005% N-lauroylsarcosine for 1 min. Fluorescence signals 
of the hybridized Agilent Oligo Microarrays were detected using a DNA 
microarray scanner (Agilent Technologies). The Agilent Feature Extraction 
Software (FES) was used to read out and process the microarray image files. 
Preprocessing of the microarray data include normalization using 
the Lowess algorithm184 and incorporation of the Rosetta error model.185 The 
resulting ratios for each reporter between the signal intensities of the co-
hybridized treated and untreated samples were transformed to logarithms to 
base 2 (log2 ratios). Individual signal detection- and ratio- p-values were 
calculated (Rosetta error model, Rosetta Inpharmatics LLC, Seattle, USA) to 
evaluate the reliability of signal, and expression based on signal to 
background intensities of both co-hybridized samples per array. Expression 
differences for individual reporters between the treated and untreated sample 
groups were identified by one-group t-test followed by multiple testing 
correction (Benjamini & Hochberg)186 on the log2 ratio data and effect size 
(fold change). Candidate genes with differential expression were selected if 
they passed a corrected p-value ≤ 0.05 in the group-wise comparison. Genes 
were additionally filtered for detection p-value ≤ 0.01 in at least four out of six 
samples per channel, followed by selection of array data sets with ratio p-
values ≤ 0.01 in all six replicate experiments. Candidate genes that passed 
these requirements are listed in Table E1 in the online repository. 
 
Reporters identified in the discriminatory genes analysis were annotated with 
information from Gene Ontology (GO), which provides information on 
molecular function, as well as various pathway resources for information on 
involvement in biological signaling pathways (The Gene Ontology Consortium, 
2000). All annotations were summarized and curated by the Miltenyi 
Bioinformatics team (Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany). Signaling pathways and targets of pathways were additionally 
curated based on information from NetPath database187. For an assessment 
of the enrichment of a category, Fisher’s exact test with Benjamini-Hochberg 
  6 Results 
 
 74 
correction for multiple testing186 was performed. Values of ≤ 0.05 indicate a 
significant enrichment relative to the background (whole reporter-sets of the 
Agilent 4x44K Whole Human Genome Oligo Microarray) of the respective 
category.  
 
Several genes encoding surface markers were differentially expressed (See 
Table E2 in the online repository). Differential expression of surface marker 
genes was based on alignment with a list of described genes encoding 
surface markers obtained from Immunome Knowledge Database.188 Genes 
that were differentially expressed between IL-10- and IL-10+ B cells were 
compared to a published list of genes that are regulated by IL-10 in human 
monocytes189 (See Table E3 in the online repository). Genes that were 
differentially expressed between IL-10- and IL-10+ B cells were compared to 
genes that were previously described to be regulated by TLR9-L in human B 
cells190 (See Table E4 in the online repository). Microarray data are available 
under GEO accession no. GSE35002. 
  6 Results 
 
 75 
Results 
Purification and characterization of human IL-10-secreting Br1 cells 
Stimulation with the TLR9-L CpG2006 was found to optimally induce IL-10 in 
purified B cells. In order to purify alive IL-10-secreting (IL-10+) B cells, 
stimulated B cells were labeled with anti-IL-10/CD45 antibody-antibody 
conjugates and subsequently incubated to allow secretion and capture of IL-
10 to the cell surface. Both resting as well as proliferating B cells expressed 
IL-10 in response to TLR9 stimulation (See Figure E1, A-C in the Online 
Repository). 
 
In order to characterize Br1 cells, IL-10+ B cells and IL-10- B cells were sorted 
and IL-10 mRNA expression was strongly confined to IL-10+ cells (Figure 1A). 
Purified IL-10+ and IL-10- B cells were subjected to whole genome microarray 
expression analysis. Several genes involved in IL-2 signaling were 
upregulated in IL-10+ cells including IL2RA, IL2RB, JAK1, STAT1, STAT3, 
STAT5A, PTPN11 (See supplementary Figure E1, D and Table E1 in the 
Online Repository). JAK1 and STAT3 are also key factors in IL-10 signaling. 
Several genes encoding surface markers were differentially expressed 
between IL-10- and IL-10+ B cells. A heat map of the five of genes showing 
the highest median differential expression between IL-10- vs. IL-10+ genes is 
shown in Figure 1B. Genes encoding surface markers that showed higher 
expression in IL-10+ cells included CD80 (4.5-fold), IL2RA (4.4-fold), TFRC 
(4.1-fold), CD274 (4.1-fold) and IL2RB (2.8-fold). Genes encoding surface 
markers that showed lower expression in IL-10+ cells included PTPRJ (2.5-
fold), NT5E (2.3-fold), CD79B (2.2-fold), CD37 (2.0-fold) and FCGR2B (1.9-
fold) (Figure 1B and Table E2 in the Online Repository). Differential 
expression of IL2RA (CD25), TFRC (CD71), CD274 (PD-L1) and NT5E 
(CD73) was confirmed by real-time PCR (Figure 1C) and flow cytometry 
(Figure 1D). Thus, IL-10+ B cells showed elevated expression of CD25, CD71 
and PD-L1 while CD73 expression was reduced. We then investigated the 
expression of other B cell markers and surface markers that have been linked 
to Breg cells in previous reports. Surface expression of CD38, CD24, CD5, 
CD27, IgM and IgD was also measured to further characterize IL-10+ B cells. 
TLR9-L-induced IL-10+ cells had similar frequencies among CD24intCD38int, 
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CD24hi CD38- and CD24hi CD38hi B cells (See Figure E1, E in the Online 
Repository). The frequency of CD27+ B cells was similar between IL-10- and 
IL-10+ B cells while the level of CD27 expression was lower among CD27+ B 
cells in the IL-10+ population.  
 
Figure 1. Characterization of IL-10- and IL-10+ B cells.  (A) Sorting of IL-10- 
and IL-10+ B cells. IL-10 expression was confirmed by real-time PCR. (B) 
Sorted fractions (n=6) (B) Gene array result showing up- or downregulated 
surface marker genes. (C) mRNA expression (relative to IL-10-) of selected 
surface markers (n=6) (D) CD25, CD71, CD274 and CD73 surface staining 
(representative example out of 3). * P<0.05, ** P<0.01. 
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The frequencies of CD5+ as well as IgM+IgD- cells were two-fold higher in IL-
10+ cells (See Figure E1, F in the Online Repository). Again, purified CD27- 
and CD27+ B cells produced similar levels of IL-10 in response to TLR9-L 
(See Figure E1, G in the Online Repository). These data suggest that B cells 
that produce IL-10 in response to TLR9-L stimulation are not restricted to a 
single subset of B cells. 
 
IL-10-producing B cells are enriched in CD73-CD25+CD71+ B cells 
In order to isolate IL-10-producing B cells, we stained CD25 and CD71 as 
high expression markers and CD73 as a low/negative expression marker on 
circulating B cells without any stimulation. PD-L1 surface expression showed 
only a mild upwards shift in IL-10+ B cells and therefore was not suitable as a 
distinguishing marker. Among CD73- B cells, CD25+ and CD71+ cells formed 
a separate population (See Figure E2 in the Online Repository) and 
CD25+CD71+ B cells had a 4-fold higher frequency in CD73- cells than in 
CD73+ cells (Figure 2A). CD73-CD25+CD71+, CD73-CD25-CD71-, 
CD73+CD25+CD71+ and CD73+CD25-CD71- B cells were sorted (Figure 2B) 
and subsequently stimulated with TLR9-L. We found that CD73-CD25+CD71+ 
B cells secreted the highest amounts of IL-10. In contrast, 
CD73+CD25+CD71+ cells secreted 3-fold less IL-10, and CD73-CD25-CD71- 
and CD73+CD25-CD71- cells showed the lowest IL-10 production (Figure 2C). 
 
IL-10 plays an essential role in T cell suppression by human Br1 cells 
Next, we wanted to determine whether Br1 cells have suppressive capacity on 
antigen-specific proliferative responses. IL-10+ and IL-10- B cells were purified 
using the IL-10-secretion assay and co-cultured at different ratios with 
autologous PBMC that were stimulated with PPD. With a ratio of 1 B cell to 25 
PBMC, we observed up to 50% suppression by IL-10+ B cells on PPD-
induced proliferative responses in PBMC whereas other B cells did not show 
suppressive capacity. This effect was reversed upon blocking the IL-10 
receptor. CFSE dye analysis confirmed these findings and furthermore 
demonstrated that proliferation of CD4+ T cells in response to PPD stimulation 
was strongly suppressed by IL-10+ B cells. PPD-induced CD4+ T cell 
proliferation was suppressed around 50% with a ratio of one IL-10+ B cell to 
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25 responder cells (Figure 3A and Figure E3 in the Online Repository). IL-10- 
B cells could also partially suppress CD4+ T cell proliferation. In the presence 
of a blocking anti-IL-10R antibody the percentage of proliferating CD4+ T cells 
was generally higher in cultures with added B cells (both IL-10- and IL-10+) 
than in PBMC (Figure 3A) possibly due to increased antigen presentation by 
B cells and neutralization of endogenous IL-10. 
 
 
 
Figure 2. Sorting of CD73, CD25 and CD71+/- populations from resting B 
cells. (A) Staining of CD25 and CD71 on CD73- and CD73+ B cells. (n=3, one 
representative example is shown) (B) Sorted B cell populations were 
reanalyzed to assess purity. (C) Sorted B cell populations (n=3, 5x104 cells in 
100µl) were stimulated for 48h and IL-10 was measured in supernatants. * 
P<0.05. 
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To identify the suppressive capacity of B cells that differentially express 
CD25, CD71 and CD73, CD73-CD25+CD71+, CD73-CD25-CD71-, 
CD73+CD25+CD71+ and CD73+CD25-CD71- B cells were sorted and co-
cultured at different ratios with autologous PPD-stimulated PBMC. Only CD73-
CD25+CD71+ B cells could suppress CD4+ T cell proliferation, whereas the 
other three B cell subsets did not show any suppressive effect (Figure 3B). 
This suppressive effect was however not fully reversed through addition of 
blocking anti-IL-10R antibody. Due to cell number limitations higher ratios of B 
cells to PBMC could not be used. 
 
 
Figure 3. Br1 cells suppress antigen-specific proliferation. (A) Co-cultures of 
CFSE-labeled PBMC with IL-10+ or IL-10- B cells (ratio: 1 B cells to 25 PBMC) 
with blocking anti-IL-10R or i.c. mAbs. Recombinant IL-10 (rIL-10) was used 
as control. Histograms show representative example. Numbers indicate 
percentage dividing CD4+ cells. (B) Co-cultures of PBMC with CD73, CD25 
and CD71+/- B cells. Combined data from four independent experiments is 
shown. * P<0.05, ** P<0.01. 
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Immunoglobulin production of Br1 cells 
We then investigated the isotype of the produced immunoglobulin by 
circulating human Br1 cells upon their differentiation to plasma cells. TLR9-L 
stimulation of purified B cells induced expression of IgG1, IgG4 and IgA, but 
not IgE at the mRNA level, whereas protein secretion of all four subclasses 
was induced. TLR9-L + IL-10 stimulation showed a synergistic effect on IgG4 
production while IgG1 and IgE induction were not affected. IgA production 
showed a tendency to be suppressed by IL-10. (Figure 4A). The small amount 
of IgG4 induced by TLR9-L was mainly derived from CD27+ B cells and was 
dependent on endogenous IL-10 production as blocking of IL-10R largely 
suppressed IgG4 production by CD27+ cells. Dual stimulation with TLR9-L 
and IL-10 particularly increased IgG4 production in CD27- B cells (See Figure 
E4 in the Online Repository). 
 
In the next step, IL-10- and IL-10+ B cells were sorted to investigate their 
immunoglobulin profile upon activation with TLR9-L. IL-10- and IL-10+ B cells 
were cultured for 5 d and the expression of immunoglobulin mRNAs were 
analyzed. IgG4 transcripts were expressed on average 10-fold higher in the 
IL-10+ population compared to the IL-10- population (Figure 4B). IgG1, IgA 
and IgE were not differentially expressed between the two populations.  
 
To further delineate this distinct upregulation of IgG4, IL-10+ and IL-10- cells 
were isolated from CD27- and CD27+ B cells that were sorted before 
stimulation with TLR9-L and immunoglobulin production was measured. IL-10- 
and IL-10+ B cells derived from CD27+ B cells showed no significant 
differences in the expression of IgG1, IgG4 or IgA. IL-10+ B cells derived form 
CD27- B cells on the other hand produced 15-fold higher IgG4 than IL-10- 
cells whereas IgG1 and IgA production was not significantly increased (Figure 
4C). 
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Figure 4. Immunoglobulin production by Br1 cells. (A) IgG1, IgG4, IgA and IgE 
mRNA expression (relative to unstimulated cells) in total B cells. Lower panel: 
IgG1, IgG4, IgA measured in supernatants. (n=5, 3 independent 
experiments). (B) IgG1, IgG4, IgA and IgE mRNA expression (average IL-10- 
expression=1) in IL-10- and IL-10+ B cells. Connected dots represent 
individual donors. (C) Secreted IgG1, IgG4 and IgA measured from IL-10- and 
IL-10+ cells derived from CD27- and CD27+ B cells (n=4). Fold increase is 
relative to average of IL-10-. IgE protein was not detectable. *P<0.05, 
**P<0.01.  
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Allergen-specific Br1 cells are confined to IgG4 production in high-dose 
bee venom tolerance 
PLA-specific B cells from highly bee venom-exposed tolerant beekeepers 
were enriched by using labeled PLA. Between 0.1% and 0.9% of beekeeper-
derived CD19+ peripheral B cells were specific for PLA (Figure 5A). 
Subsequently, PLA-specific (PLA+) and non PLA-specific (PLA-) B cells were 
sorted (Figure 5A). Immunoglobulin isotypes and IL-10 mRNAs were 
measured immediately after sorting of the cells without any stimulation. IgG4 
expression was significantly higher (median increase 14.1-fold) in PLA+ B 
cells than in PLA- B cells. IgA expression showed a modest decrease (median 
decrease 2-fold) in PLA+ B cells whereas expression of IgE and IgG1 
transcripts showed no significant difference between PLA+ and PLA- B cells. 
IL-10 mRNA expression was significantly increased (median increase 30.8-
fold) in PLA-specific B cells (Figure 5B). To measure IL-10 protein production, 
B cells from beekeepers and bee venom allergic patients before and after SIT 
were stimulated for 3 d with CpG and stained for IL-10 and PLA-binding to 
their surface. The mean frequency of IL-10+ cells was 1.8-fold higher in PLA+-
gated than in PLA--gated B cells from beekeepers. PLA+ B cells in allergic 
patients had relatively low frequencies of IL-10+ B cells (1.8-2.9 %), which 
significantly increased (5.5-13.9 %) after 110 days of bee venom SIT. (Figure 
5 C). In line with the flow cytometry data, secreted IL-10 in these samples was 
2-fold higher in PLA+ than in PLA- cells. (Figure E5). 
 
Additional in vivo evidence for the role of Br1 cells in allergen tolerance that 
links IL-10 to IgG4 was obtained by measuring of PLA-specific IgE and IgG4 
in serum of beekeepers, bee venom allergic individuals and allergic 
individuals who received 110 days of bee venom-SIT. Allergic individuals who 
received SIT showed a significantly lower (100-fold) ratio of PLA-specific 
IgE:IgG4 when compared to non-treated allergic individuals. This difference 
was even greater (1000-fold) when compared to non-allergic beekeepers. In 
both cases this was due to substantially increased levels of specific IgG4. 
(Figure 5 D). 
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Figure 5. Allergen-specific B cells from tolerant individuals upregulate IL-10 
and IgG4. (A) Enrichment of PLA-specific B cells from beekeeper-derived 
peripheral CD19+ cells. (B) Direct ex-vivo analysis of immunoglobulin and IL-
10 mRNA expression (relative to PLA- cells). (n=6) Horizontal bars indicate 
median. (C) IL-10 and PLA staining in B cells from beekeepers (n=7) or bee 
venom allergic patients (n=4) after 3d TLR9-L stimulation. Numbers in dot 
plots: mean (± SD). (D) Ratio of PLA-specific serum IgE:IgG4. *P<0.05 
**P<0.01, ***P<0.001. 
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Discussion 
This is the first study in which human inducible IL-10-producing B cells 
(designated as Br1 cells) were purified based on their secretion of IL-10. 
Gene arrays were performed and novel molecules that characterize Br1 cells 
were identified. We demonstrated a potent suppressive capacity of IL-10-
producing B cells on antigen-specific CD4+ T cell activation and, more 
importantly, we observed a striking shift towards production of anti-
inflammatory IgG4 antibodies in these cells.  
 
Despite accumulating data describing immunoregulatory functions of IL-10-
producing B cell subsets in murine models, there is still little known about the 
function and phenotype of human regulatory B cells. There are indications 
that distinct B cell subsets have immunoregulatory functions in humans.159, 166, 
167 Human CD24hiCD38hi B cells were shown to suppress the differentiation of 
Th1 cells through provision of IL-10 and possibly also through CD80- and 
CD86-mediated signaling.159, 161 In another study, a CD24hiCD27+ human B 
cell subset was identified that contained the majority of IL-10-producing B 
cells and was found at higher frequencies in patients with autoimmune 
disease compared to healthy controls.161  
 
A fraction of approximately 1-4 % of B cells secreted IL-10 in response to 
TLR9-L stimulation. These cells were not restricted to a single population of B 
cells since both CD27- (primarily naïve) and CD27+ (primarily memory) B cells 
secreted similar amounts of IL-10. Unlike the described CD24hi CD38hi Breg 
cells that produced IL-10 in a CD40L-dependent manner159,the frequency of 
Br1 cells was equally distributed among CD24int CD38int, CD24hi CD38- and 
CD24hi CD38hi B cells. Furthermore CD5+ and IgM+IgD- cells were enriched 
among IL-10+ B cells. Using whole genome expression analysis and flow 
cytometry we could identify four surface markers that were significantly 
differently expressed on Br1 cells compared to IL-10- B cells. Br1 cells 
showed elevated expression of CD25, CD71 and CD274 whereas CD73 
expression was lower. Some of these molecules are known to play a role in 
immune regulation. CD25 is expressed at high levels on natural Treg cells 
and contributes to their suppressive effect through cytokine deprivation-
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mediated apoptosis of CD4+ effector cells.191, 192 Interestingly, CD25 
expression appears to be essential for IL-10 expression by CD4+ T cells and 
thereby plays an important role in the generation of Tr1 cells.193 CD71 is the 
major transferrin receptor, which is involved in the cellular uptake of iron and 
in the regulation of cell growth. CD25 and CD71 are both known activation 
markers of T and B cells and their elevated expression may reflect an 
increased activation state.194 CD274, also named PD-L1, is an inhibitory co-
stimulatory molecule that counteracts T cells activation through binding to PD-
1 on T cells.195 PD-L1 can inhibit T cell responses by promoting both the 
induction and maintenance of inducible Treg cells.196 CD73, alternatively 
named ecto-5'-nucleotidase, is a cell surface enzyme expressed on many cell 
types including T and B cells. CD73 converts adenosine monophosphate to 
adenosine, which has potent immunosuppressive effects. CD73 expressed on 
Treg cells may be responsible for part of their immunosuppressive effects.197 
Br1 cells on the other hand express low levels of surface CD73 and therefore 
adenosine-mediated immune-suppression is unlikely to play an important role 
in suppression of T cell responses. 
 
IL-10+ cells potently suppressed antigen-specific proliferation of CD4+ T cells. 
A ratio of 1 B cell to 25 PBMC led to 50% suppression of the proliferative T 
cell response. IL-10- B cells could also weakly suppress proliferation. A 
possible explanation can be that the sensitivity of the IL-10 secretion assay 
was not sufficient to detect cells that produce minute amounts of IL-10 that 
may remain in the IL-10- fraction and render them slightly suppressive. 
Kinetics of IL-10 induction could also play a role as some cells may not 
secrete IL-10 at the time of sorting, but may do so later. The suppressive 
effect observed in our experiments is completely reversible through blocking 
of the IL-10 receptor. CD73-CD25+CD71+cells sorted from resting B cells 
could similarly suppress T cell proliferation. The strength of in vitro 
suppressive effect may differ from that of IL-10+ sorted cells due to the fact 
that not all CD73-CD25+CD71+ produce IL-10 upon activation. Control 
populations (CD25-CD71- or CD73+ cells) were not suppressive at these 
ratios. A slight blocking effect in the CD73-CD25+CD71+ Breg-mediated 
suppression was observed in the presence of anti-IL-10R mAb compared to 
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isotype control, suggesting a partial involvement of IL-10 in the suppression. 
This effect was however small and not statistically significant. It has to be 
noted that the CD73-CD25+CD71+ B cell population does not include all of the 
IL-10+ B cells. Therefore, CD73-CD25+CD71+ expression can be used to 
identify a distinct population of Breg cells that does not include all of IL-10-
producing B cells. Furthermore not all CD73-CD25+CD71+ B cells produce IL-
10. It is therefore possible that CD73-CD25+CD71+ B cells may apply 
additional mechanisms to suppress T cell proliferation. The identification of 
the mechanisms involved will require significant research effort, as there can 
be many factors that may play a suppressive role besides IL-10. For example, 
the surface markers that were used to sort the cells may play a role similar to 
the suppressive role for CD25 by means of IL-2 deprivation that has been 
described in Treg cells.198 In addition, blocking of CD80 ad CD86 has been 
shown to reverse Breg-mediated suppression of T cell responses.159 
Furthermore, these cells express PD-L1 and this interaction may also play a 
role as demonstrated in Treg cells.101 Together, these data demonstrate that 
Br1 cells are highly potent suppressors of T cell responses. This is especially 
striking when compared to Tr1 and Treg cells, which suppress around 50% of 
antigen-specific proliferation at a ratio of one suppressor cell to two or four 
responder cells respectively.101, 199  
 
In the experiments investigating the link of Br1 cells to immunoglobulin 
production we found that IgG4 production is specifically confined to IL-10+ Br1 
cells. TLR9 stimulation induced production of IgG1, IgG4 and IgA primarily in 
CD27+ B cells while simultaneous stimulation with TLR9 and IL-10 induced 
specific upregulation of IgG4 particularly in CD27- B cells without affecting 
IgG1 and IgA. These findings combined with the fact that TLR9 stimulation 
induces IL-10 in a subset of B cells raised the question whether IL-10+ cells 
are more prone to produce IgG4 than IL-10- B cells. There was approximately 
10-fold increased IgG4 mRNA in IL-10+ Br1 cells, compared to IL-10- 
counterparts. And when sorting Br1 cells from CD27- and CD27+ subsets it 
emerged that IgG4 production was specifically upregulated in CD27-IL-10+ B 
cells suggesting that naïve Br1 cells are the main precursors of IgG4 
producing cells. 
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Induction of allergen-specific IgG4 is a hallmark of successful peripheral 
tolerance induction as observed in allergen-SIT. Our data demonstrate that 
PLA-specific B cells from beekeepers mainly express IgG4. PLA-specific and 
non-PLA-specific B cells were isolated from peripheral blood and directly 
analyzed without in vitro culture. The elevated IgG4 expression in PLA-
specific B cells indicates that these cells mainly represent circulating IgG4-
switched PLA-specific memory B cells. Interestingly, IL-10 mRNA expression 
was also significantly higher in these cells suggesting that in vivo circulating 
PLA-specific B cells in beekeepers have elevated IL-10 production. 
Furthermore, when stimulated in vitro with TLR9-L, PLA-specific cells showed 
higher IL-10 secretion than non-PLA-specific B cells. This increased 
frequency of IL-10+ cells among PLA-specific B cells was not observed in bee 
venom allergic patients. However after SIT the frequency of PLA-specific IL-
10+ B cells significantly increased to the same level as in beekeepers. PLA-
specific IgG4 was detected at high concentrations in serum of non-allergic 
beekeepers who showed >1000 times lower PLA-specific IgE:IgG4 ratio than 
allergic individuals. Allergen-SIT and high-dose allergen tolerance has been 
linked to increased serum IgG4 and IL-10 production from T cells.176 Here we 
demonstrate that allergen-specific B cell IL-10 production is increased during 
allergen-SIT. Our data demonstrate that particularly CD27-IL-10+ B cells are 
precursors of IgG4 producing cells. In addition the ongoing immune response 
of memory B cells contributes to IgG4. We found elevated IgG4 expression 
and an increased frequency of IL-10+ cells among PLA-specific B cells in bee 
venom tolerant individuals. This suggests that in these individuals there exists 
a PLA-specific IgG4-switched memory B cell compartment that retains high 
IL-10 expression and may play a role in maintenance of tolerance. Whether 
these cells derive from Br1 cells requires further investigation. Interestingly, 
Schistosoma mansoni infection in children correlates with increased IL-10 
production in response to parasitic antigens and decreased atopy.200 
Furthermore Schistosoma mansoni infection mediates protection against 
experimentally induced anaphylaxis. This protective effect was dependent on 
IL-10-producing B cells.154 And, in line with our findings, high levels of IgG4 
antibodies are detected in helminth-infected individuals.201-203  
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In conclusion, the current findings demonstrate an essential role for B cells in 
inducing and maintenance of immunological tolerance. The present study 
demonstrates two ways to directly purify and analyze these cells in humans 
according to IL-10 secretion and surface CD25, CD71 high and CD73 low 
expression. By analyzing CD27, it was observed that both naïve and memory 
subsets of Br1 cells can express IL-10 upon TLR9-L stimulation. Br1 cells act 
on T cell responses by interfering with CD4+ T cell activation and they 
contribute to peripheral tolerance through production of non-inflammatory 
IgG4 antibodies. We demonstrated significant in vivo regulation of these cells 
by isolating major allergen-specific Br1 cells in high-dose allergen exposed 
beekeepers as well as in vivo induction of these cells after allergen-SIT of bee 
venom allergic subjects. Therefore, Br1 cells bring together two important 
arms of immune tolerance, namely play a role as suppressive cells and direct 
the humoral response towards IgG4, which together characterize a healthy 
immune response to allergens. 
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Online repository figures 
The online repository tables E1-E4 exceed the size suitable for printing and 
can be obtained from the original publication.116 
 
 
Figure E1. Isolation and characterization of IL-10+ B cells. (A) Purification of 
human peripheral CD19+ B cells. (B) IL-10 secretion by purified human 
peripheral B cells after 3 d stimulation with different B cell activators and 
common gamma chain cytokines. (C) CFSE dilution and IL-10 secretion in 
purified B cells. CFSE-labeled cells were left unstimulated or stimulated with 
TLR9-L for 5 d and analysed by flow cytometry. (D) Real-time PCR analysis of 
JAK1, STAT1, STAT3, STAT5A, PTPN11 and IL-2Rβ mRNA expression in IL-
10- and IL-10+ B cells measured directly after sorting. Expression is shown 
relative to IL-10- cells. (E) Frequencies of IL-10-secreting cells among 
CD24intCD38int, CD24hi CD38- and CD24hi CD38hi B cells. Data are from 3 
independent experiments. (F) Surface expression of CD27, CD5, IgM and IgD 
on IL-10- and IL-10+ B cells. One representative example out of four 
independent experiments is shown. MFI refers to geometric mean 
fluorescence intensity. (G) IL-10 production by CD27- and CD27+ B cells (n=3) 
after 3 d TLR9-L stimulation.  
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Figure E2. Flow cytometric analysis of surface expression of CD73, CD25 and 
CD71 on resting peripheral B cells. B cells were pre-enriched from PBMC and 
stained for CD19, CD73 CD25, CD71 and CD73. CD19+ cells were gated and 
CD73 expression was plotted against CD25 and CD71 expression. One 
representative example out of 3 is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure E3. IL-10+ B cells suppress antigen-specific PBMC proliferation. 
[3H]Thymidine incorporation measured in PBMC stimulated with PPD for 5 d 
with or without IL-10+ or IL-10- B cells. Proliferation is shown relative to PPD 
stimulated PBMC. Data are from 3 independent experiments (n=6). *P<0.05. 
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Figure E4. Effect of IL-10 neutralization on immunoglobulin production. CD27- 
and CD27+ B cells were sorted by flow cytometry and cultured with TLR9-L or 
TLR9-L combined with IL-10 in the presence of blocking anti-IL-10R or isotype 
control (i.c.) antibodies. Secreted immunoglobulins were measured after 10 d. 
 
 
 
 
 
 
 
 
Figure E5. IL-10 production by PLA-specific B cells from beekeepers. IL-10 
measured in supernatants from cultured PLA- and PLA+ B cells. Sorted cells 
(2x104) were cultured for 3 d (n=2). 
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Abstract 
Background: Distinct human IL-10-producing B subsets with 
immunoregulatory properties have been described. However, the broader 
spectrum of cellular targets and mechanisms of suppression have not yet 
been extensively reported, particularly in respect of direct and indirect solely 
IL-10 mediated actions. Aim of the study was to investigate the effect of IL-10 
overexpression in B cells on their phenotype and immunosuppressive 
capacity toward TLR-induced production of proinflammatory cytokines, 
maturation of dendritic cells, and antigen specific proliferation. 
Methods: Purified B cells were transfected with pORF-hIL-10 and 
characterized in their profile of cytokine and immunoglobulin production (by 
ELISA and bead-based suspension assays), antigen presentation and co-
stimulation capacity, transcription factors signature (by quantitative PCR and 
flow cytometry). Effects of autologous IL-10-overexpresing B cells on PBMC 
and monocyte-derived dendritic cells (MDDC) were addressed in co-cultures 
under stimulatory conditions. 
Results: IL-10 overexpressing human B cells quickly acquired an 
immunoregulatory profile comprising upregulation of glycoprotein A repetitions 
predominant (GARP) and interleukin-2 receptor alpha chain (IL2RA). IL-10 
overexpression in B cells was associated with a significant reduction in 
proinflammatory cytokine production (TNF-α, IL-8 and MIP-1α) and 
augmented secretion of anti-inflammatory IL-1Ra and VEGF. IL-10 
overexpression was associated with a decrease in co-stimulatory potential. 
Co-cultures of autologous PBMC with IL-10-overexpressing B cells potently 
inhibited antigen-specific proliferation of PBMC and secretion of 
proinflammatory cytokines induced by TLR2 and TLR4 stimulation. 
Furthermore IL-10-overexpressing B cells suppressed MDDC maturation and 
expression of CD80, CD86 and CD83, while inducing expression of PD-L1.  
Conclusions: Our data demonstrate a prominent role for IL-10 in inducing an 
immunoregulatory phenotype of B cells capable to exert substantial anti-
inflammatory functions and contribute to modulation of immune responses 
providing a tolerance-inducing environment. 
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INTRODUCTION 
B lymphocytes display a unique role in immunity through the production of 
antibodies. Nevertheless, B cells also substantially contribute to immune 
responses through antigen presentation and co-stimulation, cytokine secretion 
and lymphoid tissue organization.169 B cells play an important role in the 
development of pathological immune responses such as asthma and atopic 
diseases (chronic immune reactivity to non-harmful antigens in sensitized 
individuals primarily mediated through IgE), autoimmunity (lack of 
control/excessive response to self antigens) and anti-tumor immunity/defense 
(insufficient response).169, 171 
 
Since the late 1990s a growing body of evidence has accumulated supporting 
an immunoregulatory function for B cells. Distinct B cell subsets with 
suppressive potential were discovered in different models of infection,154, 179 
allergic inflammation,156, 181 autoimmunity137, 146, 177, 178 and cancer 180 and their 
actions were mainly linked with the provision of IL-10. Concomitant 
suppression of IgE and induction of IgG4 production as well as demonstration 
of strong antigen-specific IL-10 induction was observed in allergic patients 
that underwent specific immunotherapy (SIT) with successful outcome.65, 102 
These findings have raised interest in the involvement of regulatory B cells in 
the modulation of allergic diseases.101, 171, 176 The existence of regulatory B 
cells in humans was supported by the finding that B cell depletion therapy in 
patients with rheumatoid arthritis and systemic lupus erithematosus (SLE) 
was associated with colitis exacerbations and induction of psoriasis.166, 167 
The best-described human regulatory B cell subsets are: I) CD24hiCD38hi 
cells, which have been demonstrated to suppress the differentiation of T 
helper 1 cells in healthy individuals after stimulation with CD40L, but were 
functionally impaired in SLE patients159; II) B10 and B10pro cells were 
predominantly found within CD24hiCD27+ B cells that were able to negatively 
regulate monocyte cytokine production in vitro; III) TLR9-L induced IL-10+ Br1 
cells were enriched among CD25+CD71+CD73- B cells and showed potent 
suppression of PPD-induced CD4+ proliferation.161 These Br1 cells comprise 
two temporally distinct but spatially linked immunosuppressive functions: IL-10 
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production and IgG4 secretion that were demonstrated to be hallmarks of 
high-dose antigen-induced desensitization in bee venom allergic patients 
underwent successful specific immunotherapy. The link between PLA-specific 
B cells secreting IL-10 and undergoing preferential CSR toward IgG4 was 
confirmed in beekeepers as human in vivo tolerance model upon high-dose 
antigen exposure.204 These findings particularly confirm the role of B cells in 
the maintenance/establishment of specific peripheral tolerance and their 
contribution to immune homeostasis.171, 176 The suppressive mechanisms of 
most of the described regulatory B cell subsets are at least in part IL-10-
dependent. 
 
IL-10 is a pivotal anti-inflammatory cytokine not only protecting the host from 
excessive tissue damage during host defense reactions to pathogens, but 
also one of the key molecules critically involved in maintenance of 
immunological tolerance and homoestasis.62, 205 IL-10 deficiency leads to 
development of spontaneous colitis.131 IL-10 suppresses production of pro-
inflammatory cytokines and chemokines as well as antigen presentation.62 On 
the other hand, IL-10 promotes survival, proliferation, differentiation and class 
switch recombination in human B cells.62 IL-10 suppresses IL-4-induced IgE 
production and enhances IgG4 production.63, 64 However, addressing the 
exclusive role of IL-10 in the immunoregulatory potential of IL-10-producing B 
cells is largely biased by different initial antigen-dependent or antigen-
independent signals. These signals, along with IL-10 production may lead to 
concurrent induction of other factors that may alter intrinsic IL-10-mediated 
regulatory features. 
 
We hypothesized that IL-10 expression in normal human B cells together with 
its consequent IL-10R dependent signaling on the same cells is sufficient for 
B cells to acquire a regulatory phenotype, which in conjunction with secreted 
IL-10 can exert a suppressive profile impacting different niches of immune 
responses. We aim to characterize the phenotype and function of IL-10-
overexpressing B cells in terms of cytokine secretion, antigen presentation 
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and co-stimulation, antibody production and suppressive capacity on both 
innate and adaptive immune responses. 
 
MATERIALS AND METHODS 
Isolation of PBMCs and B cells  
Human PBMCs were isolated from heparinized peripheral venous blood or 
buffy coats from healthy adult volunteers using density gradient centrifugation 
on Ficoll (Biochrom, Berlin, Germany). Cells were then washed and 
resuspended in RPMI 1640 medium (Biochrom, Berlin, Germany) 
supplemented with 10% of heat-inactivated fetal calf serum and antibiotics 
(penicillin, streptomycin, kanamycin), MEM vitamin, L-glutamine, nonessential 
amino acids and sodium pyruvate (Life Technologies), further on in the text 
referred as complete RPMI medium or culture medium. B cells were purified 
from PBMC by negative selection. Non-B cells were labeled with a cocktail of 
biotin-coupled antibodies against CD2, CD14, CD16, CD36, CD43 and 
CD235a, and anti-biotin microbeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) followed by magnetic separation (AutoMACS, Miltenyi Biotec). The 
purity of isolated CD19+ B cells was assessed by flow cytometry using anti-
CD19 antibody and routinely resulted in >96% of CD19+ cells. For some 
experiments pre-enriched B cells were labeled with anti-CD27 antibody and 
CD27- (primarily naive) and CD27+ (primarily memory) B cells were sorted 
using FACSAria II cell sorter (BD Biosciences, Franklin Lakes, NJ USA). 
 
Plasmids  
An expression plasmid containing the IL-10 gene construct - pORF-hIL-10 
and its backbone containing counterpart pORF-mcs (both from Invitrogen, Life 
technologies) were introduced in DH5α strain of electrocompetent bacteria 
and propagated overnight under ampicilin-selection at 37° C. Plasmid DNA 
MaxiPreps EF kits (Qiagen) were used for purification of plasmid DNA. Their 
concentration was determined using NanoDrop 2000 and adjusted to 1 mg/ml. 
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Transfection of B cells  
Freshly purified B cells were transfected with either pORF-hIL-10 (IL-10_trB) 
or pORF-mcs (ctrl_trB) plasmid vectors using nucleofection (Human B cell 
nucleofection kit and Nucleofector, Amaxa, Lonza Cologne AG, Germany). 
Then, cells were washed, centrifuged at 250xg/8 min, resuspended in 
complete RPMI and used for experiments. For the optimization of the 
transfection protocol B cells were transfected with a commercial pmaxGFP 
construct (Lonza) and transfection efficiency along with cell death exclusion 
(7-AAD) was assessed by flow cytometry 24h post-transfection. For some 
experiments B cells were stimulated with 1 µM of synthetic phosphorothioate 
B type TLR9-L CpG 2006 (Microsynth GmbH, Balgach, Switzerland) for 72h 
prior to transfection. 
 
Preparation of monocyte-derived dendritic cells (MDDCs) 
PBMCs were seeded in at a density of 2.5x106/cm2. Monocytes were obtained 
as a fraction of adherent PBMC after 2 h while the rest of the cells were 
washed away with pre-warmed complete RPMI medium. A combination of 10 
ng/ml GM-CSF (PeproTech, London, UK) and 50 ng/ml IL-4 (Novartis) was 
used to induce differentiation of monocytes to dendritic cells (MDDCs) over 
the period of 7 days. Differentiation was confirmed by down-regulation of 
CD14 expression and retained/up-regulated expression of CD11c. 
 
Cell cultures and co-cultures 
All B cell culture conditions were set in a format of 1x106 cells/ml in complete 
RPMI. Cell culture supernatants were collected for secreted cytokine 
quantification and cell lysates for mRNA expression analysis after 24h. 
Furthermore, cells were harvested for surface and intracellular proteins 
expression measurement by flow cytometry. For the co-culture studies B cells 
were stimulated prior to transfection with 1 µM of synthetic phosphorothioate 
B type TLR9-L CpG 2006 (Microsynth GmbH, Balgach, Switzerland) for 72h. 
 
In order to test the effect of IL-10-overexpressing B cells on TLR-Ls induced 
cytokine secretion from PBMC, maturation of MDDC and antigen specific 
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proliferation of PBMC freshly isolated and IL-10 transfected autologous B cells 
were co-cultured at different cell number ratios in respect to the target cells 
which were kept at fixed density of 1x106 target cells/ml in complete RPMI. 
Cells were left rested in wells for 2h before appropriate stimuli were added. 
For the maturation of MDDCs, co-cultured cells were stimulated with 50 ng/ml 
TLR4-L lipopolysaccharide (LPS) from E.coli 0111:B4 (Sigma-Aldrich, St. 
Louis, MO USA) for 36h. Cell culture supernatants were collected for secreted 
cytokine quantification and cells harvested for surface marker expression 
analysis after 24h and 36h, respectively. For the induction of cytokine 
secretion from PBMC, co-cultures were incubated in complete medium with 
addition of either 100 ng/ml TLR2-L lipoteichoic acid from S. aureus (LTA-SA, 
Invivogen) or 50 ng/ml of TLR4-L LPS for 24h. Supernatants were taken after 
24h for quantitative cytokine measurement. Antigen specific stimulation of 
PBMC in co-cultures was elicited by tetanus toxoid antigen (TT, Serum 
Institute) during 5 days. Cells were then pulsed with 1 µCi of [3H]-
thymidine/well (DuPont; New England Nuclear), and the incorporation of 
labeled nucleotide was measured in an LKB β plate reader (GE Healthcare). 
 
Flow cytometry 
After isolation or cell culture cells were harvested, centrifuged at 300xg for 8 
min at 4° and resuspended in ice-cold PBS. Cells were then incubated with 
fixable viability dyes eFluor450 or eFluor780 (eBioscience, San Diego, CA, 
USA) in PBS for 30 minutes on ice and then washed with staining buffer 
(0.5% BSA and 2 mM EDTA in PBS). For the expression of surface markers 
cells were stained with following antibodies: CD19-FITC, CD80-FITC, HLA-
DR-ECD (Beckman Coulter, Fullerton, CA USA), IgD-FITC, IgM-PerCP/Cy5.5, 
CD27-PE, CD83-PC5, CD86-PE, CD274-FITC (BD Biosciences, Franklin 
Lakes, NJ USA), CD5-PC7, CD11c-PacBlue, CD14-PE-Cy7, CD19-APC/Cy7, 
CD19-BV510, CD24-BV421, CD27-FITC, CD38-PerCP/Cy5.5, CD38-PC7 
(Biolegend, San Diego, CA USA), CD1d-PE (eBioscience) in staining buffer 
for 30 min on ice. Cells were washed once, resuspended in 0.5% PFA/PBS 
and measured. Corresponding isotype control antibodies were used as 
negative controls. Samples were analyzed using Galios flow cytometer 
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(Beckman Coulter) or sorted using FACSAria II (Becton Dickinson). Data were 
analyzed using Kaluza software (Beckman Coulter). 
 
RNA isolation and reverse transcription 
RNA was extracted from cell lysates using RNeasy kits (Qiagen, Hilden, 
Germany) modified to additionally include DNAse digestion step. Reverse 
transcription was performed with reverse-transcription reagents (Fermentas, 
St.Leon-Rot, Germany) including random hexamers according to 
manufacturer’s recommendations. 
 
Real-time PCR 
cDNA samples were amplified using target gene specific primers  
(Microsynth) and SYBR green PCR master mix (Bio-Rad Laboratories, 
Hercules, CA, USA) according to the manufacturer’s suggested protocol on 
ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster 
City, CA USA). ΔCt method was used to obtain relative quantification of gene 
transcription to housekeeping gene EF1α. Subsequently, comparative ΔΔCt 
method was performed to obtain relative quantification among different 
samples. The following primers pairs were designed according to sequences 
reported in GeneBank and used: AID: fw 5'-AGAGGCGTGACAGTGCTACA-3' 
rv 5'-TGTAGCGGAGGAAGAGCAAT-3'; BCL-6: fw 5'-
AGACCGTCCATACCGG-3' rv 5'-CGCAAGTGAAGTCGCA-3'; BLIMP-1: fw 
5'-AGCTGACAATGATGAATCTCA-3' rv 5'-GTGAAATGTTAGAACGGTAG 
AG-3'; CD40: fw 5'-TTGGGGTCAAGCAGATTGCTA-3' rv 5'-
GCAGATGACACATTGGAGAAGA-3'; EF1a: fw 5’-CTGAACCATCCAGGCCA 
AAT-3’ rv 5’-GCCGTGTGGCAATCCAAT-3’; GARP: fw 5'-GCCCTGTAAGAT 
GGTGGACAAG-3' rv 5'- CAGATAGATCAAGGGTCTCAGTGTCT-3';   IgA: fw 
5'-CGCTGGCCTTCACACAGAA-3' rv 5'-CGCCATGACAACAGACACA-3';                                               
IgE: fw 5'-ACACATCCACAGGCACCAAA-3' rv 5'-TTGCAGCAGCGGGTCAA-
3'; IgG1: fw 5'-CTCTCAGCCAGGACCAAGGA-3' rv 5'-GGTGGGCATGTGT 
GAGTTTTG-3'; IgG4: fw 5'-ACCC/ATGGTCACCGTCTCCTCA-3' rv 5'-
GGGACCATATTTGGACTC-3'; ICOS-L: fw 5'-CTCCGCCCGCACCAT-3' rv 5'-
CTACCATCGCTCTGACTTCCTTCT-3'; IL-10: fw 5’-GTGATGCCCCAAGCTG 
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AGA-3’ rv 5’-CACGGCCTTGCTCTTGTTTT-3’; IL2RA: fw 5'-
AAACTCTAGCCACTCGTCCTG-3' rv 5'-ACTTGTTTCGTTGTGTTCCGA-3'; 
IRF-4: fw 5'-AACGCCTTACCCTTCG-3' rv 5'-CCCGGTAGTACAGGCA-3'; 
PAX-5: fw 5'-CTGATCTCCCAGGCAAACAT-3' rv 5'-TTGCTCATCAAGGTG 
TCAGG-3'; PDL1/CD274: fw 5'-ACTGGGACATTCGGGTTTTGA-3' rv 5'-
CCTCACTTTCTGAGCGATGAGT-3'; PDL2: fw 5'-GCATAATAAGATGGCTC 
CCAGAA-3' rv 5'-AAAGAGGGAAGTGAACAGTGCTATC-3'; SOCS-3: fw 5'-
CTTCAGCATCTCTGTCGGAAGA-3' rv 5'-GCATCGTACTGGTCCAGGAACT-
3'; XBP-1: fw 5'-AGGAGTTAAGACAGCGC-3' rv 5'-GAGTCAATACCGCCAG-
3'. 
 
Quantification of cytokines and immunoglobulin isotypes 
Cell culture supernatants were quantified for IL-10 content using specific 
ELISAs. Other secreted cytokines and immunoglobulins were quantitatively 
determined using fluorescence-immuno-coupled beads-based multiplex 
assays: Bio-Plex Hu Cytokine panel, 17-Plex Group I or 27-Plex Group I or 
Bio-Plex Pro™ Human Isotyping Panel (all from Bio-Rad Laboratories) 
according to manufacturer’s instructions, respectively. Fluorescent signals 
were read and analyzed using the Bio-Plex 200 System (Bio-Rad 
Laboratories). 
 
Statistical Analysis 
Unless otherwise indicated presented data are expressed as mean ± SEM. 
Statistical analysis was performed using GraphPad Prism 5.0 statistical tests. 
Wilcoxon signed rank tests and Paired t-tests were used for assessing 
statistical significance. Statistically significant scores are shown on the graphs 
indicating significantly changed values between samples having P values < 
0.05. 
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RESULTS 
Overexpression of IL-10 in human B cells  
Plasmid mediated gene transfer in normal PBMC purified B cells was efficient 
using nucleofection. Nevertheless, it came with a certain cost in viability of the 
transfected cells. Transfection conditions were tested varying B cell number 
and different amounts of either pmaxGFP or pORF-hIL-10 or pORF-mcs 
(backbone control) vectors (Suppl Fig1A, 1B). The transfection protocol was 
optimized to use 2-5x106 B cells and 5-10 µg of DNA plasmid per transfection. 
It typically resulted in approximately 50% of GFP+ cells transfected (GFP+ 
cells) among approximately 75% of viable cells, as well as in significant and 
plasmid amount dependent-IL-10 release after 24h (Suppl Fig1B). 
 
IL-10-overexpressing B cells potently suppress production of 
proinflammatory cytokines while remarkably enhancing release of IL-
1Ra and VEGF 
An average of approximately 100-fold increase in secreted IL-10 was found in 
cell culture supernatants (Figure 1A) and approximately 3500-fold increase in 
IL-10 gene transcripts in lysates of B cell transfected with pORF-hIL-10 (IL-
10_tr) when compared with pORF-mcs (ctrl_tr) transfected samples 24h post-
transfection. The transfection procedure did not significantly affect the 
stimulatory effect of TLR9-L on IL-10 induction compared to non-transfected B 
cells (non_tr) (Suppl Fig1C). High IL-10 production in IL-10-overexpressing B 
cells was accompanied by a significant decrease in production of 
proinflammatory TNF-α, IL-8 and MIP-1α, while release of anti-inflammatory 
IL-1Ra and VEGF was significantly enhanced in comparison to control cells 
(Figure 1B). Among the other cytokines detected there was a tendency for IP-
10 and MIP-1β to be inhibited, while detectable levels of IL-6, IFN-γ, RANTES, 
G-CSF, GM-CSF, FGF and PDGF did not significantly change.  
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Figure 1. Overexpression of human IL-10 and profile of concurrent 
cytokine release from IL-10-overexpressing B cells. B cells were 
transfected with pORF-hIL-10 (IL10_trB) or pORF-mcs (ctrl_trB) and cultured 
in medium for 24h. (A) Secreted human IL-10 and relative human IL-10 
mRNA expression were measured in cell culture supernatants or cell lysates 
using specific ELISA or beads-based multiplex cytokine measurement, and 
quantitative-PCR, respectively (n=15 donors). (B) Secretion of other 
cytokines, chemokines and growth factors was quantified using beads-based 
multiplex cytokine measurement (n=12). Statistical analysis of the results was 
performed using Wilcoxon matched-pairs signed rank test and significant 
changes indicated as *p<0.05, **p<0.01,***p<0.001. 
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IL-10-overexpressing B cells acquire a complex immunoregulatory 
phenotype comprising upregulated expression of GARP, IL-2RA, PD-L1 
and CD38 
IL-10-overexpressing B cells were characterized in terms of their gene 
expression on mRNA (24h) and protein level (36h) relative to control vector 
transfected B cells. There was a significant increase in expression of the 
directly IL-10-responsive suppressor of cytokine signaling-3 (SOCS3) gene in 
IL-10-overexpressing B cells (Figure 2A). A similar tendency for SOCS1 gene 
was observed (data not shown). At the same time, there was no significant 
effect on the transcription of IL-10RA chain (data not shown) suggesting no 
direct negative feedback mechanism on expression of the IL-10 receptor 
component. Among molecules previously described to be linked with the 
function of regulatory T cells: glycoprotein A repetitions predominant (GARP) 
and interleukin-2 receptor α chain (IL-2RA/CD25) were significantly 
upregulated in IL-10-overexpressing B cells. No difference was observed on 
the transcriptional level of TGF-β (data not shown). We also measured the 
expression of surface molecules that have been linked with different murine 
and human regulatory B cells. Expression of CD38 was significantly higher, 
with the same tendency observed for CD5 in IL-10-overexpressing human B 
cells while the expression of CD1d and CD24 was not changed (Figure 2A). 
 
Expression of different co-stimulatory molecules, HLA-DR, a MHC class II 
molecule responsible for the presentation of processed antigens to CD4+ T 
cells, and CD40 were assessed in IL-10-overexpressing B cells in order to 
address their role in antigen presentation and co-stimulation. Along with high 
IL-10 expression there was a significant decrease in the expression of CD80 
and a trend in the same direction for CD86 expression, while there was no 
change in expression of HLA-DR and CD83 (Figure 2B). In addition, 
expression of PD-L1, OX40-L, and CD40 was also significantly elevated at 
mRNA level. Expression of PD-L2 and ICOS-L showed no difference (Figure 
2B). 
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Figure 2. 
Expression profile of immunosuppression- and costimulation-related 
genes in IL-10-overexpressing B cells. (A) mRNA Expression of 
immunoregulatory molecules  and members of B7 family, and (B) expression 
of surface molecules involved in immunoregulation, costimulatory molecules 
and HLA-DR by flow cytometry, 24h and 36h post-transfection, respectively 
(n=4-9). Statistical analysis was done according by Paired t-test *p<0.05, 
**p<0.01.  
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Profile of IL-10–overexpressing cells is skewed toward partially 
activated plasmablasts 
In order to assess the activation status of IL-10-overexpressing B cells 
analysis of distinct surface markers and surface immunoglobulins from was 
performed. Overexpression of IL-10 in B cells resulted in consistent and 
significantly lower expression of CD19, CD27 and total surface IgM, while an 
increase in IgD expression was observed 36h post-transfection. The 
percentage of IgM+IgD+ as well as IgM-IgD- B cells tended to increase while 
there was no change in frequency of IgM+IgD- upon IL-10 overexpression 
(Figure 3A). Transcription factor genes expression showed a profile with a 
significant increase in IRF-4 and XBP-1 but not BLIMP-1 as a consequence of 
IL-10 overexpression (Figure 3B). 
 
Effect of IL-10 overexpression on class-switch recombination and 
isotype profile of immunoglobulin production  
Transcripts encoding AID, an enzyme crucial for CRS, and IgA were 
significantly decreased in IL-10-overexpressing B cells 72h after transfection. 
The transcription level of IgE, IgG1 and IgG4 was not significantly altered 
compared to control cells (Figure 3C). In order to determine secretion of 
immunoglobulins B cells prestimulated for 3 days with TLR9-L, transfected to 
overexpress IL-10 and incubated in culture medium for 7 days. A trend for 
less IgE secreted was observed in IL-10-overexpressing B cells when 
compared with control vector transfected samples (Figure 3D). There was no 
difference in the amount of other isotypes secreted between two samples. In 
order to address potential differences in IgG4 and IgE production among IL-
10-overexpressing naïve and memory B cells, naïve B (CD19+CD27-) and 
memory B (CD19+CD27+) cells were transfected to overexpress IL-10 and 
stimulated with TLR9-L for 10 days post-transfection. Among all isotypes 
measured there was the highest decrease in concentration of secreted IgE 
observed, particularly pronounced in memory B cells overexpressing IL-10 
when compared with control transfected memory B cells (Figure 3E). 
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Figure 3. Surface activation phenotype, transcription facors signature 
and profile of immunoglobulin production in IL-10-overexpressing B 
cells. Expression of (A) B cell activation-related molecules CD19, CD27 and 
surface immunoglobulins IgM and IgD was assesed by flow cytometry 36h 
post-transfection. mRNA expression of (B) transcription factors and (C) AID 
and immunoglobulin genes was determined 24h and 72h post-transfection, 
respectively using quantitative PCR (n=4-9). (D) B cells were preconditioned 
with TLR9-L for 72h, transfected and cultured in medium for additional 7days. 
Secreted immunoglobulins were measured using multiplex beads-based 
isotyping measurement (n=2).  (E) Cell culture supernatants of either total B 
or sorted naive B (CD19+CD27) or memory B (CD19+CD27-) cells 
transfected with pORF-hIL-10 or pORF-mcs and subsequently stimulated with 
TLR9-L were quantified for secreted IgE 10 days post-transfection using the 
same method (n=4). Statistical analysis was done by paired t-test but no 
statistical significant results were found.  
Stanic et al. 
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IL-10–overexpressing B cells inhibit TLR2-L and TLR4-L-induced 
cytokine release from PBMC 
In order to test the effect of IL-10–overexpressing B cells on TLR2-L and 
TLR4-L-induced cytokine production from PBMC, freshly purified B cells were 
pre-stimulated with TLR9-L (72h), transfected to overexpress IL-10, co-
cultured with autologous PBMC in cell number ratio B:PBMC=1:4 and 
stimulated with either TLR2-L or TLR4-L during 24h. Both TLR2-L- and TLR4-
L-induced production of proinflammatory cytokines including TNF-α, IL-1b, IL-
6, IL-10, IFN-γ, IL-8, MCP-1, MIP-1β, G-CSF and GM-CSF in supernatants of 
PBMC cultures (Figure 4). However, there was an increase in cytokine 
release in control vector transfixed B cell co-cultures with no stimulus added, 
which might be due to a presence of small proportion of dead/dying cells after 
transfection. In IL-10-transfected B cell co-cultures the significant IL-10 
overproduction was associated with substantial inhibition of proinflammatory 
TNF-α, IL-1b, IL-6, IL-8, IFN-γ and G-CSF induced on both TLR2- and TLR4- 
triggered pathways, when compared with control vector-transfected B cell co-
cultures under both stimulatory and nonstimulatory conditions (55-98% of 
inhibition), also in comparison with stimulated PBMC samples (60-95% of 
inhibition). There was no significant change in the extent of inhibition between 
IL-10- and control-transfected B cell co-cultures on production of MCP-1 and 
MIP-1β induced by either TLR2-L or TLR4-L in comparison with stimulated 
PBMC alone. 
 
IL-10-overexpressing B cells suppress the maturation of MDDCs and 
inhibit their cytokine release upon LPS stimulation 
To test their effect on MDDC maturation, freshly isolated B cells were 
prestimulated with TLR9-L for 72h, transfected to overexpress IL-10 and 
subsequently co-cultured with autologous MDDC in B cell:MDDC ratios 1:2, 
1:4 and 1:8. Maturation of MDDC was induced with LPS during 36h, which 
typically resulted in complete loss of CD14 expression with concomitant 
upregulation of HLA-DR, CD80, CD86, and CD83). The level of LPS-induced 
downregulation of CD14 expression on CD11c+ MDDCs was reduced in 
cultures of MDDCs with IL-10-overexpressing B cells compared to controls 
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Figure 4. Cytokine 
secretion from PBMC 
co-incubated with TLR9-
L pretreated and 
transfected B cells upon 
TLR2-L or TLR4-L 
stimulation. Purified B 
cells were prestimulated 
with TLR9-L (72h), 
transfected either with 
pORF-hIL-10 or pORF-
mcs, co-cultured with 
autologous PBMC 
(B:PBMC ratio= 1:4) and 
stimulated with TLR2-L or 
TLR4-L (or left 
nonstimulated). Secreted 
cytokines, growth factors 
and chemokines were 
quantified in cell co-culture 
supernatants using beads-
based multiplex cytokine 
measurement 24h after 
stimulation (n=4). 
Statistical analysis was 
done by paired t-test 
(*p<0.05,  **p<0.01).  
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(Figure 5A). The profile of co-stimulatory molecules on IL-10-overexpressing 
B cells co-incubated MDDC included reduced expression of CD80, CD86 and 
CD83 but augmented expression of PD-L1 when compared with control 
transfected co-cultured samples (Figure 5B). Expression of HLA-DR on 
MDDC was not affected.  Additionally, in the supernatants of MDDCs co-
cultured with IL-10-overexpressing B cells proinflammatory TNF-α, IL-12p70, 
IFN-γ and G-CSF were inhibited, while at the same time IL-10, IL-1Ra and 
VEGF were elevated compared with control co-cultures (Figure 5C). All of 
these effects were dependent on the B cells:MDDC ratio. RANTES and MCP-
1 were inhibited to a similar extent in both IL-10- and control vector- 
transfected B cell co-cultures only at the highest B cells ratio added. Levels of 
IL-6, IL-8 and MIP-1β exceeded the assay’s upper detection limit.  
 
IL-10-overexpressing B cells potently inhibit antigen-specific 
proliferation of PBMC 
Freshly isolated B cells were transfected to express IL-10 or transfected with 
the control vector or left non-transfected and co-incubated with autologous 
PBMC (ratio 1:4) in the presence of TT antigen during 5 days. Co-incubated 
non-transfected  B cell did not have a significant effect  (22% of inhibition) 
while control transfected B cells significantly inhibited TT induced PBMC 
proliferation (56% of inhibition). IL-10-overexpressing B cell co-cultured with 
PBMC strongly suppress antigen specific proliferation (86% of inhibition) of 
autologous PBMC (Figure 6). 
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Figure 5. MDDC maturation, expression of co-stimulatory molecules and 
cytokine release after co-incubation with TLR9-L pre-activated and IL-10-
transfected B cells upon stimulation with TLR4-L. MDDCs were derived 
from plastic–adhered monocytes differentiatied with GM-CSF + IL-4 for 5 
days. Autologous B cells were pretreated with TLR9-L for 72h, transfected 
with pORF-hIL-10 (hIL-10_trB) or pORF-mcs (ctrl_trB), co-incubated with 
MDDC (in three cell number ratios: 1:2. 1:4, 1:8) and subsequently stimulated 
with TLR4-L for 36h. (A) Expression of CD14 and CD11c and (B) and co-
stimulatory molecules was assessed by flow cytometry. One donor (out of 
two) results is presented. (C) Cytokine secretion was quantified in 
supernatants using beads-based multiplex cytokine measurement (n=2). 
!"#$%&'("'#)*'
+%,-.('/'
5C 
  6 Results 
 
 114 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Antigen-specific proliferation of PBMC co-incubated with IL-10-
overexpressing B cells. B cells were transfected to overexpress IL-10 and 
co-cultured with PBMC following stimulation with tetanus toxoid (TT) for 5 
days (B cell:PBMC=1:4). [3H]-thymidine was added to cultures for last 8h of 
culture. Cells were harvested and proportion of incorporated thymidine 
quantified. Results are presented as proliferation relative to TT treated PBMC 
sample (proliferation control set as 100) and expressed in % (n=5). Statistical 
significance was performed using paired t-test (*p<0.05, **p<0.01, 
***p<0.005). 
 
 
DISCUSSION 
Under physiological conditions IL-10 is often produced and secreted together 
with other immune mediators that can positively, negatively or synergistically 
impact pure IL-10-mediated effects. TLR9-triggered pathway potently induces 
IL-10 production in PBMC-derived purified human B cells cultures.204 
However, under this condition secreted IL-10 production is accompanied with 
production of a wide range of other molecules. 
 
Our aim was to investigate direct effects of IL-10 expression in B cells. Normal 
human B cells have been toughly resistant to most of the gene transfer 
techniques. Among known transfection methods of non-viral vectors 
nucleofection was the most efficient to introduce plasmid DNA into human 
pre-B cells.206 For the first time we established, optimized and demonstrated 
efficient expression plasmid vector mediated IL-10 gene transfer and 
consequent IL-10 overexpression using nucleofection in primary human 
peripheral B cells. This experimental model served us to investigate 
phenotype and immunoregulatory potential of IL-10 overexpressing B cells on 
different types of immune responses. 
!"#$%&'("'#)*'
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Transfection of the human IL-10 gene into B cells led to a rapid (overnight) 
and high expression of IL-10 and SOCS3, which is a direct IL-10-responsive 
gene,207 and can serve as a control for overexpression of biologically active 
IL-10.207 Production of proinflammatory cytokine TNF-α,208 and chemokines 
IL-8 and MIP-1α,189 strong chemoattractants for neutrophils and TH1 cells, 
were significantly decreased while concentrations of anti-inflammatory IL-
1Ra209 and VEGF were significantly elevated in IL-10-overexpressing B cell 
supernatants when compared with control transfected B cells samples. 
Relative to control samples, IL-10-overexpressing B cells acquired an 
immunoregulatory phenotype as early as 24h post-transfection characterized 
by augmented GARP and IL2RA mRNA levels, both molecules known to be 
upregulated on regulatory T cells.210 211 IL-10-overexpressing B cells partially 
share a pattern of surface molecules preferentially expressed on previously 
described human regulatory IL-10-producing Br1 cells.204 To be distinguished 
from CD24hiCD38hi cells159 and relative to control transfected cells, IL-10-
overexpressing B cells express more CD38 but not CD24. When compared 
with CD25+CD71+CD73- Br1 cells IL10-overexpressing B cells204 express 
more CD25 (protein level), while CD71 and CD73 levels did not change upon 
high IL-10 when compared with their control counterparts. There was a trend 
for higher CD5 but not CD1d observed along with IL-10 overexpression, which 
partially resembles the phenotype of mouse regulatory CD1dhiCD5+ IL-10-
producing cells.139 These data suggest that solely IL-10 may have influence 
on direct or indirect induction of CD25, CD38 and CD5 in human IL-10-
producing B cells while higher expression of CD24, CD71, CD73 may require 
either longer IL-10 exposure (possible delayed IL-10-indirect effect) or 
additional signals triggered beyond IL-10 (upon naturally IL-10-eliciting 
conditions, e.g. TLR-9).  
 
Early changes (24h) in the expression of transcription factors included 
upregulation of IRF-4 and XBP-1, which are both characteristic for memory B 
cell transition to plasma cell before terminal differentiation, which requires 
BLIMP-1 upregulation.212 
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Furthermore, access to high IL-10 in B cells caused significantly decreased 
CD80, and a tendency for CD86 downregulation. At the same time high HLA-
DR expression was retained as well as higher transcription rate for PD-L1 
gene rendering these cells’ profile to a more readily antigen-presenting one 
with lower costimulation capacity. IL-10-overexpressing B cells significantly 
downregulated expression of CD19, which is the feature of activated B cells 
but also decreased CD27 expression (both changes persisted 6 days after 
transfection regardless of additional TLR9-L stimulation (data not shown)). 
Our experimental set-up employed total peripheral blood CD19+ cells 
containing both naïve and memory B cells. 36h after transfection with IL-10 
there were significantly more total IgD+ cells and less total IgM+ cells with a 
tendency for an increase in the naïve IgM+IgD+ population the effect which in 
combination with reduced CD27 and increased CD38 expression suggests 
two possible B cell fates: more naïve-like B cells213 and “activated” ones 
underwent class- switch to IgA/IgG/IgE plasmablasts. The overall reduction in 
transcripts for AID and IgA after 72h suggests less class-switching to occur. 
Taken together, a condition with high levels of IL-10 expression supports 
possible “two lines” of B cell fate: one resembling immature transitional–like B 
cells and the other class-switched plasmablasts. Secreted immunoglobulins 
levels reflect a tendency for the IgE downregulation as a consequence of high 
IL-10 access. Since we did not observe elevated IgG4 production, additional 
signals alone or synergistic with IL-10 (e.g. TLR9 pathway-induced) seem to 
be required for an increase in secreted IgG4.204  
 
PBMC co-cultured with IL-10-overexpressing B cells and stimulated with 
either TLR2-L or TLR4-L produced less proinflammatory cytokines (TNF-a, IL-
1b and IL-6), as well as IL-8 and G-CSF than control transfected B cell co-
cultures, indicating a substantial anti-inflammatory role of IL-10-producing 
cells possibly mediated by IL-10-mediated direct or indirect actions (SOCS3, 
IL1Ra). At least in part this effect may be explained by the impact of IL-10-
overexpressing B cells on MDDC that extends from inhibition of cytokine 
release to suppression of their maturation downregulating their overall co-
stimulatory potential (reduced CD80, CD86 and CD83, and induced PD-L1 
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surface expression) and therefore rendering MDDC toward regulatory 
phenotype. 
 
Although even the total fraction of non-manipulated B cells co-cultured with 
PBMC showed a trend for inhibition of their specific proliferation induced by 
TT, IL-10 overexpressing B cells showed the capacity to reduce it down to a 
minimum, which goes in line with previously described findings.204, 214 
 
Taken together, when exposed to high IL-10 due to overexpression B cells 
quickly acquire complex immunoregulatory-like phenotype characterized by 
increase in SOCS3, GARP and IL2RA expression all three molecules 
described to be highly expressed in regulatory T cells long with persistent 
downregulation of CD19 and CD27 and increased CD1d, CD5 and CD38 
expression, decreased capacity of co-stimulation. In addition, IL-10-
overexpressing B cells are able to exert remarkable suppressive effects on 
both arms of the immune system: acting directly on mechanisms of rapid 
acting innate immunity (inhibiting release of cytokines’ elicited via TLRs in 
primarily antigen presenting cell portion of PBMC) and on professional 
antigen-presenting cells, reducing their maturation profile through reduction of 
cytokine production and co-stimulatory potential, therefore affecting initiation 
and fate of adaptive immune response. IL-10 producing B cells are particularly 
potent in inhibiting antigen-specific proliferative response in vitro supporting 
the role of antigen specific IL-10 producing B cells limiting the memory T 
responses in vivo. 
 
These data suggest that solely IL-10 provision to B cells is sufficient for a 
change in its profile toward a complex immunoregulatory phenotype, which, in 
conjunction with secreted IL-10 in co-cultures with autologous immune cells, 
is capable to exert substantial anti-inflammatory functions. These findings 
confirm the importance of IL-10-producing B cells regulating different aspects 
of immune response, particularly their effect on dendritic cells and bring better 
understanding of the capacity of solely IL-10 on B cell physiology and 
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regulatory profile applicable for their specific targeting in the fields of allergy 
and asthma, autoimmunity and tumor immunity.  
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Supplementary figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Optimization of B cell transfection efficiency 
and kinetics of IL-10 expression. B cells were transfected with indicated 
ammounts of either pmaxGFP construct or pORF-hIL-10 (IL10_trB) or pORF-
mcs (ctrl_trB) plasmid and cultured in medium for 24h. Transfection efficiency 
was determined by flow cytometry and presented as (A) proportion of live 
GFP+ cells and as (B) secreted IL-10 determined by specific ELISA in cell 
culture supernatants of transfected cells. (C) After transfection B cells were 
either cultured in medium only or stimulated with 1 µM TLR9-L during the 
period of 5 days. Secreted IL-10 was measured by specific ELISA in cell 
culture supernatants (n=2)  
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Abstract 
Background: The fine balance of immunoglobulins (Ig) E, IgG1, IgG4 and 
IgA in healthy production is maintained by the interaction of B cells with 
adaptive and innate immune responses. The regulation of toll-like receptors 
(TLR)-driven innate and adaptive immune effector B cell responses and the 
role of mammalian telomeric TTAGGG repeat elements represent an 
important research area. 
Methods: Human PBMC and purified naive and memory B cells were 
stimulated with specific ligands for TLR2, 3, 4, 5, 7, 8 and 9 in the presence or 
absence of telomeric oligonucleotides. B cell proliferation, differentiation and 
antibody-production were determined.  
Results: TLR9 ligand directly activates naive and memory B cells, whereas 
TLR7 can stimulate them in the presence of plasmacytoid dendritic cells. 
Human B cells proliferate and turn into antibody-secreting cells in response to 
TLR3, TLR7 and TLR9, but not to TLR2, TLR4, TLR5 and TLR8 ligands. 
Stimulation of B cells with intracellular TLR3, TLR7 and TLR9 induced an 
activation cascade leading to memory B cell generation and particularly IgG1, 
but also IgA, IgG4 and very low levels of IgE production. Mammalian 
telomeric ODN significantly inhibited all features of TLR ligand-induced events 
in B cells including B cell proliferation, IgE, IgG1, IgG4, IgA production, class 
switch recombination, plasma cell differentiation induced by TLR3, TLR7 and 
TLR9 ligands.  
Conclusion: B cells require specific TLR stimulation, T cell and plasmacytoid 
dendritic cell help for distinct activation and Ig production profiles. Host-
derived telomeric ODN suppress B cell activation and antibody production 
demonstrating a natural mechanism for the control of over exuberant B cell 
activation, antibody production and generation of memory. 
 
Key words: B cell, IgA, IgG1, IgG4, IgE, plasmacytoid dendritic cell, telomeric 
ODN, toll-like receptor ligand 
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Introduction 
The fine balance of immunoglobulins (Ig) E, IgG1, IgG4 and IgA is deviated to 
exuberant production of allergen-specific IgE and weak production of IgG4 in 
allergic individuals.215 The interaction of environmental factors including 
allergens and microbial components with the innate and adaptive immune 
system results in class switch recombination of immunoglobulins.216 Cells of 
the innate immunity equipped with Toll like receptors (TLR) have an immense 
capacity to recognize a diverse spectrum of microorganisms including 
bacteria, viruses, fungi and parasites.217, 218 While a TLR10 ligand is yet to be 
described in humans, the specific ligands of TLR1 to TLR9 drive innate and 
adaptive immune effector cells towards inflammation and microbicidal 
activity.217, 218 TLR1, 2, 4, 5 and 6 are expressed on the cell surface, whereas 
TLR3, 7, 8 and 9 are expressed in the endosomes of cells.219-222 The 
intracellular localization of the latter TLRs allows bacteria and virus to be 
degraded in the endosomes/lysosomes after engulfment and phagocytosis in 
innate immune cells during infection. These processes are induced by the 
association of double stranded RNA to TLR3, single stranded RNA to TLR7 
and TLR8 and unmethylated CpG motifs containing DNA to TLR9.220, 223-228 
TLR distribution intensity in the immune system cells and ligands for TLR has 
a critical role to understand host-pathogen interactions and the effects on the 
adaptive immunity.  TLR expression differs between mouse and human cells, 
especially in B cells. Mouse B cells proliferate and differentiate upon LPS and 
CpG stimulation229, 230, whereas human B cells respond to CpG231 but not to 
LPS stimulation.25, 232 
 
Bacterial DNA contains immunostimulatory CpG motifs that stimulate dendritic 
cells, NK cells and B cells and lead to their proliferation, maturation and 
secretion of a variety of cytokines, chemokines and immunoglobulins.218, 233, 
234 It has been reported that suppressive oligonucleotides (ODN) motifs can 
selectively block CpG-mediated immune activation. Suppressive motifs are 
rich in poly “G” or “GC” sequences and are present in the DNA of mammals 
and certain viruses. Suppressive ODN-expressing arrays of the hexameric 
TTAGGG repetitive elements patterned after mammalian telomeres235, 236, has 
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been demonstrated to block CpG-induced cytokine production in vitro and 
inhibit CpG-induced inflammatory reactions such as lethal endotoxic shock in 
mice.237, 238 
 
Therefore, we postulated that a natural inhibitory mechanism mediated by 
mammalian telomere motifs could help to restore B cell homeostasis. 
Stimulation of human PBMC via endosomal associated TLRs as well as direct 
activation of naive or memory B cells with CpG ODN and plasmacytoid 
dendritic cell maturation by TLR7 induces polyclonal B cell activation, 
proliferation and IgE, IgA IgG1 and IgG4 production suggesting a mechanism 
of immunological memory. After class switching in naive B cells, memory B 
cells and plasma cells that produce immunoglobulin E (IgE+ cells) develop 
through a germinal-center IgE+ intermediate cell without an IgG1 phase. In 
addition, cellular IgE memory resides in IgE+ memory B cells, and IgG1+ 
memory B cells are not an important source of IgE memory.239 Here, we 
demonstrate that a synthetic analogue of mammalian telomeres containing 
four repeats of TTAGGG motif suppresses B cell activation, proliferation and 
antibody production induced directly or indirectly by TLR3, TLR7 and TLR9 
ligands. 
 
Materials and Methods 
Isolation and purification of cells. PBMC were obtained from heparinized 
whole blood or buffy coats from healthy individuals by Ficoll (Biochrom KG, 
Berlin, Germany) density gradient centrifugation. Cells were washed three 
times and resuspended in RPMI 1640 medium supplemented as previously 
described.240 B cells were purified by magnet-activated cell separation after 
labeling of cells with anti-CD19 microbeads (MACS, Miltenyi Biotec AG, 
Bergisch Gladbach, Germany). The purity of B cells was >94% as assessed 
by flow cytometric analysis of cells stained with ECD-labeled anti-CD19 mAb 
(Immunotech, Beckman Coulter, Marseille, France). 
 
Following B cell staining with anti-CD19 mAb (Dako AG, Baar, Switzerland) 
and anti-CD27 mAb (Immunotech, Beckman Coulter), naive and memory B 
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cells were double sorted by flow cytometric sorter (FACS Vantage SE, 
Beckton Dickenson, Pharmingen, Basel, Switzerland). The purity of naive and 
memory B cells was >99% as assessed by flow cytometric analysis of cells 
stained with PE-labeled anti-CD19 mAb (Dako AG, Baar, Switzerland), PC5-
labelled anti-CD27 mAb (Immunotech, Beckman Coulter) and FITC-labeled 
anti-CD123 mAb (Miltenyi Biotec AG). Naive B cells contained <0.1% CD27+ 
memory B cells and <0.5% plasmacytoid dendritic cells and, memory B cells 
contained <1% CD27- B cells and <0.9% plasmacytoid dendritic cells. 
 
Plasmacytoid dendritic cells were isolated from PBMC by positive selection by 
using antibodies against BDCA-4 coupled to microbeads (FcRγ)-blocking 
reagent and the autoMACS magnetic separation system (Miltenyi Biotec, 
Bergisch Gladbach, Germany). 
 
Cultures of PBMC and B cells. Ligands for TLRs were Pam3-Cys-Ser-(Lys)4 
for TLR2 (Calbiochem AG, Laufelfingen, Switzerland), poly(I:C) for TLR3 
(Amersham Biosciences, Lausanne, Switzerland), E. Coli derived 
lipopolysaccharide for TLR4 (Sigma Chem. Co. Buchs, Switzerland), flagellin 
for TLR5 (Calbiochem AG), 3M-001 for TLR7 (3M Pharmaceuticals, 
Minneapolis, USA), 3M-002 for TLR8 (3M Pharmaceuticals) as described 
previously 241, CpG2006 for TLR9 (Microsynth GmbH, Balgach, Switzerland). 
Phosphorothioate-modified ODNs were synthesized at the Microsynth GmbH, 
Balgach, Switzerland. Sequences of the phosphorothioate ODNs used were 
as follows: CpG2006 ODN: 5’-TCGTCGTTTGTCGTTTTGTCGTT-3’, control 
for immunostimulatory ODN (non-CpG): 5’-ATGCACTCTGCAGGCTTCTC-3’, 
telomeric ODN: 5’-TTAGGGTTAGGGTTAGGGTTAGGG-3’, base scrambled 
“control ODN”: 5’-ACATAGTCTCTCTCTAGTCAGTCT-3’. All reagents and 
ODNs used in this study contained <0.1 U/mg endotoxin. There was no cell 
toxicity of the ODN as investigated by annexin-V and 7-amino actinomycin D 
staining after 48 h up to 10 µM doses 242. Recombinant IL-2 and IL-4 were 
from Novartis, Basel, Switzerland. Soluble CD40 ligand (sCD40L) was 
obtained from the transfected cell-line 8-40-1 (sCD40L-CD8-α fusion protein; 
Institute for Immunology, Basel, Switzerland) 243.  
  6 Results 
 
 125 
 
5 x 105 PBMC or purified naive or memory B cells were stimulated in 500 µl 
with different TLR-ligands in 48-well plates (Costar Corporation, Cambridge, 
MA). After initial experiments for dose optimization Pam3-Cys-Ser-(Lys)4 was 
used at 0.6 µM, poly(I:C) at 25 µg/ml, lipopolysaccharide at 100 ng/ml, 
flagellin at 1.8 µM, 3M-001 and 3M-002 at 1 µM, CpG2006 and control ODN 
at 1 µM. IL-2 was used at 4 ng/ml, IL-4 was 25 ng/ml, sCD40L was at 20% v/v 
as supernatant65, IFN-α and IFN-β were 100 ng/ml where indicated. TTAGGG 
telomeric ODN and control ODN were used in titrated doses and 1 µM in 
other experiments. Cells were pulsed with 1 µCi/well [3H] thymidine (Dupont 
and NEN Life Science Products, Basel, Switzerland) for the last 8 h of 
incubation, and [3H] thymidine incorporation was performed at day 3 for 
transformed B cells and T cells and at day 5 for primary B cells.  
 
Analysis of B cell activation and proliferation. Isolated PBMC from buffy 
coat were stained with 5 µM carboxyfluorescein diacetate, succinimidyl ester 
(CFSE) (Molecular Probes Europe BV Leiden, The Netherlands) for 12 min at 
40C and then washed twice with complete medium. For the analysis of 
lymphocyte subset proliferation, 5 x 104 cells were stained with ECD-
conjugated anti-CD19 mAb, PE-conjugated anti-CD4, PE-conjugated anti-
CD8 or PE-conjugated anti-CD16 (Immunotech, Beckman Coulter) for 30 min 
at room temperature. For the analysis of B cell differentiation, 5x104 cells 
were stained with ECD-conjugated anti-CD19 mAb together with anti-CD20 or 
anti-CD23-PE (Serotec Immunological Excellence, Raleigh, NC) or anti-
CD27-PE or anti-CD38-FITC (Immunotech, Beckman Coulter) or anti-CD80-
FITC or anti-CD86-PE or anti-BAFF-R-FITC (Beckton Dickenson, 
Pharmingen) or anti-TACI-PE  (R&D Systems, Abington, UK) or anti-BCMA-
FITC (Alexis Corp. Lausen, Switzerland) for 30 min at 40C or room 
temperature and washed with PBS. Stained cells were fixed in 2% 
paraformaldehyde (Sigma). The isotype controls were FITC, PE or ECD-
conjugated mouse IgG1/IgG2 (Immunotech, Beckman Coulter). Plasmacytoid 
dendritic cells were co-cultured with allogeneic naive B cells or memory B 
cells at a ratio of 1:10 with IL-2 for 5 days in 200 µL in 96 well plates. 
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Determination of IgG1, IgG4, IgA and IgE and Ig-secreting cells. Total 
IgG1, IgG4, IgA and IgE were measured in culture supernatants at day 12 by 
ELISA as described.63 Anti-human IgG1, clone JDC-1 (Beckton Dickenson, 
Pharmingen) and biotinylated anti-IgG1 (Beckton Dickenson, Pharmingen) 
were used to quantify IgG1. The detection limit of the IgG1 assay was 16 
ng/ml human IgG standard (Calbiochem AG, Luzern, Switzerland). For total 
IgA determination anti-IgA1/2 mAb (Beckton Dickenson, Pharmingen) was 
used for coating and biotinylated anti-IgA1/2 mAb (Beckton Dickenson, 
Pharmingen) was used for detection. The detection limit of the IgA assay was 
16 ng/ml and human IgA standard was from Sigma Chem Co.  
 
Ig-secreting cells were detected by isotype-specific enzyme linked 
immunospot assay (ELISPOT) on day 11 of culture. 96-well ELISPOT plates 
(Pall Corporation, MI, USA) were coated with the same mAb used for ELISA. 
After washing with PBS 0.1 % tween and blocking with PBS with 2% skimmed 
dry milk (Euroclone, Milano, Italy). 3 x 104 pre-stimulated PBMC from each 
condition were incubated in 200 µl of medium 96-well flat bottom ELISPOT 
plates in duplicate for 24 hours at 370C. Locally produced IgG1, IgG4, IgA and 
IgE were captured by anti-IgG1 (Beckton Dickenson, Pharmingen), anti-IgG4 
(Skybiolimited, Bedfordshire, UK), anti-IgA1/2 mAb (Beckton Dickenson, 
Pharmingen), anti-IgE. The immunoglobulin specific mAb were detected by a 
secondary biotinylated/detection antibody for IgG1, IgA and IgE (Beckton 
Dickenson, Pharmingen) followed by washings and incubation with 
streptavidin conjugated to alkaline phosphatase. For the development of IgG4 
spots alkaline phosphatase-conjugated anti-human IgG was used (Sigma 
Chem Co.) Colored purple spots developed after substrate addition (nitroblue 
tetrazolium and bromo-chloro-indolyl phosphate in dimethyl formamide, Bio-
Rad Lab. Inc. CA, USA), and were counted by an automated software 
(ImmunoSpot; C.T.L. Europe GmbH. Aaelen, Germany). Spot size bigger or 
smaller than average +/- 3 standard deviation was ignored. After 10 days of 
cell culture with TLR ligands, 24 hours of incubation of the cells in ELISPOT 
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plates for the secretion of immunoglobulins was found to be the optimal time 
for the determination of frequency of immunoglobulin-producing cells. 
 
Immunoglobulin mRNA transcription determination. Total RNA was 
extracted from the PBMCs using RNeasy mini kit (Qiagen, Valencia, CA, 
USA) according to the manufacturer’s instructions. Approximately 500 ng total 
RNA was reverse transcribed by ImProm-II Reverse Transcription System 
(Promega Corporation, Madison, WI, USA) into complimentary DNA (cDNA). 
The PCR primers and probes were designed based on the sequences 
reported in GenBank with the Primer Express software version 1.2 (Applied 
Biosystems, Foster City, CA, USA). A reference gene screening has been 
carried out, and elongation factor (EF)-1α was used as an endogenous 
control. Primers used for relative quantification AICDA, and Iγ-Cγ1, VHDJH-
Cγ4, Iε-Cε, Iα1/2-Cα1/2 RNA transcripts are shown in the Table 1S. 
 
The prepared cDNAs were amplified by using iTaq SYBR Green Supermix 
with ROX (Bio-Rad, Basel, Switzerland), according to the manufacturer’s 
recommendations in an ABI PRISM 7900 Sequence Detection System 
(Applied Biosystems) in triplicates. Relative quantification and calculation of 
the range of confidence was performed by using the comparative ΔΔCT 
method.244 
 
Table 1S. Forward and reverse primer sequences (5’-3’) for AICDA, and Iγ-
Cγ1, VHDJH-Cγ4, Iε-Cε, Iα1/2-Cα1/2 RNA transcripts. 
 mRNA Forward primer sequence (5'-3') Reverse primer sequence (5'-3') 
AICDA AGAGGCGTGACAGTGCTACA TGTAGCGGAGGAAGAGCAAT 
Iγ-Cγ1 CTCTCAGCCAGGACCAAGGA GGTGGGCATGTGTGAGTTTTG 
VHDJH-Cγ4 ACCATGGTCACCGTCTCCTCA GGGACCATATTTGGACTC 
Iε-Cε ACACATCCACAGGCACCA AA TTGCAGCAGCGGGTCAA 
Iα1/2-Cα1/2 CGCTGGCCTTCACACAGA A CGCCATGACAACAGACACA 
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Statistical Analysis. Results are shown as mean ± SD. Nonparametric 
statistical comparison between groups was performed by Mann Whitney U 
test. The number of donors indicated in the figure legends includes all donors 
analyzed in the relevant experiment.  
 
Results 
TLR3, TLR7 and TLR9 stimulations induce B cell proliferation, which is 
suppressed by telomeric ODN 
Activation and clonal expansion of B cells is an essential event for 
immunoglobulin production. To investigate the role of different TLRs on 
human B cell activation, proliferation and different isotypes of immunoglobulin 
production, we used different TLR-stimulated PBMC, purified B cells and 
naive and memory B cell subsets isolated from peripheral blood of healthy 
humans. First, PBMC were stimulated with ligands of TLR2, TLR3, TLR4, 
TLR5, TLR7, TLR8 and TLR9 in the presence of IL-2 for five days. [3H] 
thymidine incorporation was determined after 5 days. Ligands for TLR3, TLR7 
and TLR9 induced significant cell proliferation. Human telomeric ODN 
significantly suppressed TLR3-, TLR7- and TLR9-mediated PBMC 
proliferation in a dose dependent manner (Fig. 1A) reaching up to 60 %, 90% 
and 80% inhibition at 5 µM doses, respectively (Supporting information Fig. 
S1A). For comparison, control ODN did not show significant suppressive 
activity (Fig. S1B). Telomeric ODN, 1 µM, significantly suppressed PBMC 
proliferation stimulated by TLR3, TLR7 and TLR9 ligands (Fig. 1B). 
 
The next step was to identify the proliferating cell type within PBMC upon 
TLR3, 7 and 9 stimulations. Interestingly, stimulation of TLR3, 7 and 9 
induced CD19+ B cell, but not CD4+, CD8+ T cell or CD16+ NK cell 
proliferation (Fig. 2). Mammalian telomeric ODN significantly inhibited B cell 
proliferation induced by TLR3, 7 and 9.  
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FIGURE 1. Suppression of TLR-induced human peripheral blood 
mononuclear cell (PBMC) proliferation. A, Suppression of TLR-induced PBMC 
proliferation at different concentration of telomeric oligodeoxynucleotide 
(ODN). Human PBMC 106/ml were stimulated with ligands for TLR2 (0.6 µM, 
Pam3-Cys-Ser-(Lys)4), TLR3 (25 µg/ml, poly I:C), TLR4 (100 ng/ml, 
lypopolysaccharide), TLR5 (1.8 µM, Flagellin), TLR7 (1 µM, 3M-001), TLR8 (1 
µM, 3M-002) and TLR9 (1 µM, CpG2006) in the presence of 4 ng/ml IL-2. 
Telomeric ODN was titrated 1:2 starting at 5 µM. To determine proliferative 
responses on day 5, cells were pulsed with 1µCi/well [3H] Thymidine and [3H] 
Thymidine incorporation was determined after 8 hours. B, To further analyze 
the effects of TLRs and telomeric ODN on PBMC proliferation the decrease in 
CFSE intensity of the cells was measured by flow cytometry and was used as 
a measure of the extent of cell division. Human PBMC from healthy donors 
were labeled with CFSE and stimulated with TLR2, TLR3, TLR4, TLR5, TLR7, 
TLR8 and TLR9 ligands in the presence of IL-2 with and without 1 µM of 
telomeric ODN. TLR-induced cell proliferation stained by CFSE was 
determined on day 5 with flow cytometry. Compared to the unstimulated 
control group, TLR3, TLR7 and TLR9 ligands induced significant cell 
proliferation. Even at higher doses used in preliminary experiments TLR2, 
TLR4 TLR5 and TLR8 ligands did not induce detectable cell proliferation in 
human PBMC. Mean + standard deviation of percentage of proliferating cells 
in 5 different experiments is shown in each histogram. Telomeric ODN 
significantly suppressed cell proliferation in all conditions (P <0.01). 
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Figure 2. Telomeric ODN inhibits B-cell proliferation induced by TLR3, TLR7 
and TLR9. Human PBMCs from healthy donors were labeled with CFSE and 
stimulated with ligands for TLR3, TLR7 and TLR9 in the presence of IL-2 with 
and without telomeric ODN at the concentrations indicated in the Fig. 1. Cells 
were counterstained with CD19, CD4, CD8 and CD16. The numbers in the 
boxes represent the percentage of the proliferating CD19-stained cells. One 
representative of four experiments is shown. Telomeric ODN significantly 
suppressed CD19+ cell proliferation in all conditions (P < 0.01). In these 
experiments, IL-2 consistently induced the expansion of B cells with these 
three stimuli in PBMCs. IL-2 also induced the proliferation of a small fraction 
of CD4, CD8 and CD16 positive cells. This fraction was more visible in CD4+ 
cells, however, was always less than 4.5% of the cells and was not 
suppressed by telomeric ODN. 
 
The exact identification of B cell subsets is instrumental to understand their 
dynamics under physiological and pathological conditions. Human memory B 
cells are currently identified according to the expression of CD27, which is 
absent on naive B cells. It was shown that naive and memory B cells respond 
differently to the same TLR ligand especially to CpG25 In addition, it was 
recently demonstrated that under certain conditions including cell-cell contact 
and appropriate cytokine and growth factor support, CD27- naïve B cells 
increase TLR9 expression, proliferate in response to CpG stimulation without 
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B cell receptor signaling and differentiate into plasma cells.245 To specifically 
differentiate the proliferative responses of naive and memory B cells induced 
by TLR3, 7 and 9 stimulation, highly purified CD19+CD27- naive and 
CD19+CD27+ memory B cells were stimulated. Upon TLR9 stimulation naïve 
and memory B cells proliferated without the help of type 1 IFNs or 
plasmacytoid dendritic cells (Fig. 3A, B). TLR3 and TLR7 ligands, however, 
failed to directly induce the proliferation of highly pure naive and memory B 
cells. TLR7 stimulated a small fraction of naïve B cells in the presence of 
plasmacytoid dendritic cells, and memory B cells in the presence of IFN-α, 
IFN-β or plasmacytoid dendritic cells.  Again, mammalian telomeric ODN 
significantly suppressed TLR7- and TLR9-ligand-induced CD19+CD27- naive 
and CD19+CD27+ memory B cell proliferation independent of the combination 
with IFN-α, IFN-β and the presence of plasmacytoid dendritic cell help. 
 
These data demonstrate direct and indirect activation and clonal expansion of 
B cells by TLR stimuli. TLR3 and TLR7 ligands cannot directly stimulate naive 
and memory B cells. In a mixed population of PBMC, when they coexist with 
the T cell help or dendritic cells, they become capable of B cell stimulation.  
As a strong stimulator for B cells, CpG induces direct activation of memory 
and a fraction of naive B cells. TLR7 stimulates B cells in the presence of IFN-
α, IFN-β secreted by the plasmacytoid dendritic cells. 
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Figure 3. Distinct stimulation of naive and memory B-cell proliferation by 
TLR3, TLR7 and TLR9 ligands and suppression by telomeric ODN. Purified 
CD19+CD27− naive and CD19+CD27+ memory B cells were labeled with 
CFSE to investigate their proliferation by TLR3, TLR7 and TLR9 stimulation 
with and without interferon-alpha (100 ng/ml), interferon-beta (100 ng/ml). 
Human plasmacytoid dendritic cells 4 × 104 were added to naïve and memory 
cells. (A) TLR9 ligand induce the proliferation of naive B cells. The addition of 
plasmacytoid dendritic cells induces the proliferation of naïve B cells by TLR7 
ligand. (B) High proliferation rate of memory B cells with CpG (TLR9 ligand) 
and moderate proliferation by TLR7 ligand with IFN-α, IFN-β and the addition 
of plasmacytoid dendritic cells. The proliferation rates of naïve and memory B 
cells were suppressed by telomeric ODN. One representative of three 
experiments is shown. 
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Regulation of class switch recombination and IgE, IgG1, IgG4, IgA 
production by TLR3, TLR7, TLR9 ligands and telomeric ODN  
B cells are continuously exposed to substances that stimulate the innate 
immune response from commensal flora bacteria in respiratory and 
gastrointestinal mucosae and they produce immunoglobulins against 
pathogens. After demonstration of the difference in TLR3-, 7- and 9-ligand-
induced direct or indirect B cell proliferation, we examined the effects of these 
ligands on AICDA mRNA expression and immunoglobulin synthesis by B cells 
and PBMC as well as the role of IL-2, IL-4 and sCD40L stimulation. 
 
PBMC were stimulated with ligands for TLR3, 7 and 9 in the presence and 
absence of telomeric ODN and control ODNs. IL-2, IL-4 and sCD40L were 
used to mimic T cell help and promote B cell clonal expansion. IgE, IgG1, 
IgG4 and IgA were measured on day 5 cell lysates (as mRNA) and day 12 
culture supernatants (Fig. 4A, B, C). IgE antibody synthesis and Iε-Cε RNA 
transcripts expression was induced by TLRs in combination with IL-4 and 
sCD40L, but not induced with IL-2 and sCD40L in healthy individuals (data 
not shown). 
 
As observed in B cell proliferation, the profiles of immunoglobulin production 
showed differences in PBMC and purified B cells (Fig. 4A, B and Fig. S2). In 
PBMC, stimulation via TLR3, 7 and 9 even in the absence of IL-2 induced 
IgG1, IgG4 and IgA, in detectable quantities. IL-2 significantly increased the 
synthesis of IgG1, IgG4 and IgA stimulated with TLR3, 7 and 9 ligands. 
Stimulation of cells with sCD40L had no significant effect on the production of 
immunoglobulins in the absence of IL-2, whereas IL-2 and sCD40L 
combination boosted IgG1 levels, and they had no additional contribution to 
the induction of IgG4 and IgA. Increased expression of Iγ-Cγ1, VHDJH-Cγ4, 
Iα1/2-Cα1/2 RNA transcripts for IgG1, IgG4 and IgA in IL-2 and sCD40L-
stimulated PBMC with TLR3, TLR7 and TLR9 verified our results (Fig. 4C).  
Consistent with the proliferation studies, telomeric ODN significantly 
suppressed IgE, IgG1, IgG4 and IgA secretion and their mRNA expression 
independent  of  the  type  of  TLR  ligand  in  the  presence  of  IL-4,  IL-2 and  
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Figure 4. Different requirements in IgE, IgG1, IgG4 and IgA production by 
PBMC with TLR3, TLR7 and TLR9 stimulation and their suppression by 
telomeric ODN. (A) IgG1, IgG4 and IgA immunoglobulin synthesis by PBMC 
0.5 × 106/ml in 500 µl in 48-well plates was stimulated with TLR3, TLR7 and 
TLR9 ligands in the absence or presence of IL-2 and sCD40L or both. TLR7 
and TLR9 ligands and telomeric ODN were used at 1 µM, and TLR3 ligand 
was used at 25 ug/ml. IgG1, IgG4 and IgA were measured in day 12 
supernatants. (B) PBMCs 0.5 × 106/ml in 500 µl in 48-well plates were 
stimulated with TLR3, TLR7 and TLR9 ligands in the presence of IL-4 and 
sCD40L. IgE was measured in day 12 supernatants by ELISA. (C) Relative Iε-
Cε, Iγ-Cγ1, VHDJH-Cγ4, Iα1/2-Cα1/2 RNA transcripts for IgE, IgG1, IgG4 and 
IgA quantified with real-time PCR. The measurements after TLR ligand 
stimulations were expressed as fold increase relative to the measurement 
from unstimulated cells. Results are representative of four experiments. (D) 
Suppression of AICDA mRNA expression by telomeric ODN. PBMCs cultured 
with sCD40L + IL-2 were stimulated TLR3, TLR7 or TLR9 ligands alone or in 
combination with telomeric or control ODN. mRNA expression of AICDA was 
measured after 5 days and its expression is calculated relative to sCD40L+IL-
2. Horizontal bar shows mean (±SEM). Results are representative of four 
independent experiments. *P < 0.05. 
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sCD40L experimental conditions. Upon exposure to the infections or 
immunizations, activation-induced cytidine deaminase (AICDA) regulates 
class switch recombination and somatic mutation in B cells.246 The expression 
of AICDA mRNA, was measured after 5 days (Fig. 4D). Telomeric ODN 
suppressed the expression of AICDA mRNA even in PBMC cultured with IL-
2+sCD40L and in combination with TLR3, TLR7 and TLR9 ligands. Control 
ODN did not show any stimulatory or inhibitory effect on the effect of TLR 
ligand and telomeric ODN. 
 
We then investigated the effect of TLR3, TLR7 and TLR9 stimulation on 
antibody forming cell frequency and whether it is also inhibited by telomeric 
ODN. Human PBMC were stimulated with TLR3, TLR7 and TLR9 ligands in 
the presence of telomeric ODN, IL-2 and sCD40L. Secreted immunoglobulins 
were captured on ELISPOT plates between day 10 and day 11 of cultures. 
Stimulation via TLR3, TLR7 and TLR9 significantly increased IgG1, IgG4 and 
IgA producing cell frequency (Fig. 5A). Particularly, a relatively high frequency 
of cells produced IgA after TLR3, TLR7 and TLR9 ligand stimulation. It has to 
be noted here that secreted immunoglobulins determined in the supernatants 
by ELISA represent a cumulative value after 12 days. However, ELISPOTS 
represent the number of Igs secreting cells in a certain time fragment within 
the course of cultures. Telomeric ODN significantly suppressed the number of 
antibody-forming cells producing IgG1, IgG4 and IgA in all experiments (Fig. 
5B) supporting the data obtained by ELISA.  
 
Suppression of TLR3, TLR7 and TLR9 ligand induced B cell 
differentiation by telomeric ODN 
Since B cells undergo differentiation towards plasma cells to produce 
immunoglobulins, we next aimed to investigate, whether B cell differentiation 
is affected by TLR ligands and whether telomeric ODN influence B cell 
differentiation. Human PBMC were double stained with mAbs for CD19, 
CD20, CD27, CD38, CD80, CD86, B cell activating factor of the TNF family 
(BAFF)-receptor, transmembrane activator and cyclophilin ligand interactor 
(TACI) and B cell maturation antigen (BCMA), which are expressed on B cells 
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depending on the stage of maturation and activation of the B cell. Stimulation 
of PBMC via TLR3, TLR7 and TLR9 in the presence of IL-2 resulted in a 
significant increase in the numbers of CD19+ B cells. These proliferating B 
cells expressed high levels of CD27, CD38, CD86 and, demonstrating that a 
fraction of proliferating B cells stayed as memory B cells and their APC 
function was increased and some of them matured to antibody-forming cells 
(Fig. S3A). The formation of memory B cells (CD19+CD27+) was significantly 
inhibited by telomeric ODN. This was in parallel to suppression of CD20+, 
CD86+ and CD38 high+ B cells. The expression rate of BAFF-R, TACI and 
BCMA showed different patterns depending on TLR ligand types (Fig. S3B). 
TLR3 stimulation induced moderate increase in BAFF-R, TACI and BCMA 
expression, TLR7 stimulation induced TACI and BCMA expression and finally 
the  expression  rate  of  these  B  cell surface markers were not stimulated by  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The number of TLR3-, TLR7- and TLR9-ligand-induced IgG1, IgG4 
and IgA producing cells decreases by telomeric ODN. (A) Human PBMCs 
were stimulated with TLR3, TLR7 and TLR9 ligands with and without 
telomeric ODN. 3 × 104 PBMCs from each condition on day 10 were 
incubated for 24 h. The ELISPOTs of duplicate wells for each treatment 
condition on ELISPOT plates are shown. The numbers of spots in each well is 
indicated on upper left corner. (B) Results representative of four independent 
experiments are shown in the bar graphs. The open bar represent TLR 
stimulation and the filled bars represent the addition of telomeric ODN for 
IgG1, IgG4 and IgA spots number. *P < 0.05. 
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TLR9-ligand. CD27+ and CD86+ B cells development, TACI+ and BCMA+ B 
cells development were suppressed by telomeric ODN. In contrast, BAFF-R-
expressing B cells were not suppressed, whereas BAFF-R-negative B cells 
showed a significant decrease by telomeric ODN. 
 
Finally in order to evaluate the plasma cell differentiation in B cells, we 
determined surface CD138 expression in parallel to CD19+ expression. 
Surface CD138 expression, which is a highly and specific marker of plasma 
cells, was determined in 10 days of PBMC cultures with sCD40L+IL-4 and 
stimulated by TLR3, 7 or 9 alone or in combination with telomeric or control 
ODN. Stimulation with TLR3 or TLR7 ligands did not induce detectable 
CD138 expression, but TLR9 ligand induced its expression at the level of 
1.6% of CD138+CD19+CD3-CD16-CD14-7-AAD- cells (Fig. 6A). Control ODN 
did not change the ratio of CD138+CD19+ cells induced by TLR9 ligand. 
However, telomeric ODN significantly suppressed the CD138+CD19+ plasma 
cell differentiation from B cells induced by TLR9 ligand (Fig 6B, C).  
 
 
 
 
 
 
 
 
 
 
Figure 6. Suppression of plasma cell differentiation by telomeric ODN. PBMCs 
cultured with sCD40L+IL-4 were stimulated TLR3, TLR7 or TLR9 alone or in 
combination with telomeric or control ODN. (A) Surface CD138 expression 
was measured by flow cytometry after 10 days culture. CD3−CD16−CD14−7-
AAD− cells were gated. Stimulation with TLR3 or TLR7 ligands did not induce 
detectable CD138 expression. One representative example is shown as dot 
plots. (B) Connected dots show percentage of CD138+ from three 
independent experiments. (C) Bar graphs show mean (±SEM) percentages of 
CD138+ cells relative to TLR9 ligand stimulated cells (set to 100%). Results 
are representative of three independent experiments, *P < 0.05. 
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Discussion 
The present study demonstrates that TLR3, TLR7, TLR9 have distinct 
stimulatory pathways for B cell activation and immunoglobulin production. We 
demonstrate here a synthetic analogue of mammalian telomeres suppresses 
direct and indirect effects of TLR3, 7 and 9 ligands as strong inducers of B cell 
proliferation, differentiation and immunoglobulin production. 
 
Here, we report that in addition to direct stimulation of B cells via TLR9, 
stimulation of PBMC via TLR3 and 7 indirectly leads to human B cell 
proliferation and immunoglobulin production. Although TLR3, 7 and 9 are 
expressed at the same cellular location, in the endosomes, their expression 
rates differ depending on the type of the cells. In addition to TLR9, human 
peripheral blood B cells express high levels of TLR1, TLR6 and TLR10, 
intermediate levels of TLR7, and low levels of TLR2, and TLR4, but not TLR3 
247. In the present study, we demonstrate that stimulation via TLR9 directly 
activates CD27+ memory B cells and a fraction of CD27- naive B cells. As 
shown by Huggins et al.245 CpG stimulates not only CD27+ memory B cells, 
but CD27- naïve B cells under special in vitro conditions. The present study 
demonstrates that CpG stimulates highly purified naïve and memory B cells 
and this stimulation is potentialized in the presence of IL-2. Both TLR3 and 
TLR7 stimuli significantly induced B cell proliferation only when PBMC were 
stimulated, suggesting that there is an indirect effect on B cells mediated by 
other cells or mediators that are present within the PBMC population. The role 
of other factors was demonstrated in the present study by co-cultures of 
highly purified cells. The role of IL-2 is demonstrated as one of the essential 
factors for B cell proliferation and antibody production by TLR3 and TLR7 
stimuli. It was recently shown that IFN-α released by plasmacytoid dendritic 
cells upon stimulation with TLR7 was responsible for B cell polyclonal 
expansion and differentiation into Ig-producing plasma cells.248 In the present 
study, the proliferation of purified human B cells, particularly memory B cells 
in the presence of IFN-α, IFN-β and plasmacytoid dendritic cells induced by 
TLR7 shows that this stimulatory effect was mediated via plasmacytoid 
dendritic cells. The activation of plasmacytoid dendritic cells by TLR7 results 
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in the secretion of IFN-α and IFN-β that induce B cell activation, proliferation 
and IgE, IgG1, IgG4 and IgA production.  
 
Whereas previous studies reported that TLR9 stimulation by CpG inhibited 
CD40/IL-4-driven IgE synthesis in human B cells and IgG1 and IgE synthesis 
in murine B cells.249, 250 A recent study by Ozcan et al.251 demonstrated that 
murine naïve B cells when stimulated by TLR9 ligand with the cooperation of 
CD40, TACI and IL-4 produce IgG1 and IgE. In human PBMC, stimulation via 
TLR3, 7 and 9 even in the absence of IL-2, IL-4 and sCD40L induced IgG1, 
IgG4 and IgA, in detectable quantities and IgE with the combination of IL-4 
and sCD40L. In contrast to PBMC, purified human CD19+ B cells produce 
IgG1, IgG4 and IgA upon TLR9 stimulation but not TLR3 and TLR7 (Fig. S2). 
The production of IgG1, IgG4 and IgA was increased by TLR3 and TLR7 in 
the presence of IL-2 and this response was boosted when combined with 
sCD40L, but sCD40L alone did not induce additive effect on purified B cells. 
The production of IgE by purified B cells was not induced by TLR3, TLR7 and 
TLR9 in the presence of IL-4 and sCD40L contrary to the findings in PBMC. 
The production amount of IgE by intracellular TLRs is not robust when 
compared to IgG1, IgG4 and IgA in PBMC and moreover was not detectable 
in human purified B cell cultures. This finding suggests that intracellular TLR 
ligands may have a critical role in changing the balance against IgE and more 
in the direction of IgG1, IgG4 and particularly IgA in allergic diseases.65 
 
In the present study, we investigated step by step all aspects of B cell 
activation, proliferation, Ig class switch recombination, AICDA expression and 
plasma cell differentiation and demonstrated that mammalian telomeric ODN 
significantly suppressed all of the features. Suppression of B cell activation 
and Ig production by suppressor ODN represents an important way for the 
treatment of diseases related to B cell over activation. It can also be used for 
allergic diseases. Rituximab, a chimeric mAB to CD20 that efficiently 
eliminates circulating and overactive B cells that have CD20 on their surfaces 
and is therefore used to treat diseases characterized by high number of active 
B cells. A pilot study was already conducted in extrinsic atopic dermatitis 
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characterized by highly elevated concentrations of IgE and the early results of 
treatment with rituximab suggest that it may be a promising treatment option 
for patients with severe atopic dermatitis.171, 252 
 
Previous studies have demonstrated that suppressor ODN possessing four 
repeats of TTAGGG motifs inhibits CpG-induced inflammation in mice.170, 235, 
253 Human telomeres consist of tandem repetitive arrays of the hexameric 
sequence TTAGGG.236 The enzyme telomerase is a cellular ribonucleoprotein 
responsible for adding telomeric repeats onto the 3’ ends of chromosomes 
and thus compensates for cell division-associated telomere loss.254 
Elongation of telomeres with the telomerase results in an extended lifespan of 
a cell. Therefore, it was suggested that the length of the telomere rather than 
telomerase itself is responsible for limiting cell proliferation. Suppressive 
activity of TTAGGG motifs has been demonstrated to correlate with the ability 
of the sequence to form G-tetrads.235 Individual mammalian cells contain 
phosphodiester TTAGGG motifs and some of them including some synthetic 
analogues are in single-stranded form. Therefore, it can be expected that high 
cellular concentrations of TTAGGG elements with suppressive capacity can 
be released to microenvironment following host cell death or following cell 
division. It is possible that self-DNA released by injured cells could down-
regulate TLR-mediated inflammation response. 
 
Another way to control TLR responses is the TLR tolerance phenomenon, 
which is explained by the unresponsiveness of the immune cells to the same 
or different TLR ligands upon the occurrence of repeated or chronic 
stimulation through TLRs.255 The tolerant state in macrophages and B cells 
was associated with reduced NF-κB, MAPK activation and c-Jun 
phosphorylation.256 However, B cells may receive general signals through 
TLRs and specific signals through BCR. The prestimulation of B cells with 
TLR7 may result in reduced B cell proliferation and IgM secretion upon 
subsequent TLR7 restimulation, but simultaneous BCR signaling may prevent 
or reverse TLR7- or TLR9-mediated TLR tolerance in human B cells. This 
distinct response of TLRs and BCR to the TLR7 and TLR9 ligands may be a 
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potential way to study the effects of telomeric ODNs on B cell responses 
induced by TLR ligands. The TLR9-ligand is a nucleic acid sequence that may 
bind to TLR9 localized in the endosomes. Telomeric ODNs, which are also 
nucleic acid sequences may have a potential to regulate B cell response 
similar to the tolerance phenomenon that takes place by repeated or chronic 
stimulation through TLRs. 
 
In both PBMC and B cell cultures, mammalian telomeric ODN suppressed 
TLR3, TLR7 and TLR9 ligand induced B cell proliferation without regarding 
direct or indirect stimulation. Whereas the generation of both TACI and BCMA 
positive and negative B cells were suppressed, the BAFF-R expressing B 
cells were resistant to suppression by telomeric ODN. Moreover telomeric 
ODN significantly suppressed the proliferation of the antibody forming cells. 
These findings were fully supported by demonstration of significant decrease 
in secreted Igs to the supernatants of PBMC and purified B cells by telomeric 
ODN. It remains to be elucidated whether the different levels of B cell memory 
and serum antibodies to different pathogens depends on the amount of cell 
death and released telomeric ODN to the microenvironment during exposure 
and generation of the immune response. 
 
It has been suggested that environmental stimuli such as CpG maintain 
continuous polyclonal memory B cell activation, proliferation and 
differentiation.257 In this way, a constant level of plasma cells and serum 
antibodies could theoretically be maintained throughout a human life span. 
Our study showed that in addition to CpG, TLR3 and TLR7 ligands have a 
capacity to induce B cell activation in PBMC, which was significantly 
enhanced by IL-2. These findings demonstrate that direct or indirect 
stimulation of human B cells through endosomal associated TLRs plays a 
pivotal role in polyclonal B cell activation and immunoglobulin production to 
maintain long-term serological memory in humans. Suppression of this 
response by host-derived telomeric ODN suggests a natural mechanism to 
overcome hyper activation of B cells and hyper production of immunoglobulins 
under chronic inflammatory conditions. The distinct effects of intracellular 
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TLR3, 7 and 9 and telomeric ODN on B cell activation, proliferation, AICDA 
expression, Ig class switch recombination, IgE, IgG1, IgG4, IgA production 
and plasma cell differentiation suggest a crucial role for the 
immunomodulation of B cell-mediated diseases as well as allergic 
inflammation. 
 
Acknowledgments 
The authors’ laboratories are supported by Swiss National Science 
Foundation, Grants No: 320030-132899 and 320030-125249, and CK-CARE: 
Christine Kühne-Center for Allergy Research and Education, MEDALL: EU 7th 
frame work project No:261357. C.S. was supported by the European 
Academy of Allergy and Clinical Immunology (EAACI) exchange research 
fellowship. 
  6 Results 
 
 143 
Supplementary figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE S1. Percentage suppression of TLR-induced PBMC proliferation at 
different concentrations of telomeric ODN. (A) One representative of 5 
different experiments is shown and (B), control ODN. 
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FIGURE S2.  Different requirements in IgG1, IgG4 and IgA production by B 
cells with TLR3, 7 and 9 stimulation and their suppression by telomeric ODN. 
IgG1, IgG4 and IgA immunoglobulin synthesis by B cells   2x106/ml in 200 µl 
in 96-well plates was stimulated with TLR3, 7 and 9 ligands in the absence or 
presence of IL-2 and sCD40L or both. TLR7 and TLR9 ligands and telomeric 
ODN were used at 1 µM and TLR3 ligand was used at 25 ug/ml. IgG1, IgG4 
and IgA were measured in day 12 supernatants. In order to examine TLR3, 7 
and 9 mediated antibody secretion from pure B cells, highly pure CD19+ B 
cells were used in stimulation assays. In contrast to PBMC, poly(I:C) and 
imidazoquinolone stimulation did not induce any antibody production by pure 
B cells, whereas stimulation with CpG 2006 was sufficient to induce IgG1, 
IgG4 and IgA production. The induction of IgG1, IgG4 and IgA by TLR3 and 
TLR7 stimuli was observed in the presence of IL-2. Similar to PBMC, 
stimulation of sCD40L alone did not show any additive effect in the absence 
of IL-2 on B cells, but significantly increased IgG1 production. Albeit at 
different suppressive levels, telomeric ODN significantly inhibited 
immunoglobulin synthesis by pure B cell cultures in all conditions tested. 
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FIGURE S3. TLR3-, TLR7- and TLR9-ligand induced B cell differentiation and 
suppression by telomeric ODN. Human PBMC were stimulated with TLR3, 7 
and 9 ligands in the presence of IL-2 with and without telomeric ODN for 6 
days. Cells were stained with mAbs to CD19, CD27, CD38, CD80, CD86, 
BAFF-R, TACI and BCMA for flow cytometric analysis. (A) The gated area 
shows the percentage of positive cells for CD20, CD27 and CD86. 
Mean±standard deviation of percentage of surface expression in 2 different 
experiments is shown in each histogram. (B) Telomeric ODN suppressed 
CD19+CD27+, CD19+CD27+ in all conditions and CD19+CD20+, CD19+CD86+ 
cell proliferation stimulated with TLR7 and TLR9. One representative of 3 
experiments is shown. *P<0.05. 
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6.4 Contributions to publications 
For the publication titled: “IgG4 production is confined to human IL-10-
producing B regulatory cells that suppress antigen-specific immune 
responses”, I contributed to all experiments except the methodology of the 
whole genome microarray expression analysis.  
 
For the publication titled: “Human IL-10-overexpressing B cells possess 
extensive regulatory capacity toward both innate and adaptive immune 
responses”, I contributed to the experiments depicted in figures 2, 3, 4 and 5. 
 
For the publication titled: “Suppression of B-cell activation and IgE, IgA, IgG1 
and IgG4 production by mammalian telomeric oligonucleotides”, I contributed 
to the experiments depicted in figures 2, 3, 4 and 6. 
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7 General Discussion 
B cells play an essential role in the sensitization phase of allergic responses 
mainly by production of allergen-specific IgE antibodies. Th2 cells and their 
cytokines IL-4 and IL-13 play a key role in the induction of IgE. A physiologic 
way to dampen IgE-mediated allergic reactions is to skew allergen-specific 
IgE, towards allergen-specific anti-inflammatory IgG4. IL-10 can suppress 
allergic responses in several ways including suppression of antigen-
presentation, suppression of T cell activation and suppression of IgE induction 
in B cells. On the other hand, IL-10 has been shown to enhance IgG4 
production by B cells. Recent developments in the field of B cell biology have 
uncovered previously underappreciated functions of B cells that are primarily 
mediated by production of IL-10.  
 
7.1 Human IL-10-producing Br1 cells are potent 
suppressors of antigen-specific T cell responses 
and selectively upregulate IgG4 production. 
The primary aim of our study was to characterize human inducible IL-10-
producing B cells. To study these cells, we used healthy donors, bee venom 
allergic patients that received bee venom SIT and healthy beekeepers who 
were exposed to high doses of bee venom. We applied the commonly used 
TLR9-L CpG2006 to induce IL-10 production in B cells and isolated IL-10-
producing B cells using a cytokine secretion assay. This approach allowed the 
isolation of a pure population containing all B cells that produce IL-10 in 
response to this stimulus. Furthermore, because this system does not require 
permebealization of the cell membrane, viable cells could be isolated, which 
were used to perform functional experiments. 
 
Phenotype of Br1 cells 
In analogy to inducible IL-10-producing Tr1 cells, we designated these 
inducible IL-10-producing B cells as Br1 cells. Analysis of Br1 cells and non-
IL-10-producing cells by gene arrays provided us with a list of differentially 
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expressed genes. These included among others surface markers and 
transcription factors. We have not succeeded to identify a master transcription 
factor that is specific for Br1 cells. Expression of CD25, CD71 and CD73 
showed marked differences between both subsets and these differences 
could be confirmed by flow cytometry. Therefore these markers could be used 
as surrogate markers for isolation of Br1 cells. Indeed, sorting of resting 
CD19+CD73-CD25+CD71+ B cells followed by TLR9-L stimulation 
demonstrated that the most of the IL-10 production in response to this 
stimulation originated from this B cell population. We found marked 
differences regarding the phenotype of Br1 cells and the previously described 
CD19+CD24hiCD38hi human regulatory B cell population.159 Br1 cells were not 
enriched among CD19+CD24hiCD38hi B cells but were equally distributed 
among CD24intCD38int, CD24hi CD38- and CD24hi CD38hi B cells. Furthermore, 
Br1 cells were not restricted to naïve or memory B cells since both CD27- and 
CD27+ B cells produced IL-10 in response to TLR9-L stimulation. This 
suggests that there are multiple subsets of B cells that can produce IL-10 in 
response to distinct stimuli. CD19+CD24hiCD38hi represents a subset of B 
cells that produces IL-10 in response to CD40 ligation (a surrogate for T cell 
help) while CD19+CD73-CD25+CD71+ Br1 cells produce IL-10 in response to 
TLR9-L stimulation (representing microbial exposure). Similar to other 
proposed markers for isolation of IL-10-producing B cells this set of markers 
does not include all Br1 cells and cell sorting based on IL-10 expression 
remains the best strategy to purify the total Br1 population.  
 
Function of Br1 cells in the regulation of T cell responses and 
the production of immunoglobulins 
Regarding the function of Br1 cells we investigated two main directions: 1) 
Direct suppression of antigen-specific T cell responses and 2) 
Immunoglobulin production by Br1 cells. Co-cultures of Br1 cells with antigen-
stimulated autologous PBMC demonstrated that Br1 cells are very potent 
suppressors of antigen-specific T cell proliferation that can inhibit up to 50% of 
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CD4+ T cell proliferation at a ratio of 1 B cell to 25 responder cells. Similar 
findings have been reported using other regulatory B cell populations.  
 
We were primarily interested in the isotype of immunoglobulins that are 
produced by Br1 cells. It has been previously demonstrated that IL-10 can 
augment IgG4 production in B cells while at the same it suppresses IgE.63, 64 
TLR9-L stimulation induced IgG1, IgG4, IgA and IgE production in purified 
peripheral CD19+ cells from healthy donors. IL-10 had a selective synergistic 
effect on TLR9-L-induced IgG4 production while the production of other 
immunoglobulin isotypes was not increased. Most importantly, we found that 
Br1 cells, which secrete IL-10 in response to TRL9-L stimulation, show an 
increased expression of IgG4 at the mRNA level while expression of IgG1, 
IgA and IgE was not increased in Br1 cells. We then isolated IL-10-secreting 
Br1 cells from naïve TLR9-L-stimulated (CD19+CD27-) and memory 
(CD19+CD27+) B cell populations and measured the immunoglobulin isotype 
produced by these populations. IgG1, IgG4 and IgA were produced in all 
populations. The highest amounts of these immunoglobulins were produced 
by memory B cells (both Br1 and IL-10-negative cells), which was to be 
expected based on the fact that the CD27+ B cell population includes the vast 
majority of IgG- and IgA-switched memory cells while CD27- B cells are 
primarily non-switched naïve B cells. Interestingly, there was a striking 
increase in the production of IgG4 by the IL-10+ Br1 cells compared to the IL-
10- cells that were isolated from the CD27- B cells. The absolute quantity of 
IgG4 that was produced CD27-IL-10+ Br1 cells was up to 6-fold lower than the 
amounts that were produced by both IL-10- and IL-10+ CD27+ B cells. But 
where IgG4 produced by CD27+ B cells was most likely the result of 
differentiation of already switched memory B cells to plasma cells, the 
production of IgG4 in the CD27-IL-10+ Br1 cells suggests a switching event 
that is selectively occurring in naïve Br1 cells and specifically induces CSR 
from IgM to IgG4. 
 
Induction of allergen-specific IgG4 is a hallmark for a healthy response to 
high-dose antigen exposure. Allergic individuals develop allergen-specific IgE 
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antibodies without a strong allergen-specific IgG4 response. Allergic patients 
who receive allergen SIT frequently develop allergen-specific IgG4 antibodies, 
which reach sufficiently high concentrations and/or affinities within 3 months 
to efficiently compete with IgE for allergen binding. This reduces binding of 
allergen to IgE and consequently can suppress IgE-FAP as well as mast cell 
and basophil degranulation.76, 98 Both these mechanisms are important 
targets for intervention aimed at ameliorating allergic responses. Clearly, 
prevention of mast cell and basophil degranulation in response to allergen 
exposure will prevent the onset of immediate type hypersensitivity reactions. 
Prevention of IgE-FAP will suppress priming and reactivation of allergen-
specific T cells.98, 258, 259 
 
Increase in frequency of allergen-specific Br1 cells during SIT  
A shift towards IL-10-producing allergen-specific Tr1 cells during tolerance 
induction has been reported in beekeepers.102 Furthermore, healthy IL-10-
producing Tr1 cells are the dominant allergen-specific Th cell subset in 
healthy individuals while IL-4-producing Th2 cells have a high frequency in 
allergic individuals.101 In this study we determined the frequency of PLA-
specific IL-10-secreting Br1 cells from allergic individuals before and after 110 
days of ultra rush bee venom SIT and compared these frequencies to those 
observed in highly exposed healthy individuals (beekeepers). We found that 
the frequency of PLA-specific Br1 cells increased in patients receiving SIT 
and reached levels comparable to those observed in highly exposed healthy 
individuals. At the same time a strong decrease in the ratio of circulating PLA-
specific IgG4 vs. IgE antibodies was observed.  
 
Taken together, our data strongly supports a role for IL-10-producing Br1 cells 
in peripheral tolerance induction mediated by secretion of IL-10 and 
production of IgG4. 
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7.2 Characterization of IL-10-overexpressing B cells 
In addition to the characterization of inducible IL-10-producing Br1 cells, we 
wanted to investigate direct effects of IL-10 expression in human B cells. 
Therefore we established and optimized a method for efficient transfection of 
human peripheral B cells to overexpress IL-10. Using the approach, we 
studied the effects of IL-10-overexpression on the phenotype and 
immunoregulatory potential of B cells on different types of immune responses. 
 
Transfection of IL-10 gene into B cells led to rapid upregulation of expression 
of IL-10 and SOCS3, which is a direct IL-10-responsive gene and could serve 
as a control for overexpression of biologically active IL-10. Production of 
proinflammatory cytokines and chemokines were significantly decreased while 
concentrations of anti-inflammatory cytokines were significantly elevated in IL-
10-overexpressing B cells. Furthermore, IL-10-overexpressing B cells showed 
upregulation of GARP and IL2RA expression, molecules that are associated 
with regulatory T cells. When compared to CD25+CD71+CD73- Br1 cells, IL10-
overexpressing B cells express more CD25, while CD71 and CD73 were not 
affected by IL-10 overexpression. In addition CD5 expression showed a trend 
towards an increase on IL-10-overexressing B cells. These data suggest that 
IL-10 overexpression directly or indirectly induces CD25, and CD5 expression 
in human B cells. Furthermore, IL-10-overexpressing B cells downregulated 
activating co-stimulatory molecules (CD80 and CD86) while upregulating 
inhibitory PD-L1.  
 
We did not observe a significant upregulation of IgG4 production in IL-10-
overexpressing B cells. In fact, a modest suppression of IgE production was 
the only effect of IL-10 overexpression at the level of immunoglobulin 
production. This indicates that IL-10 in itself is not sufficient to induce IgG4 
production (This can also be concluded from figure 4B of chapter 6.1). 
 
IL-10-overexpressing B cells potently suppressed TLR2-L- and TLR4-L-
induced proinflammatory cytokines and chemokines production by PBMC. 
This effect may result from the impact of IL-10-overexpressing B cells on 
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MDDC that extends from inhibition of cytokine release to suppression of their 
maturation downregulating their overall co-stimulatory potential (reduced 
CD80, CD86 and CD83, and induced PD-L1 surface expression) and 
therefore rendering MDDC toward a regulatory phenotype. Finally, IL-10 
overexpressing B cells showed the capacity to potently suppress proliferation 
of antigen-stimulated PBMC cultures.  
 
Taken together, IL-10 overexpression in B cells induces SOCS3, GARP and 
IL2RA expression all three molecules described to be highly expressed in 
regulatory T cells, along with increased CD1d, CD5 and CD38 expression and 
decreased capacity of co-stimulation. IL-10-overexpressing B cells are able to 
exert remarkable suppressive effect by acting directly on mechanisms of 
rapid-acting innate immunity through inhibiting the release of cytokines from 
TLR-L stimulated PMBC. Furthermore, IL-10-overexpressing B cells act on 
professional APCs by reducing their maturation profile resulting in reduction of 
cytokine production and co-stimulatory potential. IL-10-producing B cells are 
particularly potent in inhibiting antigen-specific proliferative response in vitro 
supporting the role of antigen specific IL-10 producing B cells limiting the 
memory T responses in vivo. 
 
These findings confirm the importance of IL-10-producing B cells regulating 
different aspects of immune response, particularly their effect on dendritic 
cells and bring better understanding of the capacity of solely IL-10 on B cell 
physiology and regulatory profile applicable for their specific targeting in the 
fields of allergy and asthma, autoimmunity and tumor immunity. 
 
7.3 Suppression of B-cell activation and IgE, IgA, IgG1 
and IgG4 production by mammalian telomeric 
oligonucleotides. 
Ligands for seven human TLRs were tested for their capacity to activate 
human peripheral B cells. TLR3-L, TLR7-L and TLR9-L induced proliferation 
of human B cells in whole PMBC. Only TLR9-L directly induced proliferation of 
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purified naïve and memory B cells while B cell activation by TLR3-L and 
TLR7-L was indirect and required the help of other cells, as purified B cells did 
not proliferate upon stimulation with these factors. Addition of IFN-α, IFN-β or 
pDCs to TLR7-L-stimulated B cells facilitated proliferation of purified naïve 
and, more pronouncedly, of memory B cells. The combination of TLR3-L with 
IFN-α or IFN-β induced detectable proliferation only in memory B cells. All 
these proliferative responses were suppressed by telomeric ODN.  
 
IgG1, IgG4 and IgA production was induced in PBMC cultures upon 
stimulation with TLR3-L, TLR7-L or TLR9-L while only TLR9-L induced 
detectable amounts of these immunoglobulins in cultures with pure B cells. 
Addition of CD40L and IL-2 augmented TLR-L-induced immunoglobulin 
production in most cases. IgE could only be detected in PBMC cultures 
stimulated with CD40L + IL-4 with or without TLR-L. Telomeric ODN 
suppressed the production of all measured immunoglobulin isotypes. This 
suppressive effect may be attributed to reduced CSR, as the expression of 
the gene (AICDA) encoding a key enzyme in this process (activation-induced 
deaminase) was significantly reduced in the presence of telomeric ODN. 
Another level of suppression mediated by telomeric ODN was observed at the 
level of plasma cell differentiation. The frequency of plasma cells induced by 
TLR9-L stimulation was suppressed by approximately 50% in the presence of 
telomeric ODN.  
 
These findings demonstrate that direct or indirect stimulation of human B cells 
through endosomal associated TLRs plays a pivotal role in polyclonal B cell 
activation and immunoglobulin production to maintain long-term serological 
memory in humans. Furthermore, these data reveal a direct and general 
suppressive effect of mammalian telomeric ODN on the activation of human B 
cells at the level of proliferation, CSR, plasma cell differentiation and 
immunoglobulin production. Suppression of B cell responses by telomeric 
ODN may represent a natural mechanism to control B cell activation and 
maintain immune homeostasis under chronic inflammatory conditions. 
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7.4 Conclusion and outlook 
We conclude that the immunoregulation by B cells and the regulation of B cell 
responses have a pivotal role in the maintenance and induction of peripheral 
tolerance. This thesis demonstrates that human regulatory B cells can 
contribute to the control of immune responses in several ways: I) Direct 
suppression of antigen-specific T cell proliferation; II) production of anti-
inflammatory IgG4 immunoglobulins, III) IL-10-mediated inhibition of pro-
inflammatory cytokine production in response to TLR-triggering; IV) 
Suppression of maturation and antigen-presentation capacity of DCs. We also 
demonstrated that allergen-specific inducible IL-10-producing Br1 cells 
expand during SIT, which supports a role for these cells in the course of 
peripheral tolerance induction. The suppression of B cell responses by 
telomeric ODN provides a mechanism to prevent exaggerated B cell 
responses during chronic inflammation and as such can play a role in 
maintenance of peripheral tolerance. 
 
Further characterization of human regulatory B cells and delineation of the 
mechanisms that play a role in their function may provide novel therapeutic 
options for the treatment of chronic inflammatory diseases.  
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